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ABSTRACT
Interleukin 1 (IL1 alpha and beta) and tumour necrosis factor (TNF
alpha and beta) are inducible cytokines with potent and wide-ranging
immunopotentiating, pro-inflammatory and catabolic activities. These
activities suggest a potential role in the pathogenesis of inflammatory
diseases.
The present study investigated the induction, synthesis and release of
IL1 and TNF alpha from human monocytes in vitro. This included measurement
of kinetics of mRNA accumulation, immunoreactive and bioactive protein
production and extracellular translocation. Several microbial products and
pro-inflammatory crystals associated with human arthritis were tested for
their ability to induce IL1 and TNF production.
All microbial - derived agents tested were potent, concentration-
dependent stimuli for both immunoreactive and bioactive IL1 and TNF, but
only monosodium urate of three crystal types tested was effective, showing
that non-specific membrane perturbation was not a sufficient stimulus for
monocyte cytokine induction.
No preformed immunoreactive IL1 alpha, TNF alpha or IL1 beta could be
demonstrated in unstimulated cells, while on cellular activation cytokine-
peptides accumulated rapidly in the intracellular compartment. This was
followed for TNF alpha and IL1 beta, but not for IL1 alpha, by efficient
extracellular translocation.
Analysis of mRNA confirmed that IL1 beta or TNF alpha transcripts only
accumulated after cellular activation and there was no untranslated mRNA
pool or pre-formed intracellular protein in resting cells, indicating that
control of cytokine production was predominantly at the stage of gene
transcription.
To test in vivo the potential role of these cytokines in rheumatic
diseases, it was important to demonstrate their presence at the site of
inflammation.
Unfractionated synovial exudate fluids from a large number of patients
with different rheumatic diseases contained no biodetectable IL1, but high
levels of immunoreactive IL1 beta and IL1 alpha were demonstrable in these
samples. This discrepancy could reflect the presence of biological
inhibitor(s) or the immunodetection of IL1 in a biologically inactive form.
In contrast, bioactive TNF was detectable in approximately 30% of the
fluids tested; when assayed in specific immunoassays, excellent agreement
with bioactivity was obtained.
Thus, both IL1 and TNF were present at high concentrations in synovial
exudate fluids from several rheumatic diseases. Since their production
appears to be inducible at transcriptional level, it can be concluded that




Akkadian cuneiform inscription (600-700 B.C.) adapting an earlier
Sumerian pictographic symbol of a flaming brazier to denote in a single
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INTRODUCTION
l.a. SOLUBLE MEDIATORS OF IMMUNITY: CYTOKINES
The efficiency and discrimination of the "adaptive" immune system are
regulated by the selective expansion of lymphocyte clones. When T and B
cell surface receptors recognize an exogenous antigen, they become
susceptible to activation by soluble polypeptide growth factors, termed
"cytokines" which are produced in rapid succession during the
inflammatory/immune reaction. If the expansion of antigen-specific clones
and the MHC restriction of antigen presentation provide the basis for
discrimination, the fine tuning of the proliferative, maturational or
functional actions of different cytokines on target cells is mediated by
their cellular receptors and by diverse mechanisms that can alter this
interaction or its effects.
The description of the different cytokines began with the
identification of specific biological phenomena and the demonstration that
they were linked to a peptide entity that mediated this action. At this
stage, the "factors" were given names reflecting their biological action
(and often different actions of the same mediator), more frequently
indicating the target rather than the producing cells. The huge impetus
provided by molecular cloning in recent years provided new techniques to
answer questions about gene regulation, protein structure, processing and
translocation, receptor structure and interactions. It became clear that
many biologically - described "factors" were, in fact, single molecular
species and it was agreed that a known amino acid sequence was an essential
criterion for the description of a new cytokine.
Named after particular biological activities, a few families of
cytokines have emerged, including Interferons, Transforming Growth Factors,
Colony Stimulating Factors, Tumour Necrosis Factors and the family of
Interleukins , to which now virtually all new entries can be assigned. The
agreed criteria for designation as an Interleukin (known primary structure^
main but not necessarily exclusive production by leukocytes, and action
during immune reactions or inflammation) are so broad that many of the
previously mentioned cytokines would, if described today, be called
Interleukins.
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Each one of these mediators plays potent roles in cell activation,
differentiation or modulation during the immune response. Much of classical
immunology, including "innate immunity" and antibody response is today
explicable through a complicated but increasingly defined network of
cytokine-receptor interaction and expression of recognition structures on
definite cell types. The main features of some families of peptide
cytokines (human molecules, unless specified) are summarized in Tables 1.1
to 1.7.
In man, the earliest response to exogenous, pathogenic agents appears
to be mediated by two major cytokines, Interleukin 1 (IL1) and Tumour
Necrosis Factor (TNF). These mediators can be produced by simple recognition
of microbial components, such as bacterial wall constituents or exotoxins,
without the need for specific antigen recognition. Their production can
preceed antigen presentation and activation of lymphocytes, producing a
reaction known as the "acute phase response", characterized by fever,
metabolic changes, production of acute phase proteins from the liver and
bone marrow activation. These actions are probably the most ancient
biological properties of these cytokines, which evolved well before the
"adaptive" immune response.
The reasons why IL1 and TNF are of special interest to the study of
chronic inflammatory diseases, and rheumatic conditions in particular, are
inherent in their biology as outlined in the following sections.
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TABLE 1.1 Human Interferons













Viral IFN, Type I IFN Viral IFN, Type I IFN
Leucocytic IFN Fibroblastic IFN
Products of 14 genes: 1 gene
alpha 1, alpha 2 ....
Mainly T and B cells; mainly fibroblasts; also

















MHC class II (+)
decreased c-myc
expression
14 loci, chrom 9
no introns
1 gene, chrom 9
no introns
IFN gamma
Immune IFN, Type II IFN
MAF
1 gene








class II MHC expression
(DR +++, SB +++, DC +)
enhancement monocytic
cytotoxicity


























IFN beta-1 and IFN alpha's
1 chain, glycoprotein of 95 to 110 KDa







16, 20, 25 KDa
2 subunits 53/75Kd
RMI; 10 M Kd
different aggregation
(70-92-163-325 KDa)
Main Sources Trinchieri, Perussia, 1985; Pestka et al. 1987; Friedman, Vogel, 1983.
Abbreviations MAF = Macrophage Activating Factor
RMI = Receptor Mediated Internalization
GF = Gel filtration
*NB: IFN-beta 2 (or IL6) is in Table 1.4
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location chrom 5 chrom 5 chrom 17 chrom 5
structure 8 exons, at least 1 intron 5 exons, 4 introns 5 exons, 4 introns
at least 1 intron
mRNA 1.5 to 4.5Kb 1Kb 1.6Kb 1Kb
Rec. molecule
propeptide 224aa (26KDa) 144aa 207aa 152aa
glyc. sites 2 2 no N-glyc 2
mature pept. 127aa (14.5KDa) 127aa (18-24KDa) 177aa (19KDa) 133aa(14.6KDa)
leader seq. 22aa yes yes 19 aa
homology none none none none
Native molec.
structure homodimer monomer monomer monomer
MW GF 40-45KDa 22KDa 23KDa (O-glyc) 28KDa









































Main Sources: Nicola, Vadas. 1984: Metcalf, 1987; Nicola, 1987; Kawasaki et al, 1985; Wong et al, 1985;
Souza et al. 1986; Schrader, 1986; Lopez et al, 1987.
Abbreviations used:
MG1 Macrophage/granulocyte inducer CSF
BPA Burst promoting activity G
HCGF Haemopoietic cell growth factor M
MCGF Mast cell growth factor MEG
PSF P-cell stimulating factor DF
NIF-T Neutrophil inhibiting factor. T-derived GF




























also T, B cells, endothelial
cells, mast cells.










actions on enzyme of lipid and carbo¬
hydrate metabolism
PGE, from several cell types
antiviral
induction of IL1, GM-CSF, IL6, TNF
neutrophil activation
induction of ICAM 1
augm. MHC class I and class II expression
bone, cartilage resorption
(see also tables 1.11, 1.12)
TNF beta
Lymphotoxin
Activated T cells during AP.
also monocytes and B cells.
viruses (herpes, vescic. stomatitis)
T cell activation
IL2, and gamma IFN + IL2
poly I:C
cytolytic for several cell types
mediator of CTL killing?
necrosis of tumours in vivo
increases cell mediated cytotoxicity
synergy with IFN gamma, induces IL6
augments MHC class II expression and
ICAM I expression
augments PMN phagocytosis
antiparasitic and antiviral direct
bone resorption
differentiation of monocytic lines
(HL60, THP-1S)





mature peptide 157aa (17.3KDa)















Chrom 6 (near MHC and TNF alpha)










shared by TNF alpha and TNF beta
at least 2 chains (75KDa and 95KDa) glycoprotein
upregulated by IFN gamma; high (3x10 M Kd)
and low (1.5x10 M Kd) affinity.
Internalization of TNF's and receptor
(Old, 1985; Beutler, Cerami 1986, 1987, 1988: Le, Vilcek, 1987; Ruddle et al, 1987;
Aggarwal et al, 1987; Paul, Ruddle, 1988; Cerami, Beutler, 1988.)
Abbreviations Used
AP antigen-presentation





TABLE 1.4 Human Interleukins
Definition:
Type: IL1
Also known as: BAF; ETAF; LEM; EP; LAF; HPI.l



































of IL2, IL4, IL6, IL1, TNF)
Fever, acute phase response
hypotension, slow wave sleep




resorption in organ culture
(see also tables 1.8, 1.9)
unpublished (2)





























IL1 alpha and IL1 beta mature
peptides, IL1 alpha propeptide
alpha (80KDa) and beta (lOOKDa)
chains. Alpha (murine) 576aa
Ig superfamiLy (murine)
0.2-2.5x10 M Kd
TCGF I; KHF; TRF; TSF
1 gene IL2
T cells (TH. mainly), NK cells, +
cord blood lymphocytes, some CD8
T cell lines
antigen presentation; IL1; IL2
Proliferation of T, B, TIL, LAK cell
increased cytotoxicity of NK cells
maturation and proliferation of CTL
induces IFN gamma, IL1, IL4
TNF alpha, TNF beta
increased expression of c-myb; c-myc
reduction of tumour metastasis
and lymphoid expansion in vivo












alpha (55KDa, Tac protein)
beta (75KDa) chains
no
alpha chain (=Tac) gene: chrom 10
8 ex, 7 in: 1.5-3.5Kb mRNA
down-regulated by IL2 and TGF beta
(beta = 1x10 m Kd; alpha + beta =
1x10 M Kd)
Oppenheim, Gery, 1982; Mizel, 1982; Dinarello, 1984; Durum et al, 1985; Oppenheim et al, 1986;
Dinarello, 1986; Le, Vilcek, 1987; Dower, Urdal, 1987; Smith, 1984; Robb, 1984; Greene, Leonard,
1986; Smith, 1987; Siegel et al. 1987; Fletcher, Goldstein, 1987; Sims et al. 1988.
Abbreviations Used:
TCGF T cell growth factor LAK
KHF Killer cells helper factor CTL
TRF T cell-replacing factor N'K
TSF T cell-stimulating factor HP1


























multi CSF. MCGF I ...
(see also CSF's)







TCGF II, BCGF I, BSF-I
BCDF epsilon, BCDF gamma,
MCGF II








MHC class II (+)
IgG1 enhancer (+++)
IgE " (+++)
FCe RII " (+++)
IL4R " (+++)
(all blocked by IFN gamma)
synergy on actions by:
G-CSF; M-CSF; IL3
Mast cell growth factor
IL5
TRF, BCGF II, BCDF alpha
EDF, KHF, BCDFmi










Synergy on actions by:
IL4 for IgE
IL2 for CTL genes
and IL2R
Gene
location chrom 5 chrom 5 chrom 5
Rec. molecule
propeptide 152aa 153aa 133aa
glyc. sites 2 2 2
mature p. 133aa (14.6KDa) 129aa (15KDa) 125aa (13.2KDa)
leader seq. 19aa yes yes
homology no no no
mat. molecule
structures monomer monomer dimer, trimer
MW GF 28KDa 20KDa 45,60KDa
MW SDS 15-25KDa 15-19KDa 18,20,22 KDa
Receptor (murine)
shared no no no
structure 60/75KDa 140/70KDa 92.5KDa complex
other 10"13M Kd 7xlO_11M Kd 10"11 and 10"9M Kd
internalized internalized
Main Sources Nicola, 1987: Yane et al. 1986; Schrader, 1986; Sanderson et al. 1988; Swain et al. 1988;
Takatsu et al. 1988; Yokota et al, 1988; Kishimoto, Hirano, 1988; Paul, Ohara, 1987)
Abbreviations Used:
CSF Colony stimulating factor
MCGF Mast-cell growth factor
TCGF T-cell growth factor
BCGF B-cell growth factor
BSF B-cell stimulating factor
BCDF B-cell differentiation factor
TRF T-cell replacing factor
EDF Eosinophil differentiation factor
KHF Killer-helper factor
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BCDF, BSF-2, IFN beta 2;
HPGF, HSF, CDF
activated T cells, glioblastoma
cells, fibroblasts, cardiac
mixoma cells, cervical adeno¬
carcinoma lines, monocytes
IL1, TNF, PDGF, poly I:C

































with IL2, CTL induction
B cells:
induction of Ig production
(differentiation without growth)
antiviral (??)
induction of acute phase
reactions in liver cells
fever in vivo
chrom 7











long-term growth of pre-B cells
and pro-B cells







Hirano et al, 1986; Kishimoto, Hirano, 1988; Wong, Clark, 1988; Billiau, 1987; N'amen et al 1988a;
Namen et al. 1988b
Abbreviations Used:
BCDF: B-cell differentiation factor
BSF-2: B-cell stimulatory factor
IFN: Interferon
HPGF: Hybridoma/plasmocytoma growth factor
HSF: Hepatocyte-stimulating factor
CDF: Cytotoxic cell differentiation factor
LP: Lymphopoietin
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related, but distinct to ACTIVINS, INHIBINS, MIS, DPP.C,
Vgl
TGF beta 1 TGF beta 2 TGF beta 1/beta 2
macrophage, lymphocytes B/T

































inhibition of all known IL2 effects including
IL2R expression
? activation of monocytes: IL1, TN'F alpha
chemotactic for monocytes.
Connective Tissues
fibrosis and wound healing in vivo
increases: collagen I, III, IV gene expression,
fibronectin, TIMP, PGE- and Ca release from bone,
FSH induced steroids, osteoblast proliferation,
fibroblast chemotaxis, fibroblast glycolysis, fibroblast
fibroblast collagenase
decreases: production of serum/metalloproteinases P.A.
secretion, ACTH effects on adrenal glands.
General Cellular Effects
anti-proliferative: hepatocyte, epithelial cells,
keratinocytes, T, B cells.
Control of differentiation in vitro, via expression of
IN'TEGRINS (fibronectin receptors), and influencing
cell adhesion/cytoskeleton interaction.
Inhibition of Other Cytokines
























10 M Kd, three order of receptors:
1) 280KDa receptor, most biological actions,
used by the three forms of TGF beta.
2) 65KDa and 3) 80KDa receptors, used
only by TGF beta 1.
Todaro, 1987; Sporn et al. 1986; Cheifetz et al. 1987; Massague, 1987; Assoian et al. 1987;
Ignotz, Massague, 1987.
Abbreviations Used
VGF Vaccinia growth factor
MIS Mullerian inhibitory substance
DPP.C Decapentaplegic transcript
Vgl Xenopus Vgl material mRNA product
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Based on the biochemical purification (Lobb et al. 1986A)
acidic FGF





class 2 HBGF's: TAF; EDGF-1
beta-RDGF; cHDGF; CDGF
AGF; HDGF; MDGF
neural tissue, kidney, corpus luteum,
macrophages, adrenal glands,








myoblast and cortical neuron growth
endothelial cells chemotaxis and growth
induction of IFN gamma
proliferation of neuroectodermal derived cells
angiogenesis in vivo, neovascularization























shared, 140/160KDa, high affinity
autophosphorylating-tyrosine kinase
Lobb et al. 1986B: Deuel, 1987; Lobb et al. 1986A.
Abbreviations Used:
FGF Fibroblast growth factor
ECGF Endothelial cell growth factor
EDGF Eye-derived growth factor
RDGF Retina-derived growth factor
HDGF Anionic (a) or cationic (c)
hypothalamus-derived growth factor
BDGF Brain-derived growth factor
AGF Astroglial growth factor
TAF Tumor angiogenesis factor
CDGF Cartilage derived growth factor
MDGF Macrophage-derived growth factor
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PDGF I, PDGF II
(diff. glycosilations, homo or
heterodimer)









induction of IL1, IL1R,
IFN' gamma and IFN beta



































































in vivo: angiogenic, wound healing, augmentation of
disulphide bonds in skin,
hepatic hypertrophia and hyperplasia
induces IFN gamma, PG's, hCG secretion
inhibition of gastric secretion
augmented glycolysis, ODC activity, protein
synthesis
augmented hyaluronidase acid production
enhanced by insulin












kinase product of a gene
in chrom 7 (like c-erb B)
I186aa, 132KDa glycosilated to
170KDa; 10 M Kd
Main Sources: Deuel, 1987; Ross, 1987; Johnson, Torres, 1985; Carpenter, 1987; Carpenter, Cohen, 1979.
Abbreviations Used:
PDGF Platelet-derived growth factor





Products of activated macrophages have attracted great interest as
mediators of host responses to infection, injury and immune reactions. One
family of these peptides is Interleukin 1 (IL1). IL1 has been studied for
decades for its ability to induce the acute phase response, namely fever
(Endogenous Pyrogen [EP] activity: Beeson, 1948; Atkins, 1960) and synthesis
of acute phase reactants with redistribution of metal ions and neutrophilia
(Leukocytic Endogenous Mediator [LEM] activity: Homburger, 1945;
Kampschmidt, 1978). More recently described are its action in the immune
system (Lymphocyte Activating Factor [LAF] activity; Gery et al. 1972), its
effects on mesenchymal cells with induction of PGE2 and collagenase
(Mononuclear Cell Factor [MCF] activity: Dayer et al., 1976) and its
catabolic effects on cartilage (Catabolin: Saklatvala, 1981).
Following demonstration of the substantial biochemical similarity of
these factors (reviewed by Dinarello, 1984), it was agreed (Aarden et al,
1979) to use the term Interleukin 1 to refer to the monocyte product(s)
responsible for these activities. The cloning of IL1 (Lomedico et al, 1984;
Auron et al. 1984; March et al. 1985) confirmed earlier observations on the
biochemical heterogeneity of IL1 peptides (Lachman et al. 1977; Murphy et
al; 1981): IL1 consists of two different, acidic (pI5) and neutral (pI7)
proteins, referred to as IL1 alpha and IL1 beta respectively. The
availability of recombinant proteins has now made it possible to assign to
both ILl's the extensive range of biological properties (Table 1.8 and Table
1.9) previously reported. These include direct action on human liver,
supporting a role for IL1 in the induction of acute phase proteins, and on T
cell activation, with an increase in expression of IL2 and IL2 receptor
followed by proliferation. Rabbits and mice injected intravenously with IL1
develop typical monophasic fever, confirming the role of IL1 as an
endogenous pyrogen. Interestingly, recombinant IL1 has been shown to induce
IL1 gene expression, suggesting a mechanism by which IL1 production could
amplify and sustain local inflammatory responses. The confirmed catabolic
actions of IL1 include bone and cartilage resorption, with proteoglycan loss
from the cartilage, and osteoclast activation with calcium release from the
bone. Most of these biological activities are not exclusive to IL1: the
availability of pure, recombinant reagents has demonstrated that Tumour
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Necrosis Factor (TNF) and other cytokines share some of the actions of IL1.
TNF alpha (Dinarello et al. 1986B), Interferon alpha (Dinarello et al. 1984)
and IL6 (Dinarello et al. 1988) are all able to induce fever when injected
in rabbits, and could be responsible for some of the activity of EP, but
their specific activity (10-1000 times less than IL1 in vivo) indicates that
most of this activity is probably attributable to the presence of IL1.
Similarly, MCF and catabolin-like activities are exhibited by TNF alpha
(Dayer et al. 1985; Saklatvala, 1986) but at concentrations 10-100 times
greater than IL1.
Interleukin 1 is classically described as a macrophage product, but
in keeping with its essential role in host response, many different cell
types have been reported as sources of IL1 (Table 1.10).
Interleukin 1 production is activated by the recognition of microbial
components (reviewed in 2.C.1, pp 67-69) or during antigen-mediated immune-
responses. During MHC-restricted T cell activation, production of IL1 by
the antigen-presenting cell (APC) seems important.
This was demonstrated by showing that addition of IL1 could achieve T cell
activation to specific antigen, when mononuclear cells were depleted of APC
by density centrifugation (Smith et al., 1980) or by anti la treatment
(Durum, Gershon, 1982; Durum et al, 1984). Addition of IL-1 restored
antigen presentation when APC were paraformaldehyde-fixed (Scala and
Oppenheim, 1983) or UV-treated (de Freitas et al. 1983). Interestingly, all
the cells reported to perform antigen presentation have been shown to be IL1
producers: these include monocytes/macrophages (Gery et al, 1972) B cells
(Matsushima et al, 1985), endothelial cells (Wagner et al, 1985) and
dendritic cells (Duff et al. 1985).
Cytokines produced during T cell activation (lymphokines) are able to
induce IL-1 or synergize with other cytokines in triggering such production.
These interactions are now increasingly being characterized: IFN gamma
synergizes with minute quantities of LPS or TNF in inducing IL-1 (Arend et
al, 1985; Boraschi et al. 1984; Arenzana-Seisdedas et al. 1985) and enhances
MHC class II expression, in absence of which IL-1 production is greatly
reduced (Gilman et al, 1983). Other cytokines produced during immune
response that are able to induce IL-1 include IL2 (Numerof et al. 1987), TNF
alpha (Dinarello et al, 1986; Libby et al, 1986), CSF's (Moore et al, 1980;
Ralph et al. 1987), IL-1 itself (Warner et al. 1987), and a low molecular
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weight newly characterized cytokine (Takacs et al. 1987).
In response to membrane IgM perturbation (Matsushima et al . 1985) B-
lymphoblasts release IL1, and immune complexes formed in the presence of
excess antigen will induce monocyte IL-1 production (Duff et al. 1982; Arend
et al, 1985). The multiple roles of IL1 in the immune system confer
powerful adjuvant effects in vivo (Staruch et al. 1983)
The human IL1 alpha gene (12kb) has seven exons and six introns. The
first and seventh exons code for 5' and 3' untranslated mRNA regions, the
last containing the octameric sequence probably related to mRNA instability
(Shaw, Kamen, 1986). The IL1 alpha transcript codes for a propeptide of
271aa (MW 30.6 KDa) that is then processed to a mature acidic (pI5) peptide
of 159aa (MW 17.5 KDa) (March et al. 1985).
The human IL1 beta gene, located on chromosome 2, also has seven exons;
the transcript codes for an acidic propeptide of 269aa (MW 30.75 KDa) that
is cleaved to a mature neutral peptide of 153aa (MW 17.3 KDa) (March et al.
1985). Processing of both IL1 propeptides is believed to happen near or
within the plasma membrane. The mechanism by which IL1 leaves the cytosolic
compartment is not known; unlike other secretory proteins, IL1 alpha and IL1
beta lack classical hydrophobic signal sequences. It has been suggested
that IL1 is only released from damaged cells (Gery, Lepe-Zuniga, 1983) or
that intracellular processing can provide a release mechanism different from
other secretory proteins.
Both mature IL1 forms and the IL1 alpha propeptide compete equally for
a single class of high affinity receptor on target cells. The ability of IL1
alpha and IL1 beta to bind to the same receptor and mediate similar
biological actions in vitro is surprising considering the low degree of
homology between the two molecules. When the two IL1 proteins are compared,
only a few regions of amino acid homology exist (approximately 26% overall).
Protein domains have been termed A-E (Auron et al. 1985). Since the first
two (A,B) are contained in the precursor sequence that is missing from the
mature form of IL1, regions of homology in C, D and E are likely to
represent the conformational "active site" of the IL1 molecule. The other
possibility is that the two molecules, even with different structures, are
able to interact successfully with a complex receptor molecule(s) assembled
in such a way that both IL1 molecules are recognized. In fact, no
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convincing report exists of major differences in bioactivity between IL1
alpha and beta, even if it has been recently suggested that IL1 alpha is
preferentially expressed on the cell membrane, predicting a role in cell-
cell interactions (Conlon et aj., 1987). The wide range of biological
activities of IL1 involves an enormous number of different cell types. All
of these cells have been shown to have specific cell surface receptors for
IL1 (reviewed by Dower, Urdal, 1987). The number of receptor ranges from
less than 50 in some T cell lines to about 5000 in some fibroblast lines.
Competitive binding studies indicate that IL1 alpha and IL1 beta share the
same receptor (Dower et al. 1985; Bird, Saklatvala, 1986; Matsushima et a),
1986; Mizel et al. 1987, Mosley et al. 1987).
The IL1 receptor has been characterized in human and murine cells by
covalent cross-linking and ligand blotting, as a moiety of around 80KDa
(Dower et a), 1985; Bird, Saklatvala, 1986) and 60-70KDa IL1 binding
proteins have been reported on the surface of B cells (Matsushima et al,
1986A; Horuk et al, 1988). The murine receptor appears to be a heavily
glycosylated protein: N-glycanase treatment reduces its MW from 80KDa to
62KDa and molecular cloning (Sims et al., 1988) revealed a 64.6KDa
transmembrane protein, part of the Ig supergene family. There is some
evidence consistent with the presence of a second chain within the IL1
receptor: covalent cross-linking studies have reported molecular complexes
of different sizes, indicating that IL1 also associates with polypeptides of
43KDa (Martin et al. 1988) or 100 KDa (Bird et al. 1987) on murine cells.
Of the many studies investigating the post-receptor events after IL1
binding, IL1-dependent phosphorylation has been reported for 27KDa
(Saklatvala, 1988), 41 KDa (Martin et al. 1986) and 65KDa (Matsushima et al.
1987) polypeptides.
The wide range of actions that makes IL1 a principal mediator of host
defence against infection, injury or antigenic challenge is outlined in
Tables 1.8 to 1.9. These powerful effects also confer on IL1 a major
pathogenetic potential if its production or target cell responsiveness is
dysregulated in inflammatory and immune diseases.
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Vascular Smooth Muscle Cells
Induction of IL1
(Gery et al, 1972, Maizel et al, 1981)
(Smith et al, 1980: Hagiwara et al, 1987)
(Kaye et al, 1984)
(Ho et al, 1987)
(Kasahara et al, 1985)
(Hagiwara et al, 1987)
(Kovacs et al, 1986)
(Miossec et al, 1984)
(Wood et al, 1976; Leibson et al, 1982;
Chiplunkar et al, 1986)
(Hoffmann et al,1979; Giri et al, 1984;
Chiplunkar et al, 1986)
(Luger et al, 1983; Sauder et al, 1984)
(Onozaki et al, 1985; Lovett et al, 1986)
(Dinarello et al, 1983)
(Dinarello et al, 1987)
(Herman et al, 1985)
(Dempsey et al, 1984)
(Subramanian, Bray, 1987)
(Luger et al, 1983; Sauder et al, 1984)
(Pincus et al, 1986)
(Van Damme et al, 1985)
(Zucali et al, 1986)
(see Musculo Skeletal Tissuesl
(Seelentag et al, 1987; Zuckermann et al, 1985;
Broudy et al, 1987)
(Broudy et al, 1987; Seelentag et al, 1987)
(Broudy et al, 1987; Seelentag et al, 1987)
(Wagner et al, 1985)
(Pober et al, 1986)
(Warner et al, 1987; Dustin et al, 1986)
2. CENTRAL NERVOUS SYSTEM
Astrocyte proliferation
Production of PGE,, in
hypothalamic~cells



















































(Ramadori et al, 1985; Perlmutter et al, 1986;
Darlington et al, 1986; Gauldie et al, 1987)
(Darlington et al, 1986; Gauldie et al, 1987)
(Darlington et al, 1986; Perlmutter et al,1986)
(Perlmutter et al, 1986)
(Darlington et al, 1986)
(Darlington et al, 1986)
(Gowen et al, 1983)
(Rifas et al, 1984)
(Gowen et al, 1983)
(Dingle et al, 1978; Saklatvala, 1981; Gowen et al, 1984)
(Saklatvala et al, 1984)
(Richardson et al, 1985)
(Herman et al, 1984; Gowen et al, 1984; Saklatvala et al, 1985).
(Chang et al, 1986)
(Pujol et al, 1984; Tyler, 1987)
(Tyler, 1985A; Tyler, 1985B)
(Schmidt et al, 1982)
(Korn et al, 1980; Postlewaite et al, 1983)
(Mizel et al, 1981)
(see Immune Svsteml
(Kahari et al, 1987)
(Bhatnagar et al, 1986)
(Dayer et al, 1976,; Dayer et al, 1980; Mizel et al, 1981)
(Dayer et al, 1977; Mizel et al, 1981; Krane et al, 1982)
(Ooi et al, 1983)
(Rossi et al, 1985)
(Rossi et al, 1985)
(Bevilacqua et al, 1984)
(Albrightson et al, 1985)
(Bevilacqua et al, 1985; Pober et al, 1986)
(see Immune Svsteml
6. CYTOSTATIC/CYTOTOXIC EFFECTS
Human pancreatic islet beta
cells
Some transformed cell lines
Melanoma cells
(Bentzen et al, 1986)
(Onozaki et al, 1985 B)
(Lachmann et al, 1986)
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TABLE 1.9 Some biological activities of IL1 IN* VIVO
- Hypotension
- Fever
- Slow wave sleep
- Anorexia, weight loss
- Neutrophilia
- Acute phase proteins
(SAA, SAP, Fibrinogen,









- Bone marrow cell-cycling
- Induction of circulating CSFs
- Adjuvant effect
- Decreased cytocrome P450
enzyme activity
- Neutrophils accumulation in
joints
- Cartilage proteoglycan release
- Enhanced resistance to bacterial
infection
(Dinarello, 1987; Okusawa et al, 1988)
(Beeson, 1948; Atkins, 1960; Murphy et al, 1980;
Dinarello et al, 1986)
(Kreuger et al, 1984)
(McCarthy et al, 1984)
(Kampschmidt, Pulliam, 1978)
(Kampschmidt et al, 1973; Sipe et al, 1979; Sztein et
al 1981; Dinarello, 1984)
(Kampschmidt and Pulliam, 1978)
(Besedowsky et al, 1986)
(Besedowsky, del Rey, 1987)
(Neta et al, 1986)
(Neta et al, 1987B)
(Vogel et al, 1987)
(Staruch and Wood, 1983)
(Ghezzi et al, 1987)
(Granstein et al, 1985; Pettipher et al, 1986)
(Pettipher et al, 1986)
(Ozaki et al, 1987)
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Helper T cell clones
EBV transformed B cells
B cells
NK/LGL cells





















(Gery et al, 1972; Gery and Lepe Zuniga, 1983)
(Flynn et al, 1982)
(Simon and Willoughby, 1981)
(Dinarello et al, 1968)
(Wood et al, 1985)
(Murphy et al, 1980)
(Tartakowsky et al, 1986, Acres et al, 1987)
(Matsushima et al, 1985)
(Matsushima et al, 1985; Chiplunkar et al, 1986)
(Scala et al, 1984)
(Yamashita et al, 1987)
(Libby et al, 1986)
(Libby et al, 1986; Wagner et al, 1985)
(Fontana et al, 1982)
(Giulian et al, 1985)
(Fontana et al, 1984)
(Sauder et al, 1982; Luger et al
(Sauder et al, 1984)
(Duff et al, 1985)
(Lovett et al, 1983)
(Goto et al, 1984)
(Iribe et al, 1983)
(Ollivierre et al, 1986)
(Grabner et al, 1982)
(Le et al, 1987)
(Gahring et al, 1984)
1982)
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I.e. TUMOUR NECROSIS FACTOR
Of the many effects induced in vivo by endotoxin, one of the most
impressive is haemorrhagic necrosis of tumours. This phenomenon, initially
observed at the end of the last century (Coley, 1893), was later
characterized (Shear, 1944) by isolation of the active moiety
(lipopolysaccharide, LPS) from culture broths, which had been used in the
previous experimental work (Shear, Andervout, 1936). However, the lethal
effects of LPS ("endotoxic shock": profound hypotension, coagulopathy and
multiple organ failure) precluded its use in therapy and directed the
interest of clinical cancer research in other directions.
New interest arose two decades ago, when it was demonstrated that the
phenomenon of tumour necrosis was related to a transferrable factor
(O'Malley et al. 1962) in the serum of animals in endotoxic shock. Later,
it was reported (Carswell et al. 1975) that BCG priming of the mouse before
LPS stimulation led to a higher yield of transferrable anti-tumour
activity. Tumour necrosis in the recipient animal was dose-dependent and not
related to LPS carry-over. This factor was produced by the macrophage
population (Matthews, 1978) and tumour necrosis in vivo was related to
cytotoxicity for certain cell lines in vitro (Carswell et al. 1975).
The identification of a bioassay in vitro led to the isolation of
human cell lines producing high yields of TNF activity. This allowed
biochemical purification of TNF (Aggarwal et al. 1985) and cloning of the
human TNF cDNA and genomic sequence (Pennica et al. 1984; Shirai et al.
1985; Wang et al. 1985; Marmenout et al. 1985). The molecular cloning of
human TNF led immediately to two important observations:
a. "Tumour Necrosis Factor" and "Cachectin" are the same molecule
As the name implies, "Cachectin" is a molecule isolated in the course
of studies on the metabolic changes occurring in animals with chronic
infectious diseases and leading to wasting diathesis (Rouzer, Cerami, 1980).
Cachexia could be reproduced by injection of LPS in an animal model, and it
was related to a transferrable factor, termed "Cachectin", with multiple
biological actions including the inhibition of lipoprotein lipase activity
(Kawakami, Cerami 1981). This biological activity was the basis for the
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biochemical purification of the molecule and an N-terminal sequence of
cachectin was obtained. This was found to be identical to that of TNF,
which had been cloned a few months before (Pennica et a!, 1984).
Immunological identity (Beutler et al. 1985) and subsequent molecular
cloning of cachectin (Caput et al, 1986) confirmed that this and tumour
necrosis factor were the same molecule.
b. "Tumour Necrosis Factor" and "Lymphotoxin" are different but related
polypeptides
Another cytotoxic molecule, lymphotoxin (LT), had been described as a
factor produced by T lymphocytes in the presence of antigen (Ruddle,
Waksman, 1967; Granger, Williams, 1968). The relationship between LT and
TNF was unclear because of their similar biological activities. The
molecular cloning of human LT (Gray et al. 1984) and of TNF (Pennica et al.
1984) demonstrated that the two proteins were separate entities. Regardless
of the low degree of homology (28% homology at a.a. level; Nedwin et al,
1985), the two proteins bind and compete for the same receptor (Hass et al.
1985), mediating similar actions in vitro.
Following these observations it was proposed (Shalaby et al. 1985) to
adopt the name of TNF alpha for TNF and Cachectin and to use TNF beta to
indicate lymphotoxin.
The predominant cell source of TNF alpha is the macrophage (Old,
1985). Other human cell types reported to synthesize TNF alpha include T
cells (Cuturi et al. 1987) and NK cells (Koyabashi et al. 1986), as well as
B lymphoblasts (Williamson et ai, 1983), basophils (Jadus et al, 1986) and
mast-cells (Steffen et al. 1987).
TNF production by these cells is activated by recognition of microbial
components, either by direct interaction or possibly via an antigen mediated
mechanism. TNF alpha seems to be implicated in some aspects of cell-
mediated immune responses: TNF alpha production occurs during the early
phase (4hr) of the MLR reaction (Ranges et al. 1987), treatment with anti-
TNF alpha antibody dramatically modifies GVH disease (Piguet et al. 1987)
and the presence of TNF alpha is thought to be related to several features
of the Schwartzmann reaction (Palladino et al. 1987).
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Activation of T cells with PHA or Con A within a mononuclear cell
population leads to production of TNF alpha (Debets et al. 1987) probably
due to action of T cell products on monocytes, as separated populations do
not produce TNF in these conditions (Cuturi et al. 1987). In fact, IL-2 has
been shown to induce TNF (Numerof et al. 1987; Nedwin et al. 1985), and IFN
gamma synergizes with minute quantities of LPS in TNF induction (Gifford,
Lohmann-Matthes, 1987). Both lymphokines up-regulate TNF receptor in target
cells (Scheurich et al. 1987) and IFN gamma enhances TNF alpha translation
in murine macrophages (Beutler et al, 1986). Colony stimulating factors
have also been reported to induce TNF production (Gao et al. 1987; Warren,
Ralph 1986) and TNF itself is able to induce further TNF synthesis (Old,
1987). Another potentially relevant amplification circuit could be the
induction of IL1 (Dinarello et al. 1986) which has also been shown to induce
TNF activity (Philip, Epstein 1986).
The human TNF alpha gene is located on chromosome 6, within the MHC
region, between HLA DR and HLA-A (Spies et al. 1986) and 1.1Kb upstream from
the TNF beta gene. It is composed of 4 exons and 3 introns (3.3Kb). In the
5' untranslated region there is significant homology with TNF beta and, in
common with other cytokines, the 3' untranslated region contains overlapping
repeats of an octameric sequence thought to be related to mRNA instability
(Shaw, Kamen, 1986). This duplication of functions and tandem arrangement
in the genome of different proteins able to compete for the same receptor is
not unique to TNF alpha and TNF beta within cytokines, as human IFN alpha
and beta (chromosome 9) and murine IL1 alpha and IL1 beta (chromosome 2),
also share these characteristics.
Translation of the TNF alpha mRNA produces a 233 a.a. polypeptide
containing a highly hydrophobic leader sequence of 26aa. The first 76 a.a.
of the N-terminus are cleaved during secretion, leaving 8 smaller fragments
and the mature TNF alpha peptide (157 aa). The calculated MW of the mature
peptide (17.3KDa) is in agreement with SDS-PAGE analysis of human purified
protein (Aggarwal et al. 1985). TNF alpha does not appear to be glycosylated
and aggregates to form biologically active oligomers.
Mature TNF alpha protein can represent up to 1% of total secreted
protein in activated macrophages (Beutler et al. 1985C) and concentrations
of up to 0.3uM are obtainable in the blood of endotoxaemic mice (Abe et al.
1985). When injected (Beutler et al. 1985D), the half life of TNF alpha in
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plasma was calculated as about 6 minutes, with the protein accumulating in
organs such as liver, kidneys, lungs and GI tract.
The TNF alpha receptor binds both TNF alpha and TNF beta with equal
affinity (Hass et al, 1985). The receptor is composed of at least two
chains of 75 KDa and 95KDa (Nedwin et al. 1985) and is internalized with the
ligand (Tsujimoto et al, 1985). The TNF receptor can be expressed at
relatively high levels, especially in the presence of IFN gamma (1000-10000
molecules/cells) (reviewed by Aggarwal et al. 1987).
By interaction with its receptor, TNF alpha exhibits a considerable
range of biological activities, summarized in Tables 1.11 and 1.12. Of the
many actions of TNF, its antitumoural activity in vitro and in vivo has
received the greatest attention. After experimentation in animals,
recombinant human TNF alpha is now being tested in phase I clinical trials.
A group of biological actions of TNF, on the basis of which
"Cachectin" had been isolated, are those related to endotoxin shock and
wasting diathesis (cachexia). The observation that lipaemia in cachectic
animals with chronic parasitic infections (Rouzer, Cerami, 1980) was
reproducible by LPS injection in mice led to the identification of a factor
that reduced lipoprotein-lipase activity (Kawakami, Cerami, 1981). Later
experiments demonstrated that wasting was related to the anorectic actions
of TNF (Cerami et al. 1985) and to inhibition by TNF of the expression of
enzymes involved in fat and glucose metabolism (Torti et al, 1985; Min,
Spiegelmann, 1986) leading to transient hyperglycaemia and terminal
hypoglycaemia (Lee et al, 1987). An elegant study (Oliff et al, 1987)
demonstrated that TNF alpha could produce in vivo a severe wasting
diathesis, reminiscent of cancer cachexia, if the exposure was at low but
constant dosage. On the contrary, high doses of TNF alpha injected i.v. in
rats (Tracey et ai, 1986), produced a lethal series of systemic
manifestations, indistinguishable from those of endotoxic shock (reviewed by
Beutler and Cerami, 1987). The hypothesis of a primary role for TNF alpha
in endotoxic shock was supported by experiments in mice (Beutler et al,
1985) and primates (Tracey et al. 1987) in which passive immunization with
anti TNF alpha antibodies prevented death from a lethal dose of LPS. Anti
TNF alpha monoclonal antibodies are currently being tested in human phase I
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trials. Both the general anti-tumoural activities of TNF and its role in
the body's response to microbial invasion point to a role of TNF in
maintenance of homeostasis.
It would be predictable that a factor with a first-line role in host
defence should be able to elicit two of its most basic mechanisms, i.e.
fever and inflammation. With the availability of recombinant reagents, a
role for TNF alpha in inflammation has been established. TNF alpha
administration in vivo induces fever (Dinarello et al, 1986), acute phase
response (Mortensen el al, 1987), neutrophilia (Ulich et a!, 1987) and
potentiation of the immune response (Ghiara et al, 1987). Other actions
potentially important in chronic inflammation include induction of MHC class
I and class II molecules, angiogenesis and induction of adhesion molecules
such as ICAM 1. TNF also induces the proinflammatory and catabolic (MCF-
like) activities of IL1 on musculo-skeletal tissues, such as induction of
PGE2 and collagenase release from mesenchymal cells and bone and cartilage
resorption (see Tables 1.11 and 1.12).
TNF alpha also interacts more widely in the cellular cytokine network:
it has been shown to induce directly IL1, GM-CSF, IL6, G-CSF and M-CSF and
to be induced by itself, IL1, M-CSF, GM-CSF and IL2.
The striking similarities between TNF and IL1 have recently been
reviewed (Dinarello, 1986; Dinarello, 1987; Le, Vilcek, 1987). The
mechanism by which structurally dissimilar molecules can achieve very
similar actions is unknown and further studies are needed to elucidate why
such redundancies should have been maintained through evolution.
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TABLE 1.11 Some biological effects of TNF alpha IN VITRO
1. IMMUNE SYSTEM
T Cells (previously activated)
enhancement of proliferation
enhancement of HLA DR, IL2 receptor
IFN gamma production
B Cells (previously activated)
enhancement of proliferation and ab












augment, cytotox. for Candida A
Eosinophils
enhanced cytotoxicity to parasites
Fibroblasts
induction of IL6
increased class I expression
inhibits fibroblast accessory function
induction of IL1
Endothelial cells






Other actions in vitro
augmentation of MHC class 2
on islet cells
inhibition of haematopoiesis in








2. CENTRAL NERVOUS SYSTEM
astrocyte proliferation
hypothalamic cell PGE, production
enhancement of MHC cTass II
expression of glioma cells
(Yokota et al. 1988)
(Scheurich et al. 1987)
(Kashiwa et al. 1987, Jelinek, Lipsky, 1987)
(Dinarello et_al, 1986; Nawroth et al. 1986)
(Munker et al. 1986)
(Philip, Epstein, 1986; Feinman et al, 1987)
(Philip, Epstein, 1986)
fBerkow et al. 1987; Tsuiimoto et al, 1986)
(Shalaby et al, 1985; Klebanoff et al. 1986;
Gamble et al. 1986)
(Djeu et al, 1986)
(Silberstein, David, 1986)
(Kohase et al, 1986)
(Collins et al. 1986)
(Le, Vilcek. 1987)
(Le et al. 1987)
(Collins et al. 1986)
(Munker et al. 1986; Seelentag et al, 1987)
(Seelentag et al, 1987)
(Seelentag et al. 1987)
(Libby et al. 1986; Nawroth et al. 1986)
(Pober et al. 1986)
iPuiol-Borrel et al. 1987)
(Degliantoni et al. 1985; Broxmeier et al, 1986)
(Takeda et al, 1986; Trinchieri et al. 1987)
(Wong, Goeddel, 1986; Mestan et al. 1986)
(Paraut et al, 1980)
(Palladino et al. 1987)
(Lachman et al. 1987)
(Blatteis et al, 1987)




acute phase proteins in human
hepatoma lines









increased adherence to PMN
increased ICAM 1 expression
increased procoagulant activity
and decrease of thrombomodulin
endothelial cells rearrangement
angiogenesis
5. MUSCULO SKELETAL TISSUES
(Darlington et al. 1986; Perlmutter et al. 1986)
(Torti et al. 1985; Kawakami et al. 1982)
(Torti et al. 1985; Min, Spiegelmann, 1986)
(Min, Spiegelmann, 1986)
(Lee et al. 1987)
(Gamble et al. 1985)
(Pober et al. 1986)
(Bevilacqua et al, 1986; Stein and Nawroth, 1986)
(Stolpen et al. 1986)
(Leibovich et al. 1987)
Bone
bone resorption and inhibition
of bone formation
induction of OAF activity
from osteoblasts
Cartilage














inhibition of c-myc expression
(HL60, HeLa cell lines)
(Bertolini et al, 1986; Stashenko et al, 1987)
(Thomson et al. 1987)
(Saklatvala, 1986)
(Vilcek et al. 1986)
(Dayer et al. 1985)
(Elias et al, 1987)
(Mochan, Armor, 1987)
(Dayer et al, 1985)
CTracev et al. 1986)
(Helson et al. 1975; Old, 1985; Ruggero, Baglioni, 1987)
fKronke et al, 1987; Yarden, Kimchi, 1986)
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TABLE 1.12 Some effects of TNF alpha IN" VIVO





metabolic acidosis, final hypo-
glycaemia, hyperkaliaemia, death,
diffuse visceral necrotic lesions









enhancement of in vivo response to
T cell dependent antigens




decreased p450 cytochrome activity




(Oliff et al, 1987)
(Cerami et al, 1985)
(Wei et al. 1987)
(L'lich et al. 1987)
(Reviewed by Playfair, 1987)
(Ghiara et al, 1987)
(Vogel et al. 1987)
(Mortensen et al. 1987)
(Kreuger et al, 1987)
(Okusawa et al, 1987)
(Ghezzi et al, 1987)
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l.d. RHEUMATOID ARTHRITIS
Rheumatoid arthritis (RA) is a chronic condition affecting 2-3% of the
population, with prevalence and clinical manifestations being slightly
variable in different countries. It is a disease with major social
consequences because it predominantly affects adults during their working
life. The natural history of the disease is variable, but it is
characterised by remissions and exacerbations with progressive joint
deformity.
RA is a sterile inflammation of both small and large joints, often
involved symmetrically. In addition, extra-articular manifestations such as
rheumatoid nodules, vasculitis, neuropathy, scleritis, pericarditis,
lymphadenopathy and splenomegaly may occur. The articular features of
classical RA include pain and stiffness that improve with motion, joint
swelling due to synovial proliferation and production of inflammatory
exudate (synovial fluid) within the joint cavity. The disease can have an
insidious or acute onset with an unpredictable course and prognosis. Some
patients have an unrelenting progression to deformities: more typically
episodes of acute arthritis are interspaced with periods of low activity or
occasional complete remission.
In the majority of patients, cartilage and bone involvement becomes
evident at radiographic examination as narrowing of the joint space (usually
occupied by radio-translucent cartilage) and subchondral osteopaenia which
is frequently followed by the appearance of bone erosions. The progressive
damage of the articular structures (bone, cartilage, tendons and ligaments)
by this inflammatory process, in conjunction with mechanical forces,
frequently lead to characteristic deformities of RA. These result in
varying loss of functional capacity.
The histopathology of RA in the joint consists of an initial
hyperaemic swelling of the normally oligocellular synovial membrane,
followed by hyperplasia and hypertrophy of the lining cells, extensive
proliferation of small blood vessels together with massive infiltration by
mononuclear cells. Many of these cells (mainly T-lymphocytes) are
aggregated into follicles, particularly around small blood vessels.
Transiti onal areas consist of a mixture of macrophages , B and T
lymphocytes, plasma cells and fibroblasts in the connective tissue stroma.
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This hypercellular tissue forms villous projections and is known as
"pannus". This is able to invade adjacent tissues and leads to the
destruction of articular cartilage, ligaments, bone and tendons. The
synovial exudate, that frequently accumulates in the joint space, mainly
contains polymorphonuclear cells, which are usually sparse in the
hyperplastic synovial tissue.
Symptomatic treatment relies on the use of analgesic/anti-inflammatory
drugs (NSAIDs). If the disease remains active and particularly if
progressive joint deformity is occurring, "disease modifying drugs" are
often introduced. These drugs, which include anti-malarials, gold salts, d-
penicillamine and various immunosuppressive agents may well affect the
course of the disease and occasionally induce clinical remission.
Corticosteroids (local and systemic) are also used to suppress inflammation.
Although these various treatments often improve the symptoms of RA,
they do not offer a cure. This possibility seems more likely to follow an
understanding of the aetiology and pathogenesis of the disease.
Several types of association of arthritis with infections are well
recognized (viral/bacterial arthritis, Lyme disease, rheumatic fever,
Reiter's syndrome). Despite considerable experimental effort (reviewed by
Saag, Bennett, 1987; Phillips, 1988) no clear association with infectious
agents has been shown in RA.
The expression of MHC class II products on virtually all cells present
in the synovial infiltrate (T, B cells; macrophages, dendritic cells), the
hypergammaglobulinaemia often present and the dramatic response to
"immunosuppressive" drugs such as steroids, suggest that immunopathogenic
mechanisms operate in RA. A clear manifestation of autoimmunity is the
presence of "Rheumatoid Factor", an autoantibody (usually IgM/anti-IgG) that
occurs in a majority of patients ("seropositive RA"). Ig immune complexes
are, in theory, able to activate a cascade of immune reactions, such as the
complement pathway, and induce cytokine production (IL1 included). There is
no strong evidence, however for a major pathogenetic role of rheumatoid
factors and their occurrence is mainly of diagnostic value.
An association between RA and HLA-DR4 was recognized from
epidemiological studies. Seventy per cent of UK patients with RA have this
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haplotype and an individual with HLA-DR4 is about 4 times more likely to
develop the disease. The association between class II molecules and
immunity is related to the MHC restriction of antigen presentation. It is
noteworthy that within the MHC regions (human chromosome 6) there are
complement (C2, C4, factor B) and TNF beta genes, with the TNF alpha gene
only 1100 nucleotides upstream.
This association with HLA-DR is at the moment being extensively
studied in the hope that the genetic structure might elucidate possible
pathogenic mechanisms. However, the observation that of individuals bearing
HLA DR4 only 5% actually develop RA suggests that a DR4-related mechanisms
might be one of many cofactors that can influence, but probably not
determine, the initiation of the disease (reviewed by de Vries, 1988).
Of particular interest in the pathogenesis of RA has been the
potential role of cytokines and IL1 in particular. The pro-inflammatory,
catabolic and systemic actions of IL1 seem very relevant to the pathology of
RA. At the time work for this thesis was commenced, the first reports of
IL1 in synovial fluids, showing presence of such mediator at the site of the
rheumatoid lesion, were being published.
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I.e. GOUT
This is a metabolic disease, with predominantly articular
manifestations, associated with the presence of high levels of uric acid in
the blood. In humans, uric acid is the major end product of purine
catabolism and is mainly excreted in the urine.
The elevation of uric acid levels can occur as a consequence of
overproduction or underexrection of urate or a combination of both.
Overproduction may be secondary to an increased turnover of nucleic acids as
occurs in a number of diseases such as myeloproliferative and
lymphoproliferative disorders, multiple myeloma and pernicious anaemia.
Rarely, the overproduction occurs as a consequence of an X-linked inherited
enzyme deficiency (hypoxanthine-guanine phorphoribosyl transferase [HG-PRT])
of the purine metabolic pathway or of a similarly inherited hyperactivity
(phosphoribosyl pyrophosphate synthetase [PRPPs]). More commonly, the
molecular defects resulting in overproduction are undefined, but are
probably polygenic. A defect in the renal excretion of uric acid can be
demonstrated in a high percentage of gouty patients but the precise renal
abnormality in the handling of urate is often undefined and it is, again,
believed to be of polygenic inheritance. Other conditions which can
interfere with renal excretion of uric acid include therapy with most
diuretic agents or low dose aspirin and renal insufficiency itself.
Gouty arthritis typically begins with an acute monoarthritis in the
lower limbs, often the first metatarsophalangeal joint. Unlike most other
types of arthritis the onset of joint inflammation is characteristically
very abrupt, often occurring at night with the involved joint being swollen,
painful and tender. The attacks can be polyarticular and occasionally
joints may become involved successively over a period of hours.
The gouty attack is usually accompanied by fever, neutrophilia and
elevated acute phase proteins. Compensated polarized light microscopy of
synovial fluid taken from an involved joint will reveal characteristic
needle-shaped negatively birefringent crystals of monosodium urate
monohydrate.
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These acute attacks of arthritis will resolve spontaneously over
several days or can be effectively controlled by treatment with NSAIDs or
colchicine. Between attacks the patient frequently remains asymptomatic,
usually maintaining elevated serum uric acid levels. Some individuals have
no more than a few attacks in a lifetime: when they are frequent, however,
and no exacerbating factors can be removed (e.g. cessation of diuretic
therapy), therapy is commenced with uricosuric agents or by using
allopurinol which inhibits the production of uric acid. In absence of
treatment, paroxysms of arthritis can recur with increasing frequency and
are associated with gradual degeneration of involved joints: loss of
articular cartilage, erosion of subchondral bone and infiltration of
periarticular structures by deposition of crystals. In the most severe
cases these deposits stimulate a fibrotic reaction and become clinically or
radiographically detectable ("tophaceous gout").
The acute attack of gouty arthritis is thought to be an inflammatory
response triggered by microcrystals of monosodium urate formed within the
joint as a consequence of hyperuricaemia or by shedding from pre-existing
intra-articular urate deposits.
Experimental intra-articular injection of MSU crystals in human
volunteers produced an inflammatory response very similar to gout
(Seegmiller et al. 1962). However, not all of the volunteers injected
developed the attack, suggesting that the presence of the crystals
themselves is a necessary but not sufficient stimulus for the inflammatory
sequelae.
It has been proposed that a direct effect of MSU crystals on
polymorphonuclear cells, induces release of pro-inflammatory enzymes and
chemotactic molecules in relation to phagocytosis (Phelps, 1969) or to the
membranolytic effects of these crystals (Wallingford, McCarty, 1971). Other
reported effects of MSU crystals, independent of phagocytosis or cell-lysis
include the induction of PGE2 and collagenase from fibroblast and monocytes
(McMillan et a), 1981; Hasselbacher et al, 1981) providing perhaps the
grounds for local inflammation but not explaining the systemic disturbance
observed in a patient with acute gout (fever, acute phase proteins,
neutrophilia). In a classical experiment (Phelps, McCarty, 1966) it was
proved that the presence of leukocytes was needed for gouty inflammation, as
leukopenic animals when challenged with intra-articular injection of MSU
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crystals, only developed a full attack after leukocytic reconstitution.
On theoretical grounds, a more satisfactory explanation for the
initiating mechanism of acute gouty arthritis would invoke the participation
of a soluble mediator (to explain the systemic involvement) of leukocyte
origin, released in presence of MSU crystals, with powerful inflammatory
consequences . These considerations identify pro-inflammatory cytokines as
potential candidates for this role.
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I f. OTHER CRYSTAL-RELATED ARTHRITIDES
Pseudogout
The deposition of crystals of calcium pyrophosphate dihydrate (CPPD)
is a very common x-ray observation (visible as articular cartilage
calcification) but these crystals only rarely cause arthritis. In those
patients that develop articular symptoms, the clinical pattern is varied.
An acute arthritis resembling an attack of gout is the commonest form and is
known as "pseudogout". This is usually a monoarthritis, especially
affecting the knee but more than one joint can be involved. Although to
locate the crystals may be difficult, they differ from MSU crystals because
of their irregular or rhomboid shape and positive birefringence.
A small percentage of patients have multiple joint involvement with
low grade inflammation, often mistaken for subacute RA.
Hydroxyapatite arthropathy
Hydroxyapatite (HA) is the crystal configuration in which calcium is
found in the human body, both in bones and in the majority of dystrophic
calcifications. Its commonest rheumatological association is in clinical
syndromes of calcific periarthritis, particularly affecting the subacromial
rotator cuff tendons of the shoulder.
Aggregates of apatite crystals (visible by electron microscopy) have
been found in a high percentage of osteoarthritis effusions, but HA crystal
deposition seems to be more clearly associated with an uncommon syndrome
named "Milwaukee Shoulder". This is a dramatic form of glenohumeral
osteoarthritis with bilateral rotator cuff defects (McCarty et al. 1981) and
high levels of collagenase and neutral protease in the synovial exudate,
where clumps of HA crystals can be found. In contrast to acute gouty
arthritis or RA, however, this synovial fluid is relatively acellular and
the synovial histology does not show any mononuclear cell infiltrate.
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l.g. Aims of the Study
At the start of this work (November 1984), there was only
circumstantial evidence for a pathogenic role of soluble mediators in human
arthritis.
Because of the potential role of IL1 in the genesis of chronic
inflammation and including the recently characterized TNF alpha (with its
similar pro-inflammatory activities) it was decided to investigate the
production of these cytokines. The experiments included initially the
induction of their release from human monocytes following different
stimulation and, in a second phase, the study of their gene expression and
cellular distribution.
The stimuli used in these studies included a variety of microbial
products as well as different crystals associated with human arthritis such
as Monosodium Urate, Hydroxyapatite and Calcium Pyrophosphate Dihydrate.
Monosodium Urate crystal deposition is clearly associated with the acute
attack of gout, but the events linking crystal precipitation and acute
inflammation are unclear. The inflammatory nature of acute gouty arthritis
and the systemic features of the disease seemed to be compatible with a
local overproduction of IL1/TNF following stimulation by MSU crystals.
In parallel studies, the presence of monocytic cytokines was tested at
the site of inflammation, i.e. in synovial fluids from arthritic patients.
This had not previously been done for tumour necrosis factor and only in
limited, non-quantitative studies for IL1.
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2. SECTION I :




The response of the host to microbial invasion involves several
pathophysiological mechanisms, including fever, release of acute phase
reactants from the liver, augmentation of circulating phagocytes, and
considerable changes in the functions of cell-mediated immunity. All of
these mechanisms ("acute phase response") are targeted to the removal of the
causative agent (Dinarello, 1984) and eventual activation of repair
mechanisms with tissue remodelling.
A variety of experimental evidence suggests that IL1 and TNF can play
a central role in mediating such responses through their wide range of
biological activities and with the cascade of soluble mediators triggered by
their actions on responsive cells population. The direct recognition of
microbial constituents is sufficient to induce IL1 and TNF from monocytes as
an early event in "innate immunity".
In parallel, IL1 production following antigen presentation potentiates
several aspects of the "adaptive" immune response.
Both of these host defence responses rely on recognition of the
microbial product to trigger a tightly regulated chain of events leading to
re-instatement of homeostasis. The work presented in this section studies
the induction, synthesis and release of IL1 and TNF in human monocytes in
vitro. This includes measurement of kinetics of mRNA accumulation,
immunoreacti ve and bioactive protein production and extracellular
translocation. In keeping with a putative role of IL1 and TNF in the host
response to microbial invasion, the stimuli tested included products of
bacterial and fungal origin, such as Staph. Aureus and Sacch. Cerevisiae
cell walls, E. coli endotoxin and Toxic Shock Syndrome Staph. Aureus
exotoxin.
To test the possibility that IL1 and TNF production could be induced
by non -microbial, non-antigenic, inflammatory particles, we tested the
inducing properties of three sterile, LPS-free synthetic crystal types






RPMI 1640 medium was bought as a sterile 10X liquid (Gibco Ltd,
Paisley, Scotland). Concentrated medium was reconstituted in sterile
conditions with LPS-free distilled water (Travenol) and buffered with sodium
bicarbonate (2.2g/l; Gibco). After addition of penicillin (lOOu/ml),
streptomycin (lOOug/ml) and Glutamine (2mM), pH was adjusted to 7.4 with
NaOH 6M (Sigma, Dorset, UK).
Foetal calf serum (FCS) (Gibco) was used at 5% unless otherwise
stated. Prior to purchase, samples of reserved batches were tested for LPS
content (Limulus Amebocyte Lysate- LAL test), for proliferation experiments
(murine fibroblasts and murine T cells) and murine fibroblast cytotoxicity.
Heat inactivation of FCS was carried out at 56° C, for 1 hour.
MEM (Eagle's Minimal Essential Medium; Sigma) was obtained as
powdered medium and reconstituted in sterile water, with 2.2g/l sodium
bicarbonate. The fluid was filter sterilized (Millipore, 0.22um sterile
filters). Antibiotics and glutamine were added as described for RPMI medium,
and the pH adjusted to 7.4 with NaOH.
2.b.l.2. Cell lines
Non-adherent cells not requiring defined exogenous growth factors
included the murine thymoma cells EL4.NOB.1 and human myelocytic leukemia
U937 cells. These were routinely cultured in RPMI, 1-5% FCS and divided
every 3-4 days according to their doubling times. EL4.NOB.1 was cultured at
low density (<1x10^/ml) in order to maintain responsiveness to IL1.
Non-adherent cells with special requirements for cell growth such as
the murine antigen-specific T-helper clone D10.G4.1 and the cytotoxic T
lymphocyte lines (CTL's), were cultured at low density and split every 2-4
days, when medium (RPMI 1640, 10% FCS) was replaced and 3-10%crude rat TCGF
preparation added. D10.G4.1 also required mitomycin-treated splenic antigen
presenting cells (H-2K mice) once every 7-10 days, and specific antigen
(Hen's Conalbumin) every 3-4 days. Protocols for the generation of crude
rat TCGF and feeder cells for the long term culture of D10.G4.1 are
presented in Appendix (p 209).
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Adherent cells used included a number of lines of human synovial
fibroblast origin and L929 cells (murine nipple fibrosarcoma fibroblasts),
grown in RPMI and MEM respectively, 10% FCS. The human synovial fibroblasts
were raised by culturing synovial fluid cells from patients with rheumatoid
arthritis in 10% FCS RPMI. After 2 weeks culture, all the cells were of
fibroblast morphology and the cultures were maintained with the addition of
0.01% of a highly purified IL1 peptide ("22KDa factor" from J. Van Damme,
Univ. of Leuven, Belgium) in fresh medium once weekly. These lines grew
continuously to a maximum of 22 weeks.
Adherent cells were grown to a subconfluent status, when the spent
medium was removed, the cell monolayer washed with saline and cells loosened
by Trypsin/EDTA (Gibco) treatment. Cells were removed with vigorous
pipetting in 10% FCS medium, and used for experiments or subculture.
2.b.l.3. Preparation of cells for induction experiments
Peripheral blood from normal volunteers was taken into preservative-
free heparin (20u/ml, Unihep-Leo Labs, UK) and mononuclear cells obtained by
density centrifugation (Lymphoprep, pyrogen/tested, 1077 density, Nyegaard,
Oslo). Mononuclear cells were washed twice in serum-free RPMI and allowed
to adhere to multiwell plates (24 well plates, Linbro-Flow Labs, UK; Nunc,
Denmark) or petri-dishes (4cm diameter, Nunc, Denmark). After 40 mins
adhesion at 37° C, 5% CO2, non-adherent cells were harvested and by
comparison of differential and total cell counts before and after adherence
the volume of medium to be added to the adherent cells to obtain
lxlO^monocytes/ml was estimated. In a few experiments, U937 human monocytic
leukemia cells were used, harvesting them at the third day of subculture.
Following incubation of the cells at 37° C 5% CO2 in the presence or
absence of stimuli for various lengths of time, supernatants were clarified
by centrifugation at 1800g for 15mins and stored at -70P C. Supernatants
represent the "extracellular" fraction. In some experiments, a volume of
fresh medium equal to the supernatant was used to wash the centrifuge tube
and recover cells that had become non-adherent. This was returned into the
relevant well containing the adherent population. After 3 cycles of freeze-
thawing the whole preparation will represent the "cell-associated" fraction.
In time course experiments, cells were prepared in petri-dishes and samples
individually harvested at the different time points.
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The protocol used to study the kinetics of cytokine cellular
distribution is described in more detail elsewhere (2.C.2.6., pp 71-72).
Adherent synovial exudate mononuclear cells were also used in
induction experiments. These were obtained from fresh synovial fluid from
patients with rheumatoid arthritis, treated with hyaluronidase (Sigma,
bovine testicular hyaluronidase, 150U/ml) for 45 mins at 37° C. Cells were
washed twice in serum-free medium before density centrifugation and
selection by plastic adherence.
2.b.2. STIMULI
Stimuli tested in this section for their ability to induce IL1 or TNF
production in human mononuclear cells, included:
Lipopolysaccharide (LPS)
Lipopolysaccharide (E. coli 0127:B8 strain, TCA extracted, Sigma) was
resuspended at lmg/ml in saline and stored at 4° C until used.
Heat killed Staph. Aureus cells walls (HKS)
These were kindly donated by Dr E. Atkins (Dept. Internal Medicine,
Yale University, New Haven, CT) and prepared in his laboratory according to
the method described by Morse (1962). Autoclaved, acetone-dried bacteria
(Staph. Aureus, NYH-6, 80/81 strain) were disrupted in a Mickle
disintegrator. Cell walls were prepared by centrifugation, treated with
RNase, repeatedly washed in LPS-free saline, and resuspended at 500ug =
g
4x10 cell walls/ml saline.
Toxic shock syndrome exotoxin (TSS)
This was a gift from Dr D. Shapiro (Dept. Pathological Biochemistry,
WGH, Glasgow), who also tested for the presence of contaminating LPS
(<20pg/ml by LAL assay). Bacterial broth of a Staph. Aureus isolate from a
patient with Toxic Shock Syndrome was concentrated x5 by YM-10
ultrafiltration (Amicon, UK) and stored at -2(f C until used. Staph. Aureus
strains from patients in Toxic Shock Syndrome produce a 20-30KDa exotoxin,
which has been described as one of the most powerful inducers of IL1
synthesis (Ikejima et al. 1984).
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Saccharomyces Cerevisiae cell walls (Zymosan A)
Fungal cell wall extracts were purchased from Sigma (Zymosan A,
Cat. No. Z4250). This is prepared by trypsin digestion of Saccharomyces
Cerevisiae and purified by solvent extraction and acid-washing.
Proinflammatory crystals
Crystals of monosodium urate (MSU), hydroxyapatite (HA) and calcium
pyrophosphate dihydrate (CPPD) were kindly given by Dr S.E. Malawista (Dept.
of Medicine, Yale University, New Haven, CT) and prepared in his laboratory
according to published methods (Malawista et al. 1985). Additional crystals
of each type were prepared and donated by Dr Paul Dieppe (Dept. of
Rheumatology, Bristol University, UK). Crystals of MSU (8-40um), HA
(aggregates of 3-15um), CPPD (15-50um) were of comparable size, as assessed
under incident-light microscopy (by courtesy of Dr Webb, Department of
Pathology, Western General Hospital, Edinburgh). Crystal batches were tested
for LPS content by L.A.L. assay, mixed, resuspended at lOmg/ml in LPS-free
PBS and stored in 500uls aliquots at -3CP C until used.
Before use, some crystal aliquots were pre-treated (lhr, 37° C, shaking
incubation) with heat-inactivated fresh human serum (lOmg crystals/lml
serum). After two rapid washes in PBS, these were used for induction
experiments.
Crystals were shown to be LPS-free by three different approaches:
(i) Limulus gelation test
This test is based on the clotting of a lysate from amebocytes of
limulus polyphemus (E-TOXATE L.A.L. test, Sigma) in the presence of LPS
(details in Appendix, pp 209). Crystals assayed on four different occasions
contained less than 25pg LPS/mg crystals. PBS in which the crystals had
been suspended at lOmg/ml also scored below the detection limit, indicating
that soluble factors from lmg of crystals contained less than 2.5pg/ml LPS.
When tested for the presence of inhibitors of the gelation test, 0.5mg/ml of
crystals failed to inhibit L.A.L. gelation by 250pg/ml LPS.
(ii) Polymyxin B experiments
Polymyxin B is an anionic molecule which strongly binds LPS and
inhibits its biological activities (Duff, Atkins, 1982A). When tested,
250u/ml PMB failed to inhibit MSU-induced IL1 release (crystals at
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0.4mg/ml). In the same experiment 250U/ml PMB was able to inhibit the
activity of lOOng/ml LPS. This experiment (shown in Appendix, p. 210)
strongly suggests that MSU activity is not related to the presence of
contaminating LPS.
(iii) Soluble activators of IL1 production
One of the most sensitive tests for the presence of LPS is the
induction of IL1 from monocytes (Duff, Atkins 1982B). Crystals of MSU were
suspended at lOmg/ml in PBS, thoroughly mixed for 15 mins, and supernatants
were tested for IL1 induction. Failure to induce detectable IL1 induction
from 5x10^ adherent mononuclear cells (experiment shown in Appendix, p.
210), indicates that no soluble activators of IL1 production (including LPS)
were released from the crystal surface.
2.b.3. MEASUREMENTS OF INTERLEUKIN 1
2.b.3.1 Murine thymocyte assay
This assay is based on the co-mitogenic activity of IL-1 on murine
thymocytes in the presence of suboptimal doses of lectins (Gery et al,
1972).
The murine strain C3H/HeJ is 100-1000 times less sensitive to LPS
effects than other H-2K mice, and use of this strain minimizes the
influence of contaminating LPS in the assay. We used C3H/HeJ mice from our
own breeding colony (initial stock from Harlan Olac, Oxon, UK). In some
experiments, we have however successfully used CBA/Ca mice.
To obtain thymocytes, 6 to 8 week old mice were killed by cervical
dislocation. The thymuses were removed under aseptic conditions, gently
washed in a petri-dish containing serum-free RPMI, and carefully dissociated
between 2 sterile ground glass slides. Dispersed cells in the media (about
810 /thymus) were gently aspirated, washed and the pellet resuspended in
serum-free RPMI.
Concanavalin A, at a suboptimal concentration (suboptimal activity
varies between batches: usually 0.5-2.5ug/ml) was dispensed 50ul/well in a
microtitre plate. One triplicate received lOOul of medium only ("cell
control").
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A standard preparation of IL-1 or samples were added (50ul/well) in
triplicate and in dilutions covering a range of 10-100 fold, to ensure that
comparisons between samples could be made in an appropriate part of the
dose-response curve. One triplicate received medium only ("cells + Con A"
triplicate).
Thymocytes freshly prepared as previously described were gently spun,
resuspended in fresh RPMI 10% FCS and lOOul aliquots (1x10^ cells) were
dispensed into the wells. Following 65-70 hours culture (5%C02> 36.5° C, 95%
humidity) wells were pulsed with 20ul/luCi/well of "^H thymidine (TRK296,
Amersham, Bucks, UK; specific activity 95-105mCi/mg). After 4-6 hours, cells
were harvested (Ph.D cell harvester, Cambridge Technology Ltd, Cambridge,
MA) and automatically deposited onto glass fibre filters. Dried filters
were counted by beta scintillation (Filter-count scintillation fluid,
Packard; Packard TRI Carb 4000). Using a purpose-made programme, average
and SEM of triplicate, row data and histograms were then plotted and/or
stored on an IBM PC. Typical data from a C3H/HeJ thymocyte assay is shown
in Table 2.1.
It has become evident that the C3H/HeJ thymocyte assay, previously the
standard for IL1 biological activity (LAF) measurements, responds to other T
cell growth factors (IL2, IL4, IL6). Interleukin 1-inducing cytokines (such
as TNF) could, in theory, induce IL1 production from the resident thymic
macrophages. The possibility of false positives must be considered,
especially when testing mixed cell population supernatant. However, controls
can be obtained by specific anti-ILl antibody neutralization and the absence
of TCGF activity (as measured by spleen T-lymphoblast assays) in the
supernatants can be easily checked.
2.b.3.2. D10.G4.1. T cell assay
D10.G4.1. is a murine helper T cell clone, specific for hen
conalbumin, from Drs C. Janeway and J. Kaye (Howard Hughes Institute for
Immunology, Yale University, New Haven, CT). These non-transformed cells
(Kaye J. et al, 1984) will clonally expand in the presence of IL-1 and
antigenic stimulation (Conalbumin, Concanavalin A or anti-CD3 monoclonal-
antibody).
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For the assay, cells were used at least 8 days after the addition of
mitomycin-treated feeder cells and not less than 3 days after rat crude TCGF
preparation. At this time, cells are free of feeder cells, and express low
levels of IL-2R (Kaye et a], 1984). These produce no IL-2 and are
unresponsive to IL-1 unless presented with antigen. Also, D10.G4.1
proliferate only minimally to Con A in the absence of IL-1 or feeder cell,
explaining proliferation units in the D10 assay being 10-50 times higher
than in a thymocyte assay (Fig. 1). Cells with viability in excess of 60%,
were used in the assay, which is very similar to the thymocyte assay with a
few exceptions:
1) 2xl0^cells/well are used, and the assay medium consists in RPMI
1640 with 5% FCS and 60uM mercaptoethanol.
2) Concanavalin A used at 2.5ug/ml (final conc.)
3) Supernatants tested at higher dilutions due to increased sensitivity of
the assay.
4) The cells are much more sensitive than thymocytes to environmental
changes in handling and incubation.
The assay, including cell harvesting and expression of results (in
Proliferation Units + SEM of triplicates) is otherways similar to the
thymocyte assay. Proliferation Units were defined as the ratio of cpm
obtained with cells+lectin+sample and cpm with cells+lectin. Several
control experiments were carried out using this line:
D10.G.4.1 proliferation requires presence of both IL1 and lectin
In the experiment shown in Fig. 2, requirements for D10 growth were
studied. Optimal D10 cell proliferation was obtained only when Conanavalin
A and IL1 were present.
Presence of LPS and D10.G4.1 assay of IL-1
When tested, LPS in doses from lOpg/ml to lOOng/ml did not influence
detection of IL-1 in D10 assay. Data are shown in Fig. 3.
Presence of human IFN alpha and D10.G4.1. assay for IL-1
Human leukocyte-purified IFN alpha (from Celltech, Slough, Berkshire)
was tested in absence or presence of human recombinant IL-1 beta in D10.G4.1
assay. The preparation, in doses from 2 to 2000u/ml did not cause D10.G4.1
cell proliferation and, when tested at 200u/ml in presence of hr IL-1,
showed, if any, an anti-mitogenic effect (Fig. 4).
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Presence of human TNF alpha and D10.G4.1 assay for 1L-1
Human recombinant TNF alpha (from Genentech Corp, San Francisco, US)
was tested for activity in the D10.G4.1 assay. In a series of experiments,
hr TNF alpha in doses from O.lpg/ml to lug/ml failed to induce D10.G4.1
proliferation in absence of IL-1 (data not shown). In Fig. 5, experiments
are shown in which human TNF alpha did not synergize with different
recombinant or purified IL-1 preparations for D10.G4.1 proliferation.
Anti IL1 antiserum
A rabbit antiserum raised against pI7 IL1 (from Dr C A Dinarello,
Tufts University, Boston) was used in neutralizing experiments to confirm
the identity of LAF activity as IL1. To check if this antibody was reacting
with IL2 or causing nonspecific cytotoxicity, it was tested in IL 2-driven
CTL proliferation (Fig. 6) and in D10.G4.1 cell proliferation stimulated by
hr IL1 beta or purified IL2 (Fig. 7). Only IL1 driven D10 proliferation was
inhibited by this antiserum.
The specific activity of the antiserum was approximately 400
neutralizing units/ml (one neutralizing unit defined as the antibody needed
to neutralize LAF activity by lng hr IL1 beta) and it was ineffective in
neutralizing D10.G4.1 proliferation by IL1 alpha (Fig. 8). In fact, at the
highest IL1 alpha concentrations tested, the antiserum (1:400) enhanced D10
proliferation (up to 220% with mrlLl alpha). The reasons for this were
unclear, but it was never observed when IL1 beta was used.
2.b.3.3. EL4.NOB.1/CTL conversion assay
EL4 is a murine thymoma line from which the subclone EL4.NOB.1 was
derived (Gearing et al, 1987). EL4.NOB.1, if cultured at low density, will
produce only low levels of IL-2 unless stimulated by IL-1. The IL-2
produced by the cells in response to IL1 can be assayed in a CTL assay, CTL
proliferation being proportional to the initial concentration of IL1 to
which EL4 cells had been exposed.
Briefly, resting EL4.NOB.1 cells (2xl0~Vl00ul/ml well) were washed and
resuspended in fresh medium (RPMI, 5% FCS) in presence of dilutions of the
samples, hrlLl or medium control. After 20hrs incubation (37° C, 5% CO^),
supernatants from EL4 cultures are added to CTL cultures (4x10 ^/100ul/well).
Proliferation of the CTL cultures (20hrs) was assessed by a
colorimetric method according to Mossmann (1983). This allows cell
proliferation to be assessed by MicroELISA scanning spectophotometry. In
the final stages of the assay, cellular mitochondrial enzymes will cleave
the substrate (MTT, a tetrazolium salt) to a dark formazan product, giving a
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colorimetric estimate of cell number when plates are scanned at 570-630nm
wavelength.
Interleukin 1 biological activity was calculated by comparison of the
O.Ds in the wells containing the sample (tested in triplicate, four
dilutions) with those of the standard dose-response curve of hr IL1 beta
(triplicate wells, 0.01 to lOng/ml) present in each plate. The results are
expressed in units/ml where 1 unit is arbitrarily defined as the amount of
IL-1 in the sample giving CTL proliferation comparable to 1 ng/ml hr IL-1 in
the standard dose-response curve.
2.b.3.4. Interleukin 1 immunoassays
Commercially available immunoassays were used to assess specific
immunoreactive human IL1 alpha or IL1 beta. Interleukin 1 beta RIA (Cistron
Biotech./Laboratory Impex) and interleukin 1 alpha RIA (Amersham, UK) are
based on the competition for specific antibodies ("sequential saturation")
between ligand in the sample or dilutions of standards and exogenously
12S
added, I labelled human recombinant ligand. Antibody-bound ligand was
precipitated with a polyethylene glycol-second antibody solution. After
centrifugation, radioactivity in the precipitates was assessed by gamma
counting. Detection limits are 0.25-5ng/ml for the IL1 beta RIA and 0.075-
2.5ng/ml for the IL1 alpha RIA. For the IL1 beta ELISA (Cistron
Biotech/Laboratory Impex), 96 well microtitre plates are coated with IL1
beta-specific monoclonal antibody. Samples of IL1 beta standards were added
and incubated for 2 hours at 37° C. Following extensive washing, a
polyclonal rabbit anti-human IL1 beta was added and incubated for a further
2 hours. After a final wash, horseradish peroxidase-labelled goat anti-
rabbit IgG is added, followed by enzyme substrate (O-phenylenediamine) to
produce a chromogenic reaction. Plates were scanned at 405nm in a
microELISA reader (Dynatech MR700) and the concentration of IL1 beta in the
samples derived from a standard curve obtained with hr IL1 beta. Detection
limits of the assay were 0.020-2.5ng/ml. Samples were tested in triplicate
wells in ELISA assays, and as single determinations in RIA assays, unless
otherwise stated.
2.b.4. MEASUREMENTS OF INTERLEUKIN-2
2.b.4.1 Spleen murine lymphoblast assay
This assay is based on the property (TCGF activity) of IL2-containing
supernatants to maintain T cell blast growth (Larsson et al, 1980). Whole
spleen cell populations were prepared from C3H/HeJ mice, lysing red blood
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cells by hypotonic shock. After two washes in serum free medium, cells were
resuspended at lO^cells/ml in presence of 2.5ug/ml Concanavalin A (Sigma) in
RPMI 1640, 10% FCS. Following 72 hours incubation (37° C, 5% CC^), cells
were washed and 10^ cells/lOOul/well were incubated in a microtitre plate
with lOOul of supernatant at various dilutions. Standard rat TCGF was used
to standardize the assay. After a further 72 hours incubation,
proliferation was assessed by thymidine incorporation (5 hours,
luCi/well).
This assay is very sensitive but is not specific for IL2, as TCGF
activity is shared at least with IL4 and IL6. For these reasons, it is
probably the ideal control to exclude the presence of these T cell growth
factors in crude supernatants active in the LAF/IL1 biological assay.
2.b.4.2 Cytotoxic T lymphocyte proliferation
This biological assay is based on the ability of IL2 to support the
growth of murine cytotoxic T lymphocyte clones, selected by long term
culturing and subcloning in IL2 (Gillis et al, 1978). In this laboratory,
different clones have been used (CTLL, CTL-D, CTL-1, CTLL-2) from various
sources with very similar characteristics.
For the assay, CTL cells were harvested and washed 3 to 4 days after
the last addition of TCGF to the cultures: 1x10^ to 5x10^ healthy CTL
cells/lOOul/well were cultured in different dilutions of sample, medium or
IL-2 (BRMP standard or human recombinant IL-2). Cell proliferation can be
3assessed in 24 hours incubation followed by 24 hours pulsing with H
thymidine (0.5uCi/well). An alternative to monitor clonal expansion is the
use of colourimetric methods such as MTT reduction (Mosmann et al. 1983) or
NAG activity assessment (Landergren, 1984).
2.b.5 FIBROBLAST PROLIFERATION ASSAY
Interleukin 1 has been reported to induce fibroblast proliferation
(Schmidt et al.. 1982), as have been other factors and cytokines including
TNF alpha (Vilcek et al. 1986). Supernatants from human monocytes, induced
by an arthritogenic stimulus (MSU crystals), were tested on human fibroblast
lines established from joint fluid exudate cells from patients with
rheumatoid arthritis.
Fibroblasts were cultured in RPMI 1640 or MEM with 10% FCS, glutamine
and antibiotics. Medium was changed twice weekly and cells were passaged
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1:3 to 1:10 when subconfluent by loosening the cells with trypsin/EDTA.
For the proliferation assay, fibroblasts were washed and resuspended
in fresh medium at 1x10"Vml. Aliquots of lOOul were dispensed in the wells
of a microtitre plate (1x10 ^ fibroblast/well) and incubated overnight (to
let them re-express membrane structures that could be damaged by trypsin
treatment). On the second day, the spent medium was replaced by lOOuls of
IL-1 and sample dilutions in fresh medium. The plate was then incubated for
a further 48 hours. On the fourth day, the wells were pulsed with H
thymidine (luCi/well/20ul; TRK 296, Amersham, UK). After 4 to 8 hours
incubation, the medium was removed, the wells washed with PBS, and lOOul of
trypsin/EDTA solution (IX, Gibco) were dispensed into the wells. After 30
mins at 37° C, cells were harvested and thymidine incorporation assessed by
liquid scintillation counting as previously described.
2.b.6. MEASUREMENTS OF TUMOUR NECROSIS FACTOR
2.b.6.1 L929 cell cytotoxicity assay
L929 is a mouse nipple fibrosarcoma line (ATC CCL1) and it was one of
the first cell lines established.
TNF cytotoxicity in vitro for L cells was an early observation
(reviewed by Old, 1985) but many other human and murine tumoral lines are
susceptible to lysis by TNF and thereafter suitable for TNF cytotoxicity
tests. Among these, WEHI 164 and the subclones WEHI 164.13 (Espevik,
Nissen-Meyer, 1986), WEHI 3 (Green et al. 1982), EMT-6 (Williamson et al.
1983), FELC cells (Suyama et al. 1985), U937 and A673/6 cells (Feinman et
al, 1987) have been used, quantifying cytotoxicity by photometric
measurement of neutral red, crystal violet uptake or MTT dye reduction or by
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measuring the release of H-thymidine or Cr from labelled target cells.
As none of these assays distinguishes between TNF alpha and TNF beta,
subsequent specific antibody neutralization of either cytokine is needed for
identification. L929 are undemanding cells in culture, the supply of cells
is steady and in the conditions that we used (Kramer et al. 1986) the assay
is sensitive, inexpensive and reproducible.
L929 cells, grown in non-confluent status for at least four passages,
were detached by Trypsin/EDTA treatment, washed, resuspended in MEM medium
10% FCS and seeded at 3x10 ^cells/well in the 60 internal wells of a
microtiter plate (lOOul/well). The remaining wells were filled with MEM
50
medium, and plates gently shaken to achieve an even distribution of the
cells. After 24 hours incubation at 37° C the medium was replaced in all
wells with lOOuls of fresh MEM containing lug/ml Actinomycin D (Sigma).
Wells in column 2 received 50ul of medium containing 2ug/ml Actinomycin D
and 50ul of sample, medium control or hr TNF as a standard. Samples were
then double diluted in the different rows, and plates incubated for 18 to 20
hours at 38.5° C, a temperature shift that will enhance TNF-mediated cell
killing (Kramer et al. 1986). On the third day, medium was removed and
adherent, viable cells stained and fixed with a solution of crystal violet
(0.5% in 20% methanol). After a minimum of 2 minutes, plates were washed
vigorously in water, dried and the absorbance at 470nm measured by
microELISA scanning spectrophotometry. The half-maximal cytotoxicity is
assessed by the average optical density of column 1 (no cells, equivalent to
100% killing) and the row that only received medium and Actinomycin D (100%
viable cells). By plotting dilution against O.D. and using interpolation,
the dilution of the sample giving half-maximal killing can be derived. The
readings of the standard TNF preparation express the sensitivity of the
assay.
Assay sensitivity
Scanning spectrophotometry from a TNF assay plate is shown in Fig. 9.
Under optimal conditions, the assay is able to detect (4u/ml) 100 to
200pg/ml TNF alpha or LT and the 1/2 maximal cytotoxicity unit is usually
obtained by a concentration of hr TNF alpha in the order of 25-50pg/ml.
Influence of Temperature
An increase in sensitivity (Kramer et al, 1986) can be obtained by
incubation of the plate at 38.5° C after addition of the samples (Fig. 10).
This does not affect reproducibility between samples which are assayed on
the same day using homogenous L929 cells.
Influence of cell density
Sensitivity of L929 cells to TNF-mediated cytotoxicity is related to
the cell density at which the cells are cultured. To obtain maximum
sensitivity (Fig. 11), cells were cultured for 10-14 days in a non-confluent
status and seeded in the assay plate at 3.5-4x10^ cells/well. Lower or
higher concentrations result in diminished sensitivity (Kirstein et al..
1986).
L929 assay specificity: the effects of other cytokines
To test the specificity of L929 cytotoxicity, an extensive range of
recombinant, purified and cell-derived cytokine preparations were tested
(Table 2.2). At the concentrations tested, none of the cytokine
preparations used were cytotoxic for L929 cells. In subsequent experiments,
IL-1 proteins were tested at lower concentrations, but no L929 cytotoxicity
was observed. This is apparently in contrast with previous observations,
obtained however with purified IL1 and achieving cytolysis only after a long
time in culture (Onozaki et al. 1985B). All the cytokines used were active
when tested for their specific activity.
L929 assay specificity: lack of synergy between human IL-1 and human TNF
Synergy of IL-1 and TNF has been described in a number of human
systems (Elias et al. 1987; Stashenko et al. 1987). To check if human IL-1
could synergize with human TNF in L929 cell cytotoxicity, different
concentrations of hr TNF alpha were assayed in the presence of constant
amounts of hr IL-1 beta (Fig. 12A) or vice-versa (Fig. 12B). Identical
experiments were performed in which hr IL-1 alpha instead of IL-1 beta was
used (data shown in Appendix, p. 211). IL-1 alpha and IL-1 beta failed to
demonstrate L929 cytotoxicity, and did not synergize with TNF alpha in this
biological activity on murine cells. Biological activity of both IL1
preparations was confirmed by EL4.NOB.1 assay.
Neutralization of TNF biological activity by specific monoclonal antibody
Murine purified monoclonal antibody to hr TNF alpha ("TNF-E"
1.4mg/ml) was kindly donated by Dr G. Adolf (Boehringer Institute, Wien).
This antibody exhibited no effect on TNF beta-mediated L929 cytotoxicity
(Fig. 13) and was used as a specificity control in the L929 cytotoxicity
assay. Cytotoxicity completely neutralized by the mab was interpreted as
due to the presence of TNF alpha. The specific neutralizing activity of
this antibody in the L929 cytotoxicity assay was approximately 300ng hr TNF
alpha/mg antibody (Fig. 13).
2.b.6.2. TNF alpha radioimmunoassay
This radioimmunoassay (kits were kindly donated by Medgenix, Belgium)
is based on the competition for TNF alpha-specific antibodies between
unlabelled TNF contained in the sample or in the standard tube, and
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exogenously added I-labelled human TNF alpha.
After precipitation of the immune complexes (by adding anti rabbit Ig
antiserum and PEG) the radioactivity in the pellet will be inversely related
to the amount of immunoreactive TNF alpha in the samples. These last titers
are calculated by interpolation from the standard curve. All samples tested
as single determinations unless otherways stated.
The sensitivity and limits of the assay were 0.1-5ng/ml hr TNF alpha .
Comparison of TNF alpha immunoreactive protein and biological activity in
supernatants from stimulated adherent mononuclear cells
Immunoreactive TNF alpha levels were tested in the supernatants of
cultures from different experiments. These were generated by stimulation of
human adherent mononuclear cells (1x10 ^/ml) with a variety of microbial
agents and tested for L929 cytotoxicity. Such bioactivity could be
completely neutralized by a specific mab to human TNF alpha. Biological
activity on L929 cells (normalized for lOng/ml hr TNF alpha = 256u/ml; range
270.3+20.8u/ml) was highly correlated with immunoreactive TNF alpha (Fig.
14). This is in accordance with the report that no inactive propeptide is
present in extracellular supernatant (Beutler, Cerami, 1986) and suggests
that in 12-18 hour stimulated monocyte cultures produce no major inhibitors















100pg/ml 1ng/ml 10ng/ml 100ng/ml
15466il266 25365+1034 45779+4731 35750+4339 39532+3322
1.40+0.11 2.31+0.09 4.17+0.43 3.25+0.39 3.60+0.30
17186+3074 41374+3359 43411+2024 42131+3993 48518+5081
1.56+0.28 3.76+0.31 3.95+0.18 3.83+0.36 4.42+0.46
21238+3348 31924+1535 46435+3137 47796+5321 37335+1441
1.93+0.30 2.91+0.14 4.23+0.28 4.35+0.48 3.40+0.13
14316+784 43284+1961 50328+4062 48624+2679 59774+3382






TABLE2.1ApplicationofLAFassaytmeasurement1Lbiologicalivity ShownareresultsfromC3H/H Jt ymocytesayslong-termstoragfhur c binantIL1(I amun x Corp.,SeattleUS;lug/mlhrlLinPBS/0.3%H A±0.1trehalose).R sultswerxpr s edprolif rationunit (p.u.=cpmells+lectin+sample/cells lectin)andctivi yompar dbyomparisonfhalf-maxi l proliferation. Itwasclearth tL1alphandbets oredinbsenceofr h lo(AB l )h d comparableactivity(half-m x.U=80-100pg/ml)suggestingth tIL1l handbetdi ilartolerancl termstorage.However,hencompar dtor gein0.1%trehalos(A2andBbl )la t rowhig specificactivity(half-max.U=10-20pg/ml)refle tingprotectivea ontrehal sonlong-t rmL1st r e (cells+ConA=10981±7 2cpm).
010 GV1 C3H/HeJ 010 QU1
Fig. 1 Comparison of thymocytes and D10/G4.1 T cell proliferation
Thymocyte and D10.G4.1 cells were tested for ability to proliferate in
response to "standard" crude IL1 preparation (monocytes supernatant, LPS
lOOng/ml, 20hrs). To achieve the same proliferation units D10 cells require
100-200 times less IL1 (note the difference in scale) indicating a higher
sensitivity of this assay at low IL1 concentrations. Even with the
different background (thymocyte + Con A = 2318 ± 160cpm; D10 cells + Con A =
347 ± 21cpm), D10.G4.1 proliferation (as measured by H thymidine
incorporation) appears to be 15-30 times in excess to C3H/HeJ thymocytes.
Cells + ConA = 157.67 ±15 cpm
D, q£4.1 T cell proliferation
Fig. 2 D10.G4.1 proliferation requires a double signal
D10 proliferation in presence (hatched bars) or absence (closed bars)
of 2.5ug/ml Concanavalin A. Results, expressed in proliferation units, are
means of triplicate wells. Crude IL1 reciprocal dilutions as indicated on
the horizontal axis.
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Cells + ConA = 157.7 ± 7 cpm
D, 0G4.1 assay
Fig. 3 Effects of lipopolysaccharide on D10 proliferation
Lipopolysaccharide was tested in different concentrations in presence
(shaded bars) or absence (closed bars) of crude IL1 for its effect on D10
proliferation in presence of Concanavalin A (2.5 ug/ml). LPS was not
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Cells + ConA = 293.7 ± 19.7 cpm
D, 0.G4.1 assay
Fig. 4 Effects of IFN alpha on D10 proliferation
Human purified IFN alpha was tested for D10 cell proliferation in
absence (shaded bars) or presence (closed bar) of hr IL1 beta. IFN alpha
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Fig. 5 Effects of human recombinant TNF alpha on D10 proliferation
After several experiments in which hrTNF alpha failed to stimulate
D10.G4.1 cell proliferation in presence or absence of Concanavalin A, it was
tested if it could synergize with human IL1 in D10.G4.1 proliferation. A
fixed amount of hr TNF alpha (lOng/ml) was added to different concentrations
of IL1 (5 different highly purified or recombinant proteins) and tested for
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CTLL bkg » 2310 ± 190 cpm
Fig. 6 Effects of anti-ILl antiserum on IL2- driven CTL proliferation
And IL1 antiserum did not show any neutralization of IL2 biological
activity nor nonspecific cytotoxicity for T cells. BRMP (Biological
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Fig. 7 Effects of anti-ILl antiserum on IL2 or IL1 driven D10
proliferation
In this experiment, and IL1 antiserum neutralized hrlLl beta-DIO
proliferation, but failed to inhibit the action of BRMP IL2 on the
proliferation of the same cells.
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hr IL1 (pg/ml)
Fig. 8 Effects of anti IL1 antiserum on D10.G4.1 proliferation
Antiserum to human pI7 IL1 (a gift from Dr C A Dinarello, Boston) was
tested (1:400 dilution) for its ability to inhibit LAF activity of several
IL1 preparations.
The antibody at the dilution used was able to neutralize LAF activity
by hr IL1 beta preparations but did not inhibit the action of IL1 alpha
proteins on D10.G4.1 proliferation. In fact, proliferation of D10 cells was
enhanced at the highest concentration of IL1 alpha tested (degree of
enhancement indicated in brackets): the interpretation of this phenomenon is
unclear but it was reproducible.
A hr IL1 beta from Dr C A Dinarello, (Tufts Univ, Boston, US)
A hr IL1 beta from Dr A Shaw (Biogen, Geneva, CH)
0 hr IL1 alpha from Dr S Gillis (Immunex Corp, Seattle, US)
O mr IL1 alpha from Dr P Lomedico (Hoffman La Roche, Nutley, US)



























Fig. 10 Effects of temperature on L929 cytotoxicity
Two identical plates were prepared with titrations of 3 doses of hr
TNF alpha and hr TNF beta. The plates were incubated for the second 24
hours at 38.5° C or 36.5° C.




















Fig. 11 Effects of cell density on L929 cytotoxicity
Influence of cell density on L929 cytotoxicity by TNF alpha or LT.
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Fig. 12 Effects of hr IL1 in L929 cytotoxicity
Human recombinant TNF alpha and hr IL1 beta were tested for synergy in
L929 cytotoxicity assay, (a) different concentrations of hr TNF alpha were
tested in presence or absence of hr IL1 beta (lng/ml); (b) hr TNF alpha
(lng/ml) was tested in the presence or absence of different concentrations
of hr IL1 beta. No synergy in L929 cytotoxicity was observed and hr IL1
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0.195 0.39 0.78 1.56 3.12 6.25 12.5 25
hr TNF (ng/ml)
Fig. 13 Inhibition of L929 cytotoxicity by "TNF-E", murine monoclonal
antibody
Murine monoclonal anti hr TNF alpha ("TNF-E") was tested for
inhibition of L929 cytotoxicity. This antibody neutralized hr TNF alpha
induced cytotoxicity but not hr TNF beta biological activity. Specific
activity was about 300ng hr TNF alpha/mg antibody.
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L929 cytoxicity TNF alpha R.I.A.
Stimulus in supernatants in supernatants
(U/ml) (ng/ml)
10 HKS/mo 7306 6.31
lmg/ml Zym.A 1696 5.33
0.1 HKS/mo 277 3.18
1% TSS 149 2.77
lOug/ml Zym.A 45.23 1.77
lng/ml LPS 42.24 1.22
none <4 <0.05
0.001 HKS/mo <4 <0.05
none <4 <0.05
lug/ml Zym.A <4 <0.05
Fig. 14 Comparison of extracellular TNF alpha immunoreactive protein and
biological activity
Supernatants from several experiments in which human adherent
peripheral blood mononuclear cells (1x10^ monocytes/ml) were stimulated with
different microbial agents were tested for L929 cytotoxicity and
subsequently in a TNF alpha RIA. The values obtained by TNF alpha RIA
highly correlated with TNF biological activity (semi-log scale).
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CHAPTER 1
Induction of IL1 by microbial Products
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2.c.l INTRODUCTION
Early-acting mediators of host defence such as IL1 and TNF are
produced promptly upon cellular recognition of microbial products. This
feature of IL1 induction has been studied for decades as "Endogenous
Pyrogen" (EP) activity. As Interleukin 1 is the main, if not exclusive,
mediator of E.P. activity, it can be assumed that agents reported to induce
E.P. are also IL1 inducers. Some microbial agents reported to induce
directly EP or LAF biological activities are indicated in Table 2.3.
In this study, different microbial products have been tested as
stimuli for IL1 release from adherent human mononuclear cells, measured as
LAF activity. The stimuli included three microbial cell wall products:
E. Coli Endotoxin (LPS, from gram negative bacteria); Saccharomyces
Cerevisiae cell walls (Zymosan A, from yeasts); and staphylococcal cell
walls (HKS, from gram positive bacteria). An extracellular bacterial toxin,
the exotoxin from Staph. Aureus strains that cause Toxic Shock Syndrome was
also tested. Lipopolysaccharide (LPS) is the external part of the cell wall
of gram negative bacteria. It is responsible for most effects of gram
negative bacteria, and its enormous range of activities in vivo has been
reviewed by Morrison & Ryan (1979). However, it is now clear that most of
its effects can be explained by induction of IL1 and TNF (Morrison, Ryan
1987). The macromolecule is formed of a polysaccharide moiety ("O"
antigen), an internal ("R") core and a lipid moiety ("Lipid A"). The
composition of polysaccharides in the "O" moiety determines the antigenicity
of the bacterial strain (Elin, Wolff, 1973). The "R" core is composed of
hexoses, glycosamines and KDO (2-keto-3-deoxyoctulonic acid). "Lipid A" is
composed of glycosamines linked to KDO and long-chain hydrophobic fatty
acids (Rietschel et al. 1973).
LPS has been shown to induce high levels of IL1 from a number of cell
types such as monocytes or macrophages (Gery et al. 1972; Gery, Lepe-Zuniga,
1983) and many others (Table 2.3). Early work showed that "Lipid A" was
responsible for toxicity and induction of fever by LPS (Tripoly, Nowotny,
1966; Konno, Yoshioka, 1978). Recent reports suggest however, that the
antigenic "O" part may be involved in some of the biological actions of LPS
(Vukajlovich et al. 1987) and some components of the polysaccharidic region
(glycolipid M9) might be more efficient than LPS or Lipid A in stimulating
IL1 release and equally effective in stimulating IL1 synthesis (Lasfargues
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et al. 1987). A monosaccharidic component of LPS termed "Lipid X", has also
been described as a powerful macrophage activator (Amano et al. 1986).
At the time when these studies started, there was growing evidence
(Gery, Lepe-Zuniga, 1983) that cellular distribution of IL1 and the
existence of a cell-membrane form (Kurt-Jones et al, 1985) could have
significance beyond the simple processing of the protein for secretion.
In the present experiments, the kinetics of cellular distribution of
IL1 bioactivity and immunoreactivity were determined after stimulation of
human monocytes with LPS: the aim was to test if specific patterns existed
for distribution of either of the two IL1 proteins. The methods followed
have previously been described in detail in the relevant sub-section (2.b.:
Material and Methods, p. 39)
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TABLE 2.3 Direct induction of IL1 by microbial agents
Agent Target cells Activity induced
VIRUSES
Influenza leukocytes EP
EBV B cells LAF







intrac. toxin Leukocytes EP
28KDa enterotoxin Leukocytes EP
12KDa exotoxin Leukocytes EP
TSS exotoxin Monocytes LAF
Streptococcus:












Borrelia Burgdorferi Monocytes LAF
FUNGI Leukocytes EP
S. Cerevisiae in vivo EP
Authorfsl
Atkins et al. 1964
Kanoh, Kawasaki. 1966
Atkins, Bodel, 1974
Scala et al. 1984
Okada et al. 1986
Atkins, Morse, 1967
Dinarello et al. 1978
Togawa et al, 1979
Bodel, Atkins, 1965
Shantz et al. 1972
Bruson, Watson, 1974;
Schlievert et al. 1979
Ikejima et al. 1984
Watson, Kim, 1970
Atkins, Wood, 1955
Gery et al, 1972
Gery, Lepe-Zuniga, 1983
Matsushima et al. 1985
Sauder et al. 1984
Duff et al. 1985
Scala et al. 1984
Wagner et al. 1984
Fontana et al. 1982
Lovett et al. 1983
Habicht et al. 1985




2.C.2.I. LPS induced IL-1 activity from blood monocytes
Lipopolysaccharide at concentrations from lOOpg to lug/ml induced
extracellular release of IL-1 activity from human monocytes (Fig. 15).
Different doses (lng to lug/ml) of LPS administered to the thymocytes in the
presence of lectin did not stimulate proliferation, excluding a possible
carry-over of LPS in the thymocyte assay. In the experiment shown in Fig.
15, a dose of 250u/ml of Polymyxin B was able to neutralize the IL-1
inducing activity of lOng/ml LPS.
2.C.2.2. Induction of IL-1 activity from monocytes by Saccharomyces
Cerevisiae cell walls (Zymosan A)
Zymosan A was tested for IL-1 inducing activity in concentrations
ranging from lOOng to lOmg/ml. In doses from lOOug to lOmg/ml zymosan
induced release of IL-1 activity (Fig.16). Carry-over of Zymosan could not
account for the thymocyte proliferation, and anti IL-1 antiserum (1:400)
with one of the supernatants completely abolished C3H/HeJ thymocyte
proliferation. This action of the antiserum could not be attributed to
cytotoxic effects or IL-2 neutralizing activity (experiments previously
shown in fig. 6 and 7, p. 58).
2.C.2.3. Heat-killed staphylococci induction of IL-1 activity from monocytes
Heat killed staphylococci were a dose dependent stimulus (Fig. 17) for
C O
extracellular IL-1 release, in a concentration from 10 to 10 cell walls/ml
(at 10^/ml monocytes = 0.1 to 100 bacteria/monocyte). The cell walls,
incubated in absence of monocytes did not stimulate C3H/HeJ thymocyte
proliferation when tested in the assay; the most active supernatant (6.96
p.u.) was reduced to background levels (1.689 + 0.135) by 1:400 dilution of
specific IL1 antiserum added in the thymocyte assay.
2.C.2.4. Induction by TSS exotoxin of IL1 bioactivity from human monocytes
The Staph Aureus/Toxic Shock Syndrome exotoxin (TSS) was tested as a
stimulus for release of IL1 extracellular activity. TSS was a powerful,
dose dependent stimulus (FIG.18) in dilutions from 1:10,000 to 1:100
(maximum tested). The TSS preparation itself was unable to stimulate
D10.G4.1 proliferation and the ILl-inducing activity of a 1:100 dilution of
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TSS was comparable to that of lOng/ml LPS (FIG.14). This TSS preparation
had been tested in LAL assay for LPS and contained <20pg LPS/ml (Dr D
Shapiro, personal communication).
2.C.2.5. Induction of biodetectable extracellular IL-1 from U937 cells
Several attempts were made to induce release of IL1 activity from U937
cells, using a wide range of LPS concentrations. No bioactive IL-1 could be
detected in these experiments (data not shown).
Toxic shock syndrome exotoxin was therefore tested for ability to
induce IL-1 from U937 cells (Fig. 19). TSS was incubated for 18hrs with
2x10^ U937 cells/ml with or without the use of "inducing" protocols, such as
coincubation with the Ca Ionophore A23187 (10 "^M) or incubation at 38.5°C.
As shown in Fig. 19, TSS induced IL-1 bioactivity in dilutions from 1:10 to
1:100 at 36.5°C, and this was not significantly augmented by incubation at
38.5°C.
The use of A23187 (10~^M) in conjunction with TSS, induced optimal
response at 1:100 dilution of TSS at 36.5°C, which was not increased by
incubation at 38.5°C. When tested in the IL1 assay, A23187 (10~^M) was
unable to stimulate D10 proliferation. TSS itself had already been
demonstrated to be inactive on D10 cell proliferation (Fig. 18).
In the same IL-1 assay was tested a crude supernatant from 10^/ml
human monocytes, incubated for 18hrs with lOOng/ml LPS (data not shown).
The proliferation units obtained by 1:500 of this supernatant (62.08 + 1.78)
matched the 1:100 dilution of the optimal response of U937 with TSS and
A23187 (63.48 ± 4.084). Since this IL1 activity was generated by twice as
many U937 cells, it can be calculated that this cell line is about 10 times
less efficient in producing extracellular IL-1 activity than a comparable
human monocyte preparation stimulated with LPS. Without "induction" the
release of IL1 biological activity appears to be 30-50 times lower.
2.C.2.6. Time course of IL-1 production and release by human monocytes
stimulated by LPS
Human adherent blood monocytes(10 ^/ml) were tested for IL-1 production
and release at different time points.
Cells were prepared from blood of healthy donors and before adherence
a lysate of 10^ monocytes (3x10^ mononuclear cells) was stored (cell-
associated IL-1 before adherence). After 40mins of plastic adherence non-
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adherent cells were pelleted and supernatant stored for IL-1 assay
(extracellular IL-1 after adherence). One sample of adherent cells was also
stored for IL-1 assay after reconstitution in the same volume of medium
(cell-associated IL-1 after adherence). To the adherent cells was
added a volume of medium such that the final monocyte count was 10^/ml. A
variety of stimuli was given to cultures in different Petri dishes (MSU, HA,
CPPD time course were performed at the same time) and immediately one
supernatant of each series was harvested (extracellular IL1 at time point
zero) and cells reconstituted and stored (cell-associated IL-1 at time
zero). At different time points, cell associated and extracellular
fractions were separated from cultures stimulated with the four different
stimuli or incubated in absence of stimulus: in each Petri dish, the
clarified supernatant, represented the "extracellular" fraction. The
adherent cells, reconstituted to the original volume plus the cells that had
become non-adherent were lysed by three cycle of freeze-thawing ("cell-
associated" fraction). Each sample was stored at -80° C until use.
These fractions were first tested in the EL4/CTL assay for IL-1
bioactivity. This is a very sensitive bioassay suitable for large numbers
of samples (i.e. in this experiment 140 samples assayed in triplicate at
four dilutions). Results are shown in Fig. 20. All supernatants and cell
associated fractions did not contain significant ILl-like activity before or
at the end of plastic adherence. The monocytes incubated with medium alone
did not accumulate significant IL1 bioactivity in the supernatant or in the
cells: the highest production was at 6 hours (comparable to 52pg/ml IL-1),
at least 1000 times less than a maximally stimulated macrophage population.
Cell associated IL-1, as in previous experiments, started to
accumulate at 45 mins, with a sharp increase to reach 280U/ml by 6hrs and
380-390U/ml by 12 and 18 hrs. Extracellular IL1 content was detectable at
2hrs, with a plateau at 9-18hrs (67u/ml), never however reaching the
concentrations of bioactive IL1 found within the cells.
Since IL1 biological activity is related to both IL1 alpha and IL1
beta, the fractions from the above and other similar experiments were also
tested with specific immunoassays for IL1 alpha (Fig. 21) and IL1 beta (Fig.
22).
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Intracellular proteins, as could be expected, accumulated earlier (IL1
alpha: 30 min; IL1 beta: 2hrs) than in the extracellular compartment (IL1
alpha: 2hrs; IL1 beta: 3hrs), with IL1 alpha constantly preceeding IL1 beta.
On a quantitative basis, it appears that IL1 alpha protein (Fig. 21) mainly
accumulates in the cell-associated compartment, while IL1 beta (Fig. 22)
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FIG. 15 Induction of extracellular IL1 biological activity by LPS
Lipopolysaccharide was added at different concentrations (horizontal
axis) to human blood monocytes (lxlO^/ml, hatched bars) or incubated in
absence of cells in complete medium (dotted bars). After 18hrs (37°C, 5%
CO2) supernatants were collected and assayed in triplicate, in three
dilutions (1:100, 1:20, 1:4) in a C3H/HeJ thymocyte assay for IL-1 activity.
The figure shows the results (in proliferation units [p.u.] = cpm with
sample plus Con A divided by cpm with Con A only) for 1:20 dilution (in
complete medium) of supernatant. To check that IL-1 inducing activity was
due to LPS, polymyxin B at 500u/ml was added to lOng/ml LPS prior to
incubation (18 hrs) with 1x10^ monocytes/ml. Result of the IL-1 assay (1:20
dilution) on the supernatant is shown in the solid bar. Supernatant from
monocyte cultures incubated in absence of stimulus did not release IL-1
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FIG 16 Induction of extracellular IL1 biological activity by
Saccharomyces Cerevisiae
Zymosan A was tested for IL-1 inducing activity. Human monocytes
(hatched bars, 10^ monocytes/ml) were incubated in presence or absence of
the stimulus for 20hrs (37°C, 5% CC^)- Supernatants were assayed in
triplicate cultures for IL-1 activity in a C3H/HeJ thymocyte assay at 4
dilutions (1:20, 1:100, 1:500, 1:2500), and results from the 1:100 dilution
are shown. A supernatant from the monocyte culture stimulated with lmg/ml
zymosan was assayed (1:100, solid bar) in the presence of 1:400 dilution of
an antiserum to human purified IL-1 (kindly given by Dr C.A. Dinarello,
Tufts University, Boston). Supernatant from Zymosan A (lmg/ml) incubated in
absence of monocytes (dotted bar) failed to stimulate thymocyte
proliferation.
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FIG. 17 Induction of extracellular IL1 biological activity by heat-killed
staphylococci
HKS were used to stimulate 10^/ml human monocytes for 20hrs (37°C,
5%), in concentrations ranging from 10 cell walls/monocyte to
10 /monocyte. Control wells included monocytes cultured in absence of HKS
and HKS incubated in absence of monocytes (dotted bar). One supernatant
(from a culture of 10 HKS cell walls/monocyte) was tested in the absence
(hatched bar) or presence (black bar) of anti IL-1 antiserum (1:400
dilution). Results are expressed in proliferation units of the 1:100
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FIG. 18 Induction of IL1 extracellular activity from blood monocytes by
Toxic Shock Syndrome exotoxin
Toxic shock syndrome exotoxin (TSS) in the dilution indicated
(reciprocal of dilution) on the horizontal axis was added to human monocytes
(5x10 /ml, hatched bars) or in absence of cells (solid bars). Supernatants
were harvested after 18 hours incubation and assayed in triplicate and three
dilutions (1:1000, 1:100, 1:10) in the D10.G4.1 T cell proliferation assay
for IL-1. Results are shown for 1:100 dilution of supernatant. In the same
experiment, comparable IL1 bioactivity was present in cultures stimulated
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FIG. 19 IL1 bioactivity from U937 cells stimulated by toxic shock
syndrome exotoxin
In this experiment, 2x10^ U937 cells/ml were incubated with different
dilutions of TSS (horizontal axis, reciprocal of dilution) in presence or
absence of A23187 (10~^M) and at 36.5°C or 38.5°C. Supernatants at 18hrs
incubation were then tested in triplicate and four dilutions (1:100 shown)
in the D10.G4.1 assay for IL-1 bioactivity. The hatched bar on the extreme
right refers to A23187 10incubated in the absence of monocytes and then




FIG 20 Time course of IL1 bioactivity accumulation and cellular
distribution in human monocytes
Human adherent monocytes were cultured for up to 18 hours after
stimulation (LPS, lOOng/ml) or simple addition of fresh medium.
Supernatants were assayed for IL-1 in the EL4/CTL assay. On the vertical
axis is indicated IL1 bioactivity expressed in EL4/CTL U/ml (1U = amount of
IL-1-like activity comparable to lng/ml hr IL1 beta). Supernatants were
tested in four dilutions and units calculated by best-fit in the standard
curve.
(A) cell - associated fraction from mononuclear cells after density
separation.
(B) Fractions from cells at the end of plastic adherence (40 mins).
(C) Fractions from cells to which stimuli had just been added (time zero).
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FIG 21 Time course of accumulation and cellular distribution of IL1
alpha in human blood monocytes
Extracellular and cell-associated fractions from cultures of human
monocytes incubated in presence or absence of LPS (lOOng/ml) were tested in
an IL1 alpha-specific RIA (lower detection limit = 70pg/ml). Unstimulated
cells failed to express immunoreactive IL1 alpha protein but LPS induced
cells expressed detectable cell-associated IL1 alpha at 30 minutes, reaching
a maximum at 18hrs (42ng/ml). Extracellular IL1 alpha was constantly
expressed at lower levels, to a maximum of 3.5ng/ml at 18hrs after
stimulation.
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FIG 22 Time course of accumulation and cellular distribution of IL1 beta
in human monocytes
Cellular and extracellular fractions indicated in Fig 21 legend were
tested for immunoreactive IL1 beta using a sensitive IL1 beta ELISA (lower
detection limit = 20pg/ml). Cell-associated IL1 beta was detectable by 2
hours: IL1 beta extracellular translocation started at 3 hrs, and levels
comparable to the cell-associated fraction occurred by 6 to 18 hours.
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2.C.3 DISCUSSION
In this study the production of IL1 from human monocytes in response
to several microbial products (LPS, Toxic Shock Syndrome exotoxin and cell
walls from Staph. Aureus and Saccharomyces Cerevisiae)was measured.
Unstimulated cells failed to release IL1 bioactivity and each of the
microbial components tested was a powerful, dose-dependent stimulator of IL1
bioactivity release. This could not be attributed to carry-over of the
stimulus in the bioassays used, nor to interference by parallel production
of TNF, as human TNF fails to stimulate murine T-cell comitogenesis. The
ILl-like T cell co-mitogenic activity was inhibited by specific anti IL1
antiserum.
In the hope that a cell-line could substitute for human monocytes in
studies requiring large cell populations such as time-courses of protein and
mRNA accumulation, U937 cells were tested as IL1 producers. Attempts to
induce bioactive IL1 release from this line with LPS were unsuccessful.
This could represent a failure of IL1 translocation or parallel production
of agents such as PGE2 that could inhibit IL1 production (Knudsen et al,
1986a) or interfere in the T cell assay (Stobo et al, 1979; Baker et al,
1981). When TSS, reported to induce IL1 from U937 (Knudsen et al. 1986b),
was used, IL1 bioactivity was obtained from U937 cells, with increased
production in the presence of Ca Ionophore (10 ~^M) at 36.5° C. However, the
bioactivity produced was 10 to 50 times less than that from human monocytes.
This data and the report that U937 IL1 was different from normal human ILl's
(Knudsen et al, 1986B) led to the conclusion that U937 cells are not
reliable as a model of IL1 synthesis and release. Adherent human
mononuclear cells were used in further studies.
To study the kinetics of IL1 synthesis and release, IL1 bioactivity
was tested in cell-associated and extracellular fractions from cultures of
human monocytes. These were incubated for different lengths of time in
absence or in presence of a suboptimal concentration of LPS (lOOng/ml).
Unstimulated cells failed to accumulate IL1 bioactivity in the extracellular
compartment, reaching a peak of 52pg/ml in the cell associated fraction at 6
hours. Such amounts of IL1 (about 1000 times less than in the activated,
macrophages) agree with reports that demonstrate no activation of IL1
production in unstimulated human monocytes (Matsushima et al. 1986; Bakouche
et al. 1987A). It has been reported, however, that murine (Kurt-Jones et
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al, 1985; Fuhlbrigge et al, 1987) and human (Kahn Bayne et al, 1986)
macrophages could be activated by simple plastic adherence: this could be an
effect of the type of plastic used or different experimental conditions.
In kinetic studies of IL1 bioactivity accumulation after stimulation
(LPS lOOng/ml), IL1 activity in the cell-associated compartment always
exceeded extracellular levels. This confirms previous studies (Gery, Lepe-
Zuniga, 1983) which report IL1 as mainly a cell-associated biological
activity and is in keeping with the lack of a leader sequence in either of
the two peptides. The cell-associated fraction, as prepared in the present
study, includes cytosol, intracellular organelles and cellular membranes.
Biologically active IL1 has been demonstrated on the surface of fixed
macrophages (Kurt Jones et al. 1985; Matsushima et al. 1986; Bakouche et al.
1987A; Weaver, Unanue, 1986), on B cells (Acres et al. 1987A) and in T cells
(Tartakovski et al. 1986; Acres et ai, 1987B). In human monocytes
(Matsushima et al. 1986), membrane IL1 represented about half of the total
cell associated bioactivity. Most of the remaining intracellular
bioactivity seems to be associated with lysosomes (Bakouche et al, 1987A)
and a major fraction of nonbioactive IL1 in the cytosolic compartment could
be unmasked by trypsin treatment. From these studies, based on IL1
bioactivities, IL1 precursor seem to appear first in the cytosol, then in
the lysosomal and membrane compartments, where processing to mature
bioactive IL1 takes place. The mechanisms by which IL1 would gain access to
the outer side of the membrane and behave as a membrane-bound protein are
unknown. Two hypotheses have recently been advanced: IL1 would bind to 1,2,
diacylglycerol (DAG) moieties of phosphatidyl inositol in the membrane
(Bakouche et al. 1987A), stabilizing IL1 as an integral membrane protein;
alternatively, a recent report (Brody, Durum, 1987) suggests the
stabilization of IL1 on the mouse macrophage membrane via a lectin-like
mechanism. Conjugation to DAG would explain the
discrepancy in molecular weight between the membrane IL1, which is 22-23KDa
(Matsushima et al. 1986) and the mw of 17.5KDa of the mature extracellular
protein. In a recent experiment, (Baldari et al, 1987) it has been shown
that nothing in the structure of the mature IL1 beta opposes extracellular
translocation: when linked to a recognized leader sequence, IL1 beta is
completely translocated and cleaved correctly to release mature peptide.
The interpretation of the data shown in the present study and in the
previously mentioned work based on IL1 bioactivity ignores the possibility
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that different patterns of biological inhibitors and different contributions
from IL1 types might occur in different compartments.
To test this possibility the kinetics of specific IL1 alpha and beta
distribution were measured by immunoassays. This is the first study to show
that no immunoreactive IL1 alpha or beta (mature peptides or precursors) are
detectable in cells in the absence of activation at any timepoint in an 18
hrs incubation. Both IL1 alpha and IL1 beta proteins in human monocytes are
synthesized de novo, and not by processing from a preformed inactive protein
pool.
Upon LPS stimulation, Interleukin 1 alpha protein was detectable
earlier than IL1 beta in the cell-associated compartment (Fig. 23) and
constantly exceeded IL1 beta levels within the cell. Extracellular levels
of the cytokines were lower than in the cell-associated compartment and IL1
beta was the prevalent form in the supernatants. Considering the percentage
of each cytokine which stays in the cellular fraction (Fig. 24), and
assuming that the affinity of the antibodies in the immunoassays was
comparable between the mature and unprocessed forms of IL1, it is evident
that most (over 88%) of IL1 alpha, at each time point, remains cell
associated. IL1 beta, by 6 hours, and further at 9 and 18 hours, achieved
successful (over 50%) extracellular translocation. Recent reports (Conlon
et al. 1987; Kurt-Jones et al. 1987) pointed out that the main membrane form
on human cells is IL1 alpha. The present data show that about 70-80% of the
total cell-associated IL1 is of the alpha type.
The mechanism of cellular release for IL1 beta, remains unknown but
not unique, as FGF beta, also lacking a signal sequence, is efficiently
translocated. Dissociation between IL1 synthesis and release has been
reported by administration of LPS in liposomes (Bakouche et al. 1987B) or
after anti la treatment (Durum et al, 1985). It is clear that in our
conditions LPS induced synthesis of both ILls but activated a translocation
pathway only for IL1 beta. However, we obtained similar cellular
distribution using different stimuli (data shown in Chapter 3) confirming
that this is not simply an LPS-related phenomenon.
This difference in cellular distribution is one of very few reported
biological differences between IL1 alpha and IL1 beta. Interleukin 1 alpha,
the main form of cell-associated IL1 might be more important for the role of
IL1 in the immune system, and cell-cell interactions, while Interleukin 1
beta, the "secretory" IL1, might mediate actions at a distance, such as
fever and the induction of acute phase response.
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FIG 23 Kinetics of IL1 alpha and IL1 beta protein accumulation in
stimulated human monocytes
In monocytes stimulated with LPS (lOOng/ml) immunoreactive cell-
associated IL1 alpha and IL1 beta were detectable, as expected, before
extracellular protein. In this figure, which summarizes data in Figs. 21 and
22, the amounts at different time points have been expressed as shaded
areas. Note that the origin for the single values is the lower limit of the
relevant shaded area.
At 18hrs, cell-associated IL1 was mainly IL1 alpha (IL1 alpha =
42ng/ml; IL1 beta = 16ng/ml) while extracellular protein was mainly IL1 beta
(IL1 beta = 18.5ng/ml; IL1 alpha = 3.5ng/ml). At the last time point
studied, the total IL1 of each form was comparable (IL1 alpha = 45.5ng/ml;
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FIG 24 Kinetics of cellular distribution of IL1 alpha and IL1 beta
The total amount of each cytokine at different time points has been
calculated by adding the cell-associated and extracellular fractions. By 9
hours, 88% of IL1 alpha was still cell-associated, while only 35% of IL1
beta could be found within the cells.
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CHAPTER 2
Induction of Tumour Necrosis Factor by Microbial Products
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2.d.l INTRODUCTION
Infectious diseases often result in the depletion of the host's energy
stores, vasculopathy and multiple organ failure. Tumour Necrosis Factor in
particular, has been implicated in the progressive wasting diathesis
(cachexia) of chronic infections and tumours (Rouzer, Cerami, 1980; Oliff et
al 1987) and as an early mediator of lethal endotoxaemia (Beutler et a),
1985; Tracey et al. 1987).
The TNF gene has been conserved through mammalian evolution,
suggesting that its expression confers survival advantage to the species.
TNF has, infact,been shown to exert important anti-microbial effects (Wong,
Goeddel, 1986; Paraut et a), 1980; Havell, 1987) and to act as a general
immunepotentiator in vivo (Ghiara et al. 1987, Palladino et al. 1987).
The range of stimuli of TNF production is incompletely known. A
variety of microbial agents are able to induce TNF synthesis in vitro (Table
2.4), and it seems that significant quantities of protein are produced in
vivo under pathologic conditions: TNF has been detected in mice during
listeriosis (Havell, 1987) and after experimental pneumonia by Legionella
Pneumofila (Blanchard et al. 1987) and in humans during parasitic (Scuderi
et al. 1986) and meningococcal (Waage et al. 1987) infections.
Lipopolysaccharide has been the best studied inducer of TNF: the
active moiety appears to be Lipid A (Haranaka et al, 1984), but the
mechanisms of TNF gene activation is unknown. It seems that LPS stimulation
of TNF in vitro can be selectively blocked with inhibitors of
calcium/Calmodulin kinase (Kovacs et al, 1988) and that the continuous
presence of the stimulus on the outer membrane of the producing cells is
required (Gifford, Lohmann-Matthes, 1986). Studies in vivo documented
production of TNF alpha upon LPS stimulation in mice primed with
"reticuloendothelial stimulators". These included Calmette-Guerin Bacillus
(BCG) and Corynebacterium Parvum (now called Propionibacterium Acnes), which
are facultative intracellular bacteria, described to enhance resistance to
other infectious agents (Blanden et al, 1969; Adlam et al, 1972) or to
transferrable tumours (Old et al, 1961; Halpern et al, 1966). The true
nature of this "priming" and whether this is a necessary step leading to TNF
production upon microbial recognition is unclear. It has been hypothesized
(Gifford, Flick, 1987) that basal production of different cytokines after
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"priming" infection could eventually synergize with LPS to induce TNF
production: such a phenomenon has been documented in vitro, using human IFN
gamma (Gifford, Lohmann-Matthes, 1987).
At a cellular level, the current understanding of TNF production and
release (Beutler, Cerami, 1986) is that upon activation, TNF alpha synthesis
starts with the synthesis of a 233aa long precursor polypeptide. The first
76aa represent an unusually long, highly conserved signal peptide, which is
cleaved to smaller fragments during membrane translocation of TNF, the
mature form of which (17KDa, 157aa) is released extracellularly. TNF would
seem to be therefore a classical secretory protein.
This study tested the ability of human monocytes to produce TNF alpha
upon stimulation with different bacterial and fungal constituents reported
to induce IL1 synthesis. Kinetics of TNF alpha synthesis and release were
also assessed in human monocytes stimulated by lipopolysaccharide.
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2.d.2. RESULTS
2.d.2.1 Induction of TNF alpha by LPS
Lipopolysaccharide (lOOpg to lOug/ml) stimulated dose - dependent
extracellular release of TNF from human peripheral blood mononuclear cells
(Fig. 25). Such stimulating activity of LPS, as expected, could be
completely neutralized by the addition of 250u/ml PMB; and supernatants from
LPS induced cells, but not from unstimulated cells, contained immunoreactive
TNF alpha. To check the specificity of the L929 bioactivity, three
supernatants from this experiment were tested in presence or absence of
specific monoclonal antibody to TNF alpha (Fig. 26). The bioactivity was
completely neutralized, indicating that the L929 cytotoxicity was due to the
presence of TNF alpha.
2.d.2.2. Induction of TNF alpha release from monocytes stimulated by
different microbial products
Human peripheral blood adherent mononuclear cells were stimulated in
different experiments with increasing concentrations of heat killed
Staphylococcal cell walls (Fig. 27), toxic shock exotoxin (Fig. 28) and
Saccharomyces Cerevisiae cell walls (Fig. 29). All agents were powerful,
dose dependent stimuli. Some of the supernatants were also tested by
specific TNF alpha RIA (Figs 27,28,29), and contained up to 6.3ng/ml
immunoreactive TNF alpha. In parallel experiments, this TNF bioactivity was
completely neutralized by anti-TNF alpha monoclonal antibody, and it was
shown that carry-over of the agent used as stimulus could not be responsible
for the L929 cytotoxicity measured.
2.d.2.3. Kinetics of production and cellular distribution of TNF alpha
biological activity in human monocytes following LPS stimulation
Freshly isolated human adherent mononuclear cells (10^ monocytes/ml)
were cultured in presence or absence of a suboptimal dose of LPS (lOOng/ml).
At time-points ranging from immediately after density centrifugation to 18
hrs incubation, cell-associated and extracellular fractions were collected
from stimulated and unstimulated cultures to be tested for L929 cytotoxicity
(Fig. 30).
Cells which had been lysed immediately after density centrifugation or
at the end of plastic adherence (40 mins) did not contain detectable TNF
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activity (corresponding to less than 160pg/ml hrTNF). Unstimulated cells
also failed to express detectable activity at any time-point, both in the
cell-lysates and supernatants. TNF bioactivity accumulated in LPS-
stimulated cells as early as 30mins, to reach a plateau between 9 to 18hrs.
Starting from 45mins after induction, biological activity was mainly
recovered in the extracellular fraction, and exceeded the cell-associated
activity by 20 fold at 12 hrs.
To test the specificity of this biological activity, six of these
fractions (indicated with [*] in Fig. 30) were tested in presence or absence
of monoclonal antibodies to human recombinant TNF alpha (Table 2.5).
Complete neutralization confirmed that the biological activity was entirely
related to the presence of human TNF alpha (controls on the specificity of
this mab have been previously shown).
2.d.2.4 Time course of TNF alpha production and release assessed by
specific RIA
Cellular and extracellular fractions from the previously mentioned
experiment were also tested in a TNF alpha RIA (Medgenix). The results
confirmed (Fig. 31) that unstimulated cells did not express TNF alpha in
either compartment, supporting the concept that no preformed protein pool is
stored in cells prior to activation. The kinetics of cellular distribution
reflected TNF biological activity, indicating that in these experimental
conditions, the presence of immunoreactive protein in both compartments was
proportional to TNF biological activity. At 18 hours, extracellular TNF
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FIG 25 Induction of TNF release from human mononuclear cells stimulated
by LPS
Human mononuclear cells (2x10 ^/ml) were incubated for 12hrs in
presence or absence of different concentrations of LPS (horizontal axis).
Supernatants were assayed for TNF bioactivity in L929 cytotoxicity assay
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FIG 26 Antibody-neutralization of TNF-like bioactivity induced by LPS
To check that the previously tested bioactivity (Fig 25) was related
to TNF alpha, supernatants from LPS stimulated mononuclear cells were tested
in L929 assay in presence or absence of neutralizing mouse monoclonal
antibody to human TNF alpha (1:400 dilution). Supernatant from mononuclear
cells exposed to LPS (lOOng/ml) in presence of 250U/ml Polymyxin B was also
tested.
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gj = (ma + HKS) sup —►TNF a ria
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FIG. 27 Induction of TNF alpha release by heat-killed Staphylococci cell
walls (HKS)
Cell cultures of human mononuclear cells (3.5xl0^/ml) were incubated
with different concentrations of HKS (18hrs). Supernatants were tested for
L929 cytotoxicity (hatched bars) or in TNF alpha RIA (dotted bars). The
bioactivity in the supernatant from the culture stimulated with 10
bct/mononuclear cell, was completely inhibited by mab to human TNF alpha
(1:800 dilution). Heat killed staphylococci, in absence of mononuclear
cells, failed to induce L929 cytotoxicity.
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FIG. 28 Toxic shock syndrome exotoxin (TSS) induction of TNF alpha from
human monocytes
TNF bioactivity and immunoreactivity was tested in supernatants from
cultures of adherent mononuclear cells (10^ monocytes/ml) incubated for 18
hrs with different dilutions of TSS (horizontal axis, reciprocal of
dilution). TSS was a powerful, dose-dependent stimulator of TNF alpha
release, and, when incubated in absence of monocytes, failed to elicit L929
cytotoxicity. L929 bioactivity was inhibited by preincubation of the
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FIG. 29 Release of TNF alpha from human adherent mononuclear cells
stimulated by Saccharomyces Cerevisiae cell walls (Zymosan A)
Supernatants from human adherent mononuclear cells (10^ monocytes/ml,
18hrs) incubated in presence of different concentrations of fungal cell
walls, were assayed for L929 cytotoxicity and in TNF alpha RIA. TNF
bioactivity was inhibited when supernatants were preincubated with mab to
TNF alpha (1:400 dilution); supernatant from Zymosan (lmg/ml) incubated in
absence of cells failed to induce L929 cytotoxicity.
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FIG. 30 Cellular distribution and kinetics of TNF activity in LPS-
stimulated human monocytes
Human adherent mononuclear cells (lxlO^/ml) were cultured in absence
or presence of LPS (lOOng/ml). At different time points, supernatants and
cell-lysates were prepared from the cultures, to represent extracellular or
cell-associated fractions. These were tested in the L929 cytotoxicity assay
for TNF activity.
Fractions indicated with (*) have also been tested in presence of
neutralizing monoclonal antibody to hr TNF alpha (Table 2.5).
(A) cell-lysate of monocytes after density centrifugation
(B) supernatants and cell-lysate of cells after 40 mins plastic adherence





























TABLE 2.5 Effects of anti-TNF alpha antibodies on L929 cytotoxicity
To check if the biological activity on L929 cells of the fractions
indicated in Fig. 30 was related to TNF alpha, they were tested in presence
of monoclonal antibody to human TNF alpha (1:400 dilution). Data on the
specificity of this antibody have been presented (Fig. 13, p. 64).
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Time after stimulation
FIG. 31 Time course of TNF alpha production and release as assessed by
radioimmunoassay
Kinetics of TNF alpha accumulation and cellular distribution in human
monocytes were tested by TNF alpha RIA (Medgenix; assay detection limit:
lOOpg/ml TNF alpha)
(A) cell-lysate of monocytes after density centrifugation
(B) supernatants and cell-lysate of cells after 40 mins plastic adherence




The existence of a relationship between tumour necrosis factor
production and infectious diseases was clearly indicated in the original
observations (O'Malley et al, 1962; Carswell et al, 1975), when "Tumour
Necrosis Serum" was described in BCG-primed mice injected with
lipopolysaccharide (LPS).
The relevance of this association has been demonstrated in two extreme
conditions: low levels of TNF production during infection with Lysteria
Monocytogenes prevent microbial expansion and death (Havell, 1987) and seem
therefore to have beneficial effects for the host; however, high and
sustained levels of TNF mediate lethal endotoxaemia (Beutler et al, 1985;
Tracey et al. 1987) leading to multiple organ failure and death. It could
be argued that conditions leading to massive TNF synthesis (such as
overwhelming infections) are going to be lethal anyway, and TNF could be
beneficial in an evolutionary sense by rapidly removing a source of
infection.
The production of TNF alpha by human monocytes in response to
microbial agents, such as E. Coli LPS, toxic shock exotoxin, Saccharomyces
Cerevisiae and Staph. Aureus cell walls has been tested in the absence of
"priming" events. All of these products were powerful, dose dependent
inducers of TNF activity which could be completely neutralized by specific
anti human TNF alpha antibody. This observation is consistent with a recent
analysis of the "priming" phenomenon (Gifford, Flick, 1987) which showed
that single microbial agents, such as LPS can elicit TNF production in vivo
and in vitro and the use of "priming protocols" (such as facultative
intracellular bacteria in vivo or the presence of IFN gamma in vitro), only
increase and/or extend the production of TNF.
In the experiments described here, unstimulated adherent mononuclear
cells failed to release TNF alpha indicating a requirement for cellular
activation. This was confirmed when we examined the kinetics of production
and cellular distribution of TNF alpha: no TNF biological activity or
immunoreacti ve protein could be demonstrated at any time-point in
unstimulated cells or in their supernatants.
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Upon LPS stimulation, TNF biological activity accumulated in the cell-
associated fraction from 30 mins after induction, to reach a maximum by 9-12
hours. However, most of TNF activity (neutralized by specific antibody to
TNF alpha) was found in the supernatants. These findings were confirmed
when the presence of TNF alpha was tested by specific radioimmunoassay: TNF
alpha mainly accumulated in the extracellular compartment (56.8ng/ml at
18hrs), exceeding immunoreactive TNF which remained cell associated
(4.8ng/ml at 18hrs). It is noteworthy that, even if TNF alpha translocation
appears to be efficient from the first minutes of protein accumulation, a
small but significant proportion of TNF alpha biological activity and TNF
alpha protein could be found cell-associated. This phenomenon, particularly
evident in the first hour, is compatible with recent reports of cell-
associated forms of TNF alpha (Kriegler et al. 1988; Decker et al. 1987) and
could be of importance in cellular interactions.
When compared to the kinetics of cellular distribution of IL1 alpha
and IL1 beta (Fig. 32), TNF alpha translocation mechanisms appear to be
activated simultaneously with protein accumulation (44% translocated at
30mins), to achieve 90.5% release of TNF alpha at 18 hours: extracellular
translocation of IL1 alpha and IL1 beta, on the contrary, is delayed of
about 6-9 hours for IL1 alpha (amounting to 5-10% of total protein
accumulated) and of 1 to 4 hours for IL1 beta (achieving a maximum of 65% at
9 hours after stimulation).
These differences probably reflect the different structures of these
proteins (IL1 alpha and IL1 beta, unlike TNF alpha, lack a leader sequence).
Given their broad spectrum of similar properties (Dinarello, 1987), the
observation that the kinetics of secretion of TNF alpha, IL1 beta and IL1
alpha differ so dramatically could be surprising. However, the regulation of
the activity of these three cytokines in vivo could be regulated in
different situations by the level of their release from the cell or the
availability of bioactive cytokine on the membrane during cell-cell
interaction. These differences, and the possibility that structurally
different proteins would have differential access to recognition structures
in vivo could be the reason why three separate molecules should have evolved
independently and yet remain functionally similar.
The kinetics of TNF alpha protein accumulation observed, and its
absence in unstimulated cells, identify TNF alpha as a typical secretory
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Fig. 32 Comparison of TNF alpha, IL1 beta and IL1 alpha kinetics of
cellular distribution in human monocytes upon LPS stimulation
Time-related extracellular translocation of immunoreactive cytokines in
human adherent mononuclear cells upon LPS stimulation (lOOng/ml).
On the vertical axis is expressed the relative amount of TNF alpha, IL1
beta or IL1 alpha which accumulates in the cell-associated compartment.
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CHAPTER 3
Induction of IL-1 by pro-inflammatory crystals
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2.e.l. INTRODUCTION
The role of IL1 in the host response to microbial pathogens has been
discussed. Interleukin 1 is produced both by direct interaction of
microbial products with competent cells, or within antigen-mediated immune
responses, in which IL1 acts and is produced at different stages.
Apparently unrelated to the concept of host defense against infections, a
"miscellaneous" group of agents have been reported to induce LAF/EP activity
(Table 2.6). It has to be stressed that before accepting a novel stimulus
of IL-1 production, it must be extensively demonstrated that LPS, a
ubiquitous contaminant in most laboratories was not responsible and that the
stimulus itself, if carried over in the IL-1 bioassay could not mimick IL-1
effects. There are also reports of "spontaneous" production of IL-1 by
mesangial cells (Lovett et al, 1983) glioma cell lines (Fontana et al,
1982), T cell leukemia lines (Okada et al, 1986) and in monocytes from a
variety of diseases. Before accepting the concept of "spontaneous"
production as reflection of in vivo activation, mRNA or protein data should
be provided from samples that have been metabolically arrested seconds after
excision or venepuncture.
Crystals of Monosodium Urate have previously been described as potent
stimulators of EP activity from monocytes (Duff et al. 1983). This was a
dose-dependent effect, did not require serum factors or mediation by other
blood leukocytes, and was independent from phagocytosis of the crystals, and
LPS contamination could not be implicated in this induction. Pyrogenicity
however is not unique to IL-1, since recombinant TNF (Dinarello et al,
1986), IFN alpha (Dinarello et al. 1984) and IL6 (Dinarello et al. 1988) are
also pyrogenic.
In the present study IL-1 stimulation by inflammatory crystals, was
examined measuring IL-1 in a T-cell comitogenic assay in which TNF and alpha
IFN are not stimulatory. Kinetics of cellular distribution were tested for
IL1 biological activity and specific IL1 proteins, to study the mechanism of
release involved.
The crystals tested, MSU, HA and CPPD are all associated with human
arthritis: MSU is the necessary aetiologic agent of gout (Malawista, 1977),
HA is involved in a complex inflammatory arthritis and CPPD crystals are
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agents of chondrocalcinosis, and an inflammatory condition resembling gout -
called "Pseudogout" (reviewed in Ryan and McCarty, 1985).
Establishing IL1 as a pathogenic link between endogenous crystal
formation and local and systemic pathology could provide human models for
the inflammatory consequences of acute and chronic overproduction of IL1 in
the absence of infection.
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TABLE 2.6 Inducers of IL1 Activity bv Non-Microbial Non-Immune Mechanisms
AGENT PRODUCING ACTIVITY AUTHOR(S)
CELL INDUCED
Natural Exogenous
U.V. irradiation Epithelial cells LAF Luger et al, 1983; Gahring et
Macrophages LAF Matsushima and Oppenheim, 1985
Silica Crystals Macrophages LAF Gery et al, 1981
Macrophages EP Duff et al, 1983
THP-1 cells LAF Krakauer et al, 1983
Colchicine Macrophages EP Bodel, 1976
Macrophages LAF Stosic-Grujicic, Simic, 1982
Aluminium hydroxide Neutrophils LAF Yoshinaga et al, 1985




Phorbol -Myristic Monocytes LAF
Acetate Epithelial cells LAF
Dyalisis membrane Monocytes LAF
Hydroxyurea Monocytes LAF
Ca Ionophore A23187 Monocytes LAF
Poly I; Poly C Rabbit leukocytes EP
C. Endogenous
Dinarello et al, 1978
Oppenheim et al, 1980, Gery, Lope-Zuniga, 1983
Mizel et al, 1978; Gery, Lope-Zuniga, 1983
Luger et al, 1983
Lonnemann et al, 1987
Matsushima, Oppenheim, 1985
Matsushima, Oppenheim, 1985













Duff et al, 1983
Bodel, Dillard, 1968




2.e.2.1. Crystal induced IL-1 activity from blood monocytes
Crystals of monosodium urate in doses from 0.1 to 1.6mg/ml were potent
inducers of monocyte extracellular IL-1 activity (Fig. 33). LPS-free crystal
of MSU (8-40um), HA (3-15um) and CPPD (15-50um) were added at different
concentrations to human monocytes (1x10 ^/ml). After 20hr incubation,
supernatants were assayed in triplicate for LAF activity. In Fig. 33 are
shown cumulative data from different experiments. Individual induction
experiments (Fig. 34) give much clearer dose/response relations. This is in
keeping with the well known heterogeneity of IL1 production (Endres et al.
1987) in different individuals.
These supernatants were tested for IL2 bioactivity on CTLL-2 cells or
T lymphoblasts and showed no detectable TCGF activity (data not shown). The
T cell assay used for LAF activity was not influenced by the presence of
human TNF alpha or IFN alpha (2.b.3.2, pp 46,47). When tested with rabbit
antiserum to IL-1 (Table 2.7), MSU-induced IL-1 activity was completely
neutralized. This antiserum did not neutralize T cell responses to IL2, and
we never observed nonspecific suppressive effects of this antiserum on D10
cells, thymocytes or CTLL cells (data in Figs. 6-7, p. 58).
HA and CPPD crystals did not stimulate significant extracellular
activity in any of the concentrations tested. Pretreatment of the crystals
with serum (Fig. 35) did not consistently influence the ability of the
crystals to induce IL1 activity, with exception perhaps of the highest
concentration tested.
2.e.2.2. IL1 adsorption by crystals
It has been reported (Kozin, McCarthy, 1976; Hasselbacher, 1982) that
proteins can be readily adsorbed on to the surface of crystals. It was
possible that CPPD and HA crystals were stimulating extracellular IL1
release and adsorbing IL1 on their surface, so that IL1 could not be
detected in a centrifuged supernatant.
To test this different concentrations of the three crystals were
incubated with a human monocyte-derived IL1 crude preparation. After 20hrs
(37°C, 5% CO2), the crystals were precipitated by centrifugation (1800G,
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4°C, 30mins) and supernatants tested for mitogenic effects on D10 cells,
compared with the same crude IL1 preparation that had been incubated in
absence of crystals. None of the crystals (Fig. 36) reduced the
biodetectable IL1 in the medium after coincubation. Significant IL1
adsorption cannot thereafter be responsible for the failure to detect IL1 in
supernatants from monocytes induced with HA or CPPD crystals. Similar
results were obtained when IL1 was exposed to crystals in an agitated
incubation (data not shown).
2.e.2.3. Co-stimulation with LPS and HA or CPPD crystals
HA and CPPD crystals could be stimulating intracellular IL1 production
but failing to release it extracellularly, or non-specifically inhibiting
IL1 processing, release or detection.
To test this, HA or CPPD crystals were used in conjunction with
bacterial LPS. A dose of lng/ml LPS was used (in the suboptimal range for
IL1 induction) sufficient to stimulate IL1 synthesis and its release in a
bioactive form in the medium.
The presence of HA and CPPD with LPS in co-culture did not alter the
amount of detectable IL1 activity stimulated by LPS alone (Fig. 37). This
means that HA and CPPD crystals did not interfere with mechanisms of IL1
production, release, or the detection of IL1 biological activity.
2.e.2.4. Fibroblast proliferation
Crude MSU-induced supernatants that had LAF activity on D10 cells were
tested for induction of proliferation of human rheumatoid synovial
fibroblasts (Fig. 38). Dose-dependent fibroblast growth was obtained with
the monocyte supernatant, as well as with a highly purified human monocyte
IL1 ("22KDa factor").
2.e.2.5. IL1 activity from crystal-induced synovial fluid cells
Human rheumatoid synovial exudate adherent mononuclear cells
(1x10^/ml) were incubated in presence or absence of MSU or HA crystals.
Supernatants at 20hrs showed that "unstimulated" cells released significant,
amounts of IL1 activity, reflecting in vivo activation or inadvertent
stimulation during the separation procedure. These could be further
stimulated (Fig. 39) by MSU crystals but not by HA crystals. This IL1 - like
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activity was also completely neutralized by specific antiserum to human IL1
(Table 2.7).
2.e.2.6. Time course of production and cellular distribution of IL1
bioactivity and proteins by human monocytes stimulated by crystals
Supernatants and cell-lystates prepared by incubation of human
peripheral blood monocytes with different crystals (MSU, HA, CPPD) for
variable lengths of time (15mins to 18hrs) were tested for ILl-like activity
in the EL4/CTLL conversion assay. In MSU-stimulated cells, the cell-
associated fractions (lysates) (Fig. 40) yielded more bioactive IL1,
exceeding the extracellular bioactivity at each time point. IL1 was
detectable in the cell-lysates by 45 minutes, and in the extracellular
compartment by 2 hours.
Cells cultured in presence of HA and CPPD crystals failed to release
any detectable bioactivity, but expressed low levels of bioactivity
(equivalent to 50-70pg of human recombinant IL1) in the cell lysates at 2-6
hours.
To test the relative amounts of IL1 alpha and IL1 beta in the
different compartments after MSU stimulation, the fractions from the
previous experiments were tested with specific immunoassays for IL1 alpha
and IL1 beta.
IL1 alpha was detectable after 3 hours in the cell-lysates, to reach
6.25ng/ml at 18hrs. Cell-lysate levels constantly exceeded IL1 alpha
content in the supernatants, where IL1 alpha was found at 6 hours after
stimulation, to reach 0.75ng/ml at 18hrs (Fig. 41).
The pattern of IL1 beta cellular distribution (Fig. 42) appeared to be
different, as immunoreactive IL1 beta in the supernatants exceeded cell-
associated protein by 6 hours and at 18 hours 95% of total IL1 beta
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FIG 33 Release of ILI bioactivity from human monocytes stimulated with
crystals
Supernatants from crystal-stimulated mononuclear cells were assayed in
three dilutions (1:1000, 1:100, 1:10) for LAF/IL1 activity in the D10.G4.1
assay. In the figure are shown results for 1:100 dilution (in complete
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FIG. 34 Release of IL1 activity from monocytes stimulated with MSU
crystals is dose-related.
Production of ILl from monocytes of two normal volunteers after MSU
crystal stimulation. Supernatants were assayed in three different
concentrations (1:100 shown). Data are expressed as mean +SEM of
triplicates in proliferation units.
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Table 2.7 Antiserum to IL1 inhibits LAF activity from cells stimulated with
MSU crystals
Mitogenic responses of D10 cells (in proliferation units). Mean ±SEM
of triplicate responses to IL1 and mononuclear cell supernatants are shown.
Abbreviations: IL1. human recombinant IL1 beta (lOOpg/ml): MSU-PBMC, 1:100
supernatant of 10 adherent blood mononuclear cells cultured with 0.4mg/ml
MSU crystals: MSU-SC, 1:100 supernatant of 10 adherent mononuclear synovial
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FIG 35 Serum-pretreatment of crystals does not consistently influence
induction of IL1 activity
Untreated crystal and serum pretreated crystals were tested for their
ability to induce IL1 activity from human peripheral blood monocytes
(10 /ml, 20hrs). Supernatants were tested in 3 dilutions (1:20, 1:100,
1:500) in D10.G4.1 assay. Results are expressed as mean (±SEM) of
triplicate measurement of supernatants diluted in 1:100 in medium (cells +
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FIG 36 IL1 adsorption by crystals
To test whether surface adsorption of IL1 by any of the three crystals
might remove significant quantities of IL1 from the solution, crude IL1
preparation was added to each of the crystals at 37° C for 20hrs.
Centrifuged supernatants were then tested for LAF activity in the
D10.G4.1 assay and compared with the same ILl-containing supernatants
incubated in absence of crystals. Means (±SEM) of proliferation units are
















FIG 37 Co-incubation of crystals with lipopolysaccharide
To test if HA and CPPD were inducing IL1 synthesis but interfering
with release or biodetection, crystals and bacterial LPS, an independent
stimulus for both IL1 synthesis and release, were used.
As LPS was used in suboptimal concentration, significant augmentation
or depression of IL1 release would have been detectable. Three dilutions of
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FIG 38 Fibroblast proliferation
MSU induced supernatants, with LAF activity on D10.G4.1 were tested
for stimulation of human articular fibroblast proliferation.
^H-thymidine incorporation was assessed after 3 days incubation. For
comparison, response to highly purified IL1 beta (22Kd factor) in the same
experiment is shown. Results represent mean ±SEM of triplicate wells.
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FIG 39 Crystal-induced IL1 activity from synovial fluid cells
A Adherent synovial fluid mononuclear cells (1x10 ^cells/ml) were
incubated in absence or presence of crystals (HA, MSU) at different
concentrations. Supernatants of 20hrs incubation were tested in
triplicate in a murine thymocyte assay (CBA/Ca; cells + Con A = 2493 ±
68cpm). IL1 activity in the supernatant was completely neutralized by
anti IL1 antiserum (Table 2.7). Results are from supernatants diluted
1:100 and are means ±SEM of proliferation units in triplicate wells.
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FIG 40 Kinetics of IL1 activity accumulation by crystal - stimulated
adherent mononuclear cells
Extracellular and cell-associated fractions from human adherent
mononuclear cells stimulated by crystals were tested for IL1 bioactivity in
an EL4/CTLL2 assay. Results are expressed in U/ml from triplicate wells (1U
= IL1 - like activity equivalent to lng/ml human recombinant IL1 beta).
A = cell-lysate after density centrifugation
B = cell-lysate and supernatants after 40 mins plastic adherence
C = cell-lysate and supernatants at the addition of stimulus (time zero)
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FIG 41 Kinetics of immunoreactive IL1 alpha accumulation in MSU
stimulated monocytes
Interleukin 1 alpha was tested in the different fractions using an IL1
alpha-specific RIA (Amersham, UK). Results are means of duplicate tubes.
The lower detection limit of this assay is 70pg/ml hr IL1 alpha.
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FIG 42 Accumulation of immunoreactive IL1 beta in human monocytes with
MSU stimulation
Levels of IL1 beta in the cell lysates and supernatants from 10^/ml
human adherent mononuclear cells were tested using an IL1 beta-specific




The circumstantial evidence for IL1 involvement in human arthritis and
the existence of a sterile rheumatic condition (gout) in which the
arthritogenic stimulus (precipitation of MSU crystals) is known lead us to
test whether MSU crystals were a sufficient stimulus for IL1 induction in
vitro.
It had been reported that MSU crystals were potent stimulators of
endogenous pyrogen (EP) activity from human monocytes and rabbit macrophages
(Duff et al. 1983). In the present study, MSU and other pro-inflammatory
crystals (HA, CPPD) were tested for their ability to release IL1 from human
monocytes. Interleukin 1 bioactivity was tested in a LAF assay (D10.G4.1 T
cell comitogenesis assay) insensitive to the actions of human TNF alpha and
IFN alpha, two cytokines reported to have EP activity (Dinarello et a),
1986B, Dinarello et al. 1984). These cytokines did not induce proliferation
in the T-cell assay nor modify the response to human IL1.
Monosodium urate, but not the other crystal-types tested, were potent
stimulators of extracellular IL1 activity that was neutralized by specific
anti IL1 antibodies. This property of MSU crystals was not related to the
presence of LPS, a ubiquitous contaminant able to induce IL1 synthesis:
cells that had not been deliberately stimulated failed to produce detectable
IL1, indicating the absence of bioactive LPS in the media and plasticware
used for the experiments. The crystals were LPS-free, as assessed by
different criteria: MSU crystals were negative in the Limulus Gelation Test
for LPS and did not inhibit the test; the inducing properties of MSU were
not inhibited by the presence of Polymyxin B, a known neutralizer of LPS
activities (Duff, Atkins, 1982B); and soluble products from the crystals
failed to induce any detectable IL1 activity from human monocytes.
In this study, it appeared that stimulating activity of MSU was not
related to the presence of serum factors and previous work also showed that
internalization of crystals was not necessary (Duff et al. 1983).
The widespread belief that phagocytosis is a sufficient stimulus for
IL1 production is not supported by experimental data: phagocytosis of LPS-
free latex beads in vitro and in vivo does not induce IL1 activity (Berlin,
Wood 1964; Koyabashi, Friedman, 1964; Oken et al. 1981; Duff et al, 1983),
nor do living intracellular parasites (such as Leishmania Tropica) or
phagocytosis of their killed and opsonized amastigotes (Crawford et a),
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1983). Conversely, several particulate agents were not prevented from
inducing EP/LAF by preincubation of the monocytes with agents inhibiting
internalization: colchicine did not inhibit EP induction by Staph.
Epidermidis (Bodel, 1976) and cytochalasin B did not stop stimulation by MSU
and silica crystals (Duff et al, 1983) or Borrelia spirochetae (Butler et
a], 1982).
The two other crystal-types tested, HA and CPPD, did not induce
extracellular IL1 activity at the concentrations tested. This failure
appeared to be unrelated to interference with IL1 release or detection,
since the presence of neither crystal altered the amount of extracellular
IL1 produced by monocytes in response to a suboptimal concentration of an
independent stimulus, LPS. It is also unlikely that the failure to detect
IL1 was due to direct crystal adsorption of IL1 since monocyte supernatants
did not show any loss of IL1 activity after incubation in presence of
crystals. In time-course experiments, low levels of intracellular IL1
bioactivity were detected in HA-stimulated cells but also in unstimulated
monocytes, suggesting that this was not related to the presence of the
crystals. The different inducing properties of MSU, CPPD and HA crystals
also seem to be unrelated to different crystal sizes (Malawista et al.
1985). The same HA and CPPD crystal preparations used in these experiments
were, like MSU crystals, potent stimulators of neutrophil superoxide anion
production, demonstrating that they were capable of pro-inflammatory
leukocyte activation (Palit et al. 1986).
Regarding the mechanisms of IL1 induction by crystals, it has been
suggested (Gery, Lope-Zuniga, 1983) that IL1 release was related to the
membranolytic activity of the crystals. This would require the presence of
an intracellular pool of IL1 in absence of stimulation.
In time-course experiments, we were unable to demonstrate significant
bioactive or immunoreactive IL1 in unstimulated cells: IL1 accumulation only
occurred following MSU-stimulation of monocytes. Bioactive IL1 was
demonstrable in cell-associated fraction by 45' after stimulation,
compatible with a direct induction of IL1 by MSU crystals; bioactivity in
the cell-lysates at all time points exceeded extracellular bioactivity by a
factor of 3 to 5. These data are comparable to those obtained in previous
experiments using LPS stimulation.
Use of specific immunoassay showed that IL1 alpha was the predominant
form of cell-associated IL1 (90% of the total, 6.25ng/ml) while in the
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supernatant IL1 beta was more abundant (95% of total, 6.0ng/ml). Comparing
kinetics of cellular distribution after stimulation with MSU or LPS (Fig
45), MSU crystals showed a trend towards extracellular release for IL1 alpha
(at 6-9 hours) and mainly for IL1 beta at 6-18 hours.
We have not studied the occurrence of membrane damage, but release of
unprocessed IL1 beta precursor from cells stimulated with MSU, could account
for the different cellular distribution of immunoreactive IL1 beta in these
cells (95% released) compared to IL1 biological activity.
Induction of IL1 by MSU could account for a large part of the
previously reported EP activity (Duff et a), 1983; Malawista et al. 1985).
It is, of course, possible that MSU stimulates the production of TNF or
other factors in addition to IL1 from mononuclear phagocytes and that the
multiple catabolic effects of TNF may contribute independently or
synergystically with IL1 to the pathogenesis of gout or other inflammatory
diseases.
The potential relevance of MSU crystal-induced IL1 to the pathogenesis
of gouty arthritis is certainly increased by the present findings that human
synovial adherent mononuclear cells, as well as blood monocytes, released
IL1 activity following exposure to MSU crystals. Further, the proliferation
of synovial fluid fibroblast-like cells was stimulated by urate crystal-
induced monocyte supernatants with known IL1 content. Thus, cells derived
from human joints both released IL1 and responded to IL1-containing
supernatants induced by MSU crystals. Crystals of HA and CPPD, also related
to inflammatory arthritides (Ryan, McCarthy, 1985; Nuki, 1984; Dieppe et al.
1984) failed to provide a direct stimulus for IL1 production in these
experiments. This does not exclude, however, a role for IL1 in the
pathogenesis of inflammation induced by these crystals, since IL1 release
may be activated by mechanisms other than direct crystal stimulation of IL1
producing cells (Malawista et al. 1985).
As a model for the inflammatory consequences of overproduction of IL1,
gout is the only sterile inflammatory disease where the local and systemic
pathology is compatible with such overproduction; raised IL1 levels have
been found at the site of inflammation (Wood et al. 1983) and a necessary
etiologic agent, crystalline urate (Seegmiller et a), 1962; McCarthy, 1962;
Malawista, 1977) has been shown unequivocally to be a direct activator of
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FIG 43 Comparison of kinetics of cellular distribution of IL1 alpha and
IL1 beta in LPS or MSU stimulated monocytes
Derived from data shown in Fig 41 and Fig 42, in (a) is indicated
(vertical axis) the percentage for each IL1 species which remains cell-
associated, at different times after MSU stimulation. At 2 hrs both
cytokines were below the detection limit of the assay. In (b) are
presented, for comparison, data from time courses of induction previously
shown (Fig 24), of IL1 alpha and IL1 beta in LPS-stimulated human monocytes.
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CHAPTER 4
Induction of Tumour Necrosis Factor by Pro-inflammatory Crystals
126
2.f.l. INTRODUCTION
With the molecular cloning of TNF and the availability of pure
protein, studies have flourished in the areas of TNF receptor/post receptor
effects, metabolic and therapeutic effects in vivo and effects on cell-
mediated immunity in vitro. The study of TNF alpha induction has, however,
mainly involved infectious agents and little is known about the activation
of TNF production by non-microbial agents.
In this study, we investigated the effects of several synthetic pro¬
inflammatory crystals on TNF alpha production in adherent human mononuclear
cells.
The crystals tested, monosodium urate (MSU), hydroxyapatite (HA) and
calcium pyrophophosphate dihydrate (CPPD), are associated with different
forms of arthritis and MSU induces IL1 as described previously. Induction
of TNF release by crystals might synergize with IL1 in determining the
inflammatory consequences of crystal deposition.
2.f.2. RESULTS
2.f.2.1. Induction of TNF in blood monocytes by crystals
Human blood monocytes were incubated in presence or absence of LPS-
free crystals of MSU, HA or CPPD for 18 hrs, when supernatants were
collected and assayed in the L929 cytotoxicity assay (Fig. 44) for TNF
activity. MSU-stimulated cells, and to a lesser extent, cells that had been
treated with HA crystals, released significant amounts of TNF biological
activity, while cells incubated in absence of stimulus or with CPPD crystals
failed to produce any significant extracellular activity. TNF induction by
MSU crystals was dose-dependent, and maximal stimulation occurred at 1.2mg
crystals/ml.
To test the specificity of these bioassay results, supernatants from
cells stimulated with MSU crystals were tested for L929 cytotoxicity in
presence of monoclonal anti human TNF alpha antibody (kindly provided by Dr
G Adolf, Boehringer, Wien) or irrelevant monoclonal antibody (mouse anti
human DR). Results shown in Table 2.8 demonstrate selective inhibition of
L929 cytotoxicity, indicating extracellular production of bioactive TNF
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alpha by human monocytes stimulated by MSU crystals.
2.f.2.2. Crystal-induced TNF alpha from synovial fluid cells
Freshly isolated human RA synovial fluid adherent mononuclear cells
were found to release immunoreactive TNF alpha without being stimulated.
This could reflect activation in vivo of the cells to produce TNF alpha or
inadvertent activation during separation procedures (Fig. 45). The synovial
cells could be further stimulated to release TNF by incubation with 0.4mg/ml
MSU crystals but HA failed, at the concentration tested, to induce further
significant release of TNF alpha.
2.f.2.3. Kinetics of production and cellular distribution of TNF alpha in
crystal-stimulated cells
Human adherent mononuclear cells (10^/well/ml) were prepared from
peripheral blood by density centrifugation. Cells were incubated with or
without different concentrations of crystals of MSU, HA, or CPPD. At
different time points (0 to 18hrs), supernatants were collected
(extracellular fraction), and adherent cells reconstituted with equal volume
of medium and lysed by rapid freeze-thawing (cell-associated fraction).
Fractions were stored at -8CP C until tested in the L929 cytotoxicity assay
for TNF activity.
In Fig. 46 are shown the results of such experiments: kinetics of MSU
induction of TNF activity follow the same pattern previously shown for LPS
induction of TNF (Fig 30, p. 98). After an initial peak of cell-associated
TNF at 3 hrs, extracellular TNF at 6 hours clearly exceeds cell associated
to reach a maximum at 12-18 hrs.
To confirm on a quantitative basis the kinetics of cellular
distribution, immunoreactive TNF alpha levels were tested in the same
cellular fractions (Fig. 47). The results show comparable kinetics to those
obtained by TNF biological activity (90.5% of TNF alpha translocated at 18
hrs), suggesting that in these conditions, no major accumulation of inactive
TNF alpha precursor takes place.
Interestingly, MSU induced TNF activity is detectable at 3 hours,
while upon LPS stimulation it occurred after minutes of induction; however,
the peak of accumulation seems to be at the same time point, suggesting
similar kinetics but on a smaller scale.
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In cells stimulated with HA and CPPD crystals, TNF biological activity
could not be detected in the supernatants nor in the cell-lysates.
Unstimulated cells similarly failed to express any TNF activity or TNF alpha































FIG. 44 TNF activity in supernatants of crystal-stimulated human adherent
mononuclear cells
Different doses of crystals of MSU, HA and CPPD were tested in 18 hour
incubation with human adherent mononuclear cells (10^monocytes/ml) for their
ability to induce extracellular TNF release. Supernatants were tested in
L929 cytotoxicity assay (in which 1U = 40pg/ml hr TNF alpha). Data are
expressed as mean (±SEM) for the number of experiments indicated. In the
same experiments, TNF bioactivity was not detectable in supernatants from
cells incubated with medium only (data not shown).
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Sample with Sample with
Sample mab anti-hr TNF control mab
alone 1:800 1:800
MSU induced sup. ,,
(0.4 mg/ml) ,7'61 <4 24'16
MSU induced sup. no
(0.8 mg/ml) 36'92 <4 42"77
MSU induced sup. ?
(1.2 mg/ml) 27*35 < 4 28'75
LPS induced sup. q q
(100 ng/ml) 1469'9 < 4 822'40
hr TNF hpta
(1 ng/ml) 24.08+3.34 21.68+2.85 29.52
U Ig/ml)Pha 22.13+2.45 <4 20.91
TABLE 2.8 Effect of anti TNF alpha monoclonal antibody on L929
cytotoxicity
L929 cell cytotoxicity by supernatants of mononuclear cell populations
exposed for 18 hours to different stimuli. Supernatants were tested for TNF
biological activity in presence or absence of specific anti human TNF alpha
monoclonal antibody, or irrelevant mouse anti human monoclonal (anti-human
DR). Results are expressed in half-maximal units/ml.
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Crystal conc. (mg/ml)
FIG. 45 Synovial fluid mononuclear cells produce TNF alpha
Synovial fluid mononuclear cells were separated by density
centrifugation from freshly aspirated RA synovial exudate fluids, followed
by adherence in plastic Petri-dishes (40 mins). Crystals of MSU or HA at
the concentrations shown in the horizontal axis were added, and after 20 hr
incubation supernatants were collected to be tested in a monospecific TNF
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FIG. 46 Time course of TNF production and cellular distribution upon
crystal stimulation
TNF biological activity in extracellular and cell-associated fractions
from cells incubated for different times (horizontal axis) in presence or
absence of different crystals. Fractions represent individual cultures of
adherent mononuclear cells.
*A: cell associated TNF activity in 3x10 human mononuclear cells
immediately after density centrifugation.
*B: cell-associated and extracellular supernatants of cells at the end of
plastic adherence (40 mins). ^
*C: cell - associate d and extracellular activities in cells (10
monocytes/ml) at the addition of stimuli (time-point zero).
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FIG. 47 Kinetics of TNF alpha cellular distribution
Fractions from the previous experiment (Fig. 46) were tested in a




A previous report showed that crystals of monosodium urate were potent
stimulators of monocyte endogenous pyrogen activity (Duff et al. 1983). In
further studies, the same authors (Malawista et al, 1985) demonstrated that
such induction was not a universal property of arthritis-associated
crystals, as HA and CPPD crystals, in similar conditions, failed to induce
EP activity release from human monocytes.
Pyrogenicity is one of the diverse biological activities of IL1, but
it is not unique to IL1 since recombinant TNF (Dinarello et al. 1986), alpha
interferon (Dinarello et al, 1984) and IL6 (Dinarello et al, 1988) are also
pyrogenic, even if with lower specific activity.
Using a biological assay insensitive to TNF and specific
radioimmunoassays, we have shown (Chapter 1, pp 66-68) that IL1 production
certainly occurred upon MSU crystal stimulation of human monocytes and MSU
itself was a potent stimulus for both synthesis and release of IL1 peptides.
We report here that MSU crystals, but not CPPD, are dose-dependent,
powerful inducers of TNF activity from human monocytes. HA in some
experiments induced release of low level of TNF bioactivity but this could
not always be reproduced and in subsequent time-course experiments was not
confirmed.
The biological assay used (the standard L929 cytotoxicity assay) is
not sensitive to human IL1 (2.b.6.1, p. 52), but will respond equally to TNF
alpha and the lymphocytic product TNF beta (lymphotoxin). However, the
biological activity induced by MSU crystals was completely neutralized by
monoclonal antibody to human TNF alpha.
In these studies, we also show production of TNF alpha from rheumatoid
arthritis synovial fluid adherent mononuclear cells. These released
"spontaneously" significant amounts of TNF alpha, and such production could
be further stimulated by addition of MSU, while HA crystals had no effect.
The failure of HA and CPPD to induce high levels of TNF synthesis
(rather than a failure to stimulate release) was confirmed in time-course
experiments where both crystals failed to induce cell-associated TNF
biological activity, and in parallel experiments (2.g.3.3., p. 150) TNF
alpha mRNA did not accumulate in HA or CPPD treated cells.
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In contrast, LPS-free crystals of MSU induced time - dependent
accumulation of TNF alpha protein and biological activity in both cell-
associated and extracellular compartments, with detectable levels at 3 hours
in cell-lysates, followed by steady extracellular translocation of
biologically active TNF alpha, found mainly in the supernatants at 9-18
hours (extracellular TNF alpha = 2.24ng/ml - 90.5% of total). These kinetics
of accumulation of TNF alpha upon stimulation of monocytes with MSU crystals
seem thereafter to be comparable to those obtained with LPS stimulation,
i.e. those of a typical secretory protein.
In different studies we have demonstrated that in similar conditions
LPS-free crystals of MSU induce dose and time-related synthesis and release
of biologically active IL1 alpha, IL1 beta and TNF alpha peptides. Such
production could be triggered from both normal human blood adherent
mononuclear cells and synovial adherent mononuclear cells from a patient
with rheumatoid arthritis.
All of these cytokines have independent pro-inflammatory, catabolic
and immunopotentiating activities and each can thereafter contribute
independently to the inflammatory consequences of MSU crystal deposition.
In view of the reported synergy of TNF and IL1 in several human systems
(Elias et a), 1987; Stashenko et al, 1987; Ruggiero, Baglioni, 1987), and
the possibility of mutual activation via cytokine - mediated amplification
circuits (Oppenheim et al. 1987), overproduction of both IL1 and TNF could
provide a pathogenetic link between MSU crystal deposition and the
inflammation and tissue damage of gouty arthritis.
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2.g. CHAPTER 5
Interleukin 1 beta and tumour necrosis factor alpha mRNA
accumulation in human blood mononuclear cells
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2.g.l. INTRODUCTION
The work reported in the previous chapters indicated that IL1 and TNF
alpha are "transiently" induced proteins, i.e. cell products which are not
released by resting cells and whose translocation only follows new protein
synthesis, as no cell-associated protein pool could be demonstrated in
absence of cell activation. New IL1 protein synthesis is believed to be
related to rapid translation of newly formed mRNA (Oppenheim et al. 1986).
In maximally stimulated cells, IL-1 beta mRNA represents, according to
different authors, from 0.1% (March et al. 1985) to 5% (Webb et al. 1985) of
total cellular mRNA, exceeding by 40 (E. Kovacs, unpublished) to 300 (Fenton
et al, 1987) times the low levels found in unstimulated monocytic cells.
The levels of IL-1 beta mRNA appear to exceed, after stimulation, those of
IL-1 alpha in a ratio of 10:1 (March et al, 1985) to 500:1 (Dinarello,
1986). The variability of these data can be related to the type and quality
of stimulus used, duration of stimulation, conditions of cultures and cell-
type used.
In the present study we tested IL-1 beta mRNA accumulation and protein
synthesis in a 36 hours time-course in serum-free conditions and using
stimuli at a concentration previously shown to be the most effective for the
production in vitro of IL-1 bioactivity. In particular, LPS was used at a
concentration of lOOng/ml, that is 10-100 times lower than commonly used.
Most studies regarding induction of TNF synthesis have been performed
in vivo, as previously indicated. After analysis of protein and mRNA
accumulation Beutler et al. (1986) reported the presence of an untranslated
TNF alpha mRNA pool in "resting" cells (elicited murine peritoneal
macrophages) and the ability of IFN gamma to synergize with LPS in inducing
translation of this mRNA. Lipopolysaccharide was able greatly to enhance
mRNA accumulation in these cells representing up to 0.5% of the total
cellular mRNA.
When the present study was started no description of TNF alpha mRNA
accumulation kinetics in human monocytes was available. To investigate
kinetics of TNF alpha mRNA accumulation, we used a concentration of LPS
(lOOng/ml) lower than those used by other authors (l-10ug/ml). High levels
of LPS have, in fact, been reported to be down-regulators of IL-1 and TNF
production, possibly via induction of PGE2 (Kunkel et al. 1986; Wallach and
Hahn, 1983).
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In these experiments we also tested the inducing properties of the
same range of pro-inflammatory crystals previously tested at a protein
level. This was useful to complete the characterization of MSU as
stimulator of IL1 and TNF gene expression as well as providing grounds for
comparison with LPS-induced cellular activation.
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2.g.2. MATERIALS AND METHODS
2.g.2.1 Cellular activation
Human peripheral blood mononuclear cells were separated on density
gradient (Lymphoprep, pyrogen-tested, 1.077 density, Nyegaard, Oslo). After
careful washes in LPS-free phosphate buffered saline, cells were incubated
in RPMI 1640 medium (2mM glutamine, penicillin lOOU/ml, streptomycin
lOOug/ml) in absence or presence of different stimuli, such as LPS
(lOOng/ml) or MSU, HA, CPPD crystals (0.4mg/ml). In previous experiments,
these concentrations had been demonstrated optimal or suboptimal for IL1 and
TNF release from human monocytes.
For kinetic studies, cells were cultured in 1ml aliquots (4x10^
mononuclear cells/ml; 50% monocytes; 1.5ml sterile tubes, Sarstedt, UK), for
times ranging from lhr to 36 hrs. After incubation, tubes were spun at
800G, 15 mins and supernatants stored for extracellular cytokine assay. The
cell pellets were stored at -7Cf C until the experiment reached completion
and then used for mRNA analysis.
In cultures that were going to be used for Northern analysis, cells
were selected for plastic adherence (40 mins) before addition of stimuli
(1x10^ monocytes/ml; 20 to 30ml cultures in Petri dishes from Nunc,
Denmark). After 6 hours incubation, supernatants were removed and cells
lysed by direct addition of 3ml 4M Guanidinium and immediately processed for
mRNA analysis.
2.g.2.2. cDNA probes
Human TNF alpha cDNA (1606 bp, inserted in the unique Pst I site of
pAT 153) was kindly donated by Dr W. Fiers (Univ. Ghent, Belgium). To
detect TNF alpha mRNA, we used the 1180 bp Pst I fragment, which contains
the complete coding region (699 bp) for the human TNF alpha precursor
(Marmenout et al. 1985).
Interleukin 1 beta mRNA was detected using a Pst I insert in pBr 322
(from Dr D. Carter, The Upjohn Company, Kalamazoo, MI) of a cDNA coding for
aa 5 to 269 of the human IL1 beta propeptide (D. Carter, unpublished data).
The control probe was a 708 bp Pst I-Dra I fragment from p7B6 insert
in pBr 322 (from Dr U Torelli, Univ. Modena, Italy), which codes for a
species of mRNA whose levels are constant throughout the cell cycle. This
was identified from a cDNA library prepared from a patient with chronic
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lymphocytic leukemia (Kaczmarek et al. 1985).
All fragments were P-labelled by random oligo-priming (Feinberg,
Vogelstein, 1984). After separation on Sephadex G50 from unincorporated
label, cDNA probes labelled, as assessed by Cerenkov radiation, at a
8
specific activity of 4-10x10 cpm/ug DNA were obtained.
2.g.2.3. mRNA analysis
In kinetic studies, total cytoplasmic RNA was prepared from cells
according to the method by White & Bancroft (1982). Cells were harvested by
centrifugation (600G, 5 mins), resuspended in ice-cold lOmM Tris, ImM EDTA
(pH 7.0) and after detergent lysis (Nonidet P-40, Sigma) the nuclei were
pelleted by spinning at 15000G (3 mins). Whole cytoplasmic extracts were
transferred to tubes containing standard saline citrate and formaldehyde
(final 0.9M NaCl/90mM Sodium Citrate, 7.4% formaldehyde) and incubated at
60° C for 15mins to denature RNA.
Cytoplasmic extracts were serially diluted 1:5 in a microtiter plate
(in 2.25M NaCl/0.22M Sodium Citrate; starting from 4xl0^cells/100ul/slot),
and transferred on to nylon membranes (Hybond N, Amersham, UK) using a
Minifold II slot blot apparatus (Schleicher & Schuell, FRG). The membrane
was exposed to UV (5 mins) to fix cytoplasmic macromolecules and
prehybridized for 8-20 hrs at 37° C in prehybridization solution (50%
Formamide, 240mM NaCl, 30mM Sodium Citrate, 40mM Sodium Phosphate, 0.02%
Ficoll, 0.02% polyvinyl pyrrolidine, 0.02% bovine serum albumin).
Hybridization was carried out in fresh prehybridization solution to which
calf thymus DNA (50ug/ml) and the P-labelled probe had been added. After
18-24 hours at 37° C, membranes were washed four times (15 mins) in 0.1%
sodium dodecyl sulphate and decreasing salt concentrations (from 0.3M NaCl,
30mM Sodium Citrate to 15mM NaCl, 1.5mM Sodium Citrate) and exposed to Agfa
X-ray films at -8CP C with intensifying screens for 12 hours to 4 days.
Autoradiographs were scanned at OD^q in a Shimadzu CS9000
densitometer using a calibration of 16x (Fig. 48). The integral of the area
of the peaks was used as measure of the presence of specific mRNA within
each particular series of cultures (Scanning Densitometry Units = SD units).
To ensure that these methods were producing consistent RNA extraction,
loading and transfer, and to monitor variations in cell numbers during the
kinetic studies, control experiments were performed (Fig. 49), probing with
7B6 cDNA which recognizes a cell-cycle independent form of human mRNA
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(Kaczmarek et al. 1985).
For Northern analysis, total cellular RNA was isolated using a
modified version of the guanidinium/hot phenol method (Feramisco et al,
1982). Briefly, cellular protein structures were disintegrated in 4M
guanidine isothiocyanate and the preparations were treated with hot phenol
(BRL, 60° C, 5 mins), followed by addition of ice-cold buffer (0.1M Sodium
Acetate, pH 5.2; lOmM Tris, pH7.4; ImM EDTA) and chloroform/isoamyl alcohol
mixture. The extracted upper phase was transferred and underwent a second
cycle of treatment. Total RNA in the final aqueous phase was precipitated
in 70% ethanol. Final RNA pellets were resuspended in water and their
concentration was determined by UV spectrophotometry. Samples were size-
fractionated in agarose/formaldehyde gels (1.3% Seakem agarose, 6.7% BRL
formaldehyde, 20mM MOPS, 5mM Sodium Acetate, ImM EDTA), using as markers
Lambda/Hind III digests, and transferred to nylon membranes (Hybond N,
Amersham, UK) by capillary blotting. UV treatment, prehybridization,
hybridization and all following procedures were as previously indicated for
total cytoplasmic RNA preparations.
2.g.2.4. Immunoassays of IL1 beta and TNF alpha
IL1 beta and TNF alpha concentrations in the supernatants of cultures
used for mRNA analysis were assessed by IL1 beta RIA (Cistron Technology)
and TNF alpha RIA (Medgenix) as previously indicated (2.b.3.4, p. 48 and
2.b.6.2, p. 52). Results reflect specific translocated cytokine
accumulation at different time points from cultures which were assessed in
parallel for kinetics of cytokine-specific mRNA accumulation.
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Fig. 48 Scanning Densitometry
Scanning densitometry of all autoradiography was performed with a
Shimadzu CS9000 densitometer, 16x calibration, ODr™. ,,Ihe area of the
peaks, proportional to the amount of hybridization of the P-labelled probe
to the membrane, was measured in "Scanning Densitometry Units" (SD Unit).
Semi-quantitative data obtained in such a way were used for kinetic
analysis. The scan shown refers to unstimulated cells and LPS-induced
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2.g.3. RESULTS
2.g.3.1. Time related accumulation of IL1 beta mRNA and extracellular IL1
beta protein
Human peripheral blood mononuclear cells (4xlO*Vml, 50% monocytes)
were incubated for times ranging from 1 hour to 36 hrs in presence of LPS
(lOOng/ml) or MSU (0.4mg/ml), HA (0.4mg/ml), CPPD (0.4mg/ml) crystals or
medium control (serum-free RPMI). At different time points, cells were
lysed for analysis of mRNA accumulation, and supernatants from MSU and LPS
stimulated cultures, as well as from control culture, were tested for
immunoreacti ve IL1 beta. Autoradiographs of cytoplasmic slot blot
hybridized with IL1 beta cDNA probe are shown in Fig. 50, and quantitative
data obtained by scanning densitometry are in Fig. 51-54.
Unstimulated cells (Fig. 51) and cells treated with CPPD (Fig. 52)
failed to accumulate IL-1 beta mRNA, while HA induced low levels of IL-1
beta mRNA (Fig. 52). Lypopolysaccharide induced an early accumulation of IL-
1 beta mRNA (probably from the first minutes after stimulation), with a
first peak at 2.5 hours and a second at 9-20 hours (Fig. 53). MSU induced a
first peak of accumulation at 6 hours and a second at 20 hours (Fig. 54).
As expected, unstimulated cells, which did not accumulate specific
mRNA also failed to express any IL1 beta release; in MSU or LPS-stimulated
cells, mRNA accumulation was followed concordantly by detection of IL1 beta
protein in the supernatants, possibly with an earlier translocation in the
MSU-treated cultures.
2.g.3.2. Northern analysis (IL1 beta)
Total cellular RNA extracted by the guanidinium/hot phenol method from
adherent mononuclear cells was examined by Northern Analysis. In Fig. 55,
are shown results from a 6 hour induction experiment in which crystals of
MSU, HA or CPPD had been used. The cells incubated with medium alone or HA
or CPPD crystals failed to induce accumulation of IL-1 beta mRNA, while MSU-
induced cells show at 6 hours an mRNA species that migrates as 1.6Kb and





—1.0 —1.5 —2.5 3.5 6.0 9.0 20 36 hours







0 0 LI beta, extracellular protein
f/°i T xy-








Fig. 51 IL1 beta mRNA and released protein accumulation in unstimulated
mononuclear cells
Results from cultures of 4x10 mononuclear cells/ml (50% monocytes)
incubated and harvested at different time points. Shown are mRNA levels
expressed in S.D. (scanning densitometry) units = integrated area (xl0""j of
the peaks above background, obtained by scanning of autoradiographs (Fig. 50)
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Fig. 52 IL1 beta mRNA accumulation in HA and CPPD crystal-stimulated
mononuclear cells
Culture conditions and expression of results as in Fig. 51 legend.




1.0 1.5 2.5 15 6 9 20 36
■ hours after stimulation
Fig. 53 IL1 beta mRNA and extracellular IL1 beta protein in cells
stimulated with LPS
Cultures condition and expression of results as in Fig. 51 legend.
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Fig. 54 IL1 beta mRNA and released protein in MSU crystal-stimulated
cells
Expression of results and culture conditions as in Fig. 51 legend.






Fig. 55 Northern analysis of crystal-induced adherent mononuclear cells
1L1 beta mRNA
Northern analysis of human adherent mononuclear cells (mnc) RNA.
Total hot phenol / guanidine isothiocyanate-purified RNA (5ug/lane) from
1x10 /ml adherent m.n.c. culture (a-d) was fractionated oh
agarose/formaldehyde gel and transferred to nylon membrane for hybridization
to the IL1 beta probe, (a) stimulated with CPPD crystals, 0.4mg/ml; (b) HA
crystals, 0.4mg/ml; (c) MSU crystals, 0.4mg/ml; (d) incubated in absence of
stimulus. Molecular sizes are shown on the left.
149
2.g.3.3. Time course of TNF alpha mRNA accumulation
Cytoplasmic RNA preparations described in (2.g.3.1.) were transferred
to nylon membranes and hybridized with TNF alpha cDNA. Autoradiographs are
shown in Fig. 56 and quantitative data obtained by scanning densitometry are
reported in Fig. 57-60. Unstimulated cells (Fig. 57) appear to accumulate
low but significant levels of TNF mRNA at 6hrs and at 20-36 hours.
Surprisingly, this was not followed by TNF alpha protein detection in the
cellular supernatants. HA and CPPD-induced cells (Fig. 58) failed to
accumulate TNF alpha mRNA, but LPS and MSU crystals (Figs. 59 and 60)
stimulated early accumulation of TNF alpha mRNA. Such mRNA accumulation in
LPS and MSU-treated mononuclear cells was followed by protein synthesis, and
immunoreactive TNF alpha accumulated concordantly in the extracellular
compartments.
2.g.3.4. Northern analysis (TNF alpha)
Specific TNF alpha mRNA accumulation was examined by Northern analysis
on adherent mononuclear cells stimulated with LPS (lOOng/ml), or MSU, HA or
CPPD crystals (0.4mg/ml). Cells were harvested and total RNA extracted at
6hrs time point. As shown in Fig. 61, bands are visible in the 1.5Kb
region in the MSU and LPS-stimulated cells but not in cells incubated in
presence of control medium or crystals of HA and CPPD.
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Fig.56Totalcy oplasmicRNAslot-blotanalysis(TNFphacDNA) Totalcy oplasmicRNAextractions,sfroFig.50lege d,weretransferredylonm mbranesandhybridizedtoP-lab lledhumanTNFa phaprobe.Sh wnrresultsfr m1/10ilution(4x10mono uclearcelltotalRNA/slot).Quantitatived abyscanningdens tometryrshownFig.57-60.(CM)=unstimulatedcells;(LPS)= ,lOOng/ml;(M U),(HACPPD)=differentcrystals,0.4 g/ml.
Fig. 57 TNF alpha mRNA and released protein in unstimulated cells
Scanning densitometry of autoradiograph shown in Fig. 56. Culture






m.n.c. ♦ CPPD (0.4mg/rrH)
2 «
hours after stimulation
Fig. 58 TNF alpha mRNA accumulation
mononuclear cells
Expression of results and culture
(legend Fig. 51). Autoradiograph scanned
in HA and CPPD-stimulated human
conditions as previously described
is in Fig. 56.
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Fig. 59 TNF alpha mRNA accumulation and TNF alpha protein release in cell
stimulated with LPS
Details of cultures and scanning densitometry as in legend to Fig. 51.
Original autoradiograph in Fig. 56.
1.0 1.S 2.5 3.5 0 9 20 36
hours after stimulation
Fig. 60 Kinetics of accumulation of TNF alpha mRNA and extracellular
protein in MSU-stimulated cells
Culture conditions and expression of results as in legend to Fig. 51.







Fig. 61 Northern analysis of adherent mononuclear cells TNF alpha mRNA
Total extracted RNA (as described in 2.g.2.1) from 1x10^ adherent
mononuclear cells/ml cultures (6 hours stimulation) was fractionated (^-^8
RNA/lane) and transferred to Hybond N membranes. Hybridization to "P
labelled human TNF alpha cDNA was monitored by autoradiography.
(a) CPPD crystals stimulation, 0.4mg/ml; (b) HA crystals, 0.4mg/ml; (c) MSU
crystals, 0.4mg/ml; (d) LPS, lOOng/ml; (e) unstimulated cells.
154
2.g.4. DISCUSSION
We previously showed that TNF alpha and IL1 beta were released from
human monocytes only upon activation by competent stimuli, such as different
microbial products or MSU crystals. As preformed proteins could not be
demonstrated in unstimulated cells, this was not a mere activation of
extracellular release, but induction of new protein synthesis. This view
was also supported by very typical kinetics of protein accumulation in
different compartments upon stimulation.
To investigate the control of production of these cytokines, in this
study we tested the kinetics of IL1 beta and TNF alpha mRNA accumulation in
human mononuclear cells upon activation.
The data demonstrate that IL1 beta and TNF alpha cytoplasmic mRNA
rapidly accumulated in cells stimulated with lipopolysaccharide or MSU
crystals. IL1 beta and TNF alpha proteins were subsequently synthesized and
can be readily detected in the extracellular supernatants.
Interleukin 1 beta message accumulated only in cells that had been
stimulated: unstimulated cells or cells stimulated with calcium
pyrophosphate dihydrate failed to accumulate IL1 beta mRNA over a period of
36 hours. The absence of specific transcripts in unstimulated cells
supports the view (Oppenheim et al. 1986) that IL1 beta is an inducible,
transiently expressed cytokine and that, in contrast with previous reports
(Fuhlbrigge et al. 1987), IL1 gene expression in human monocytes requires
specific stimulation.
In our experiments, we studied IL1 beta mRNA accumulation in
peripheral blood mononuclear cells, using a low dose of LPS (lOOng/ml) or a
separate stimulation, MSU crystals, that we previously reported to be a
powerful inducer of IL1 synthesis and release. In these conditions, IL1
beta mRNA accumulates following biphasic kinetics, with a first peak at 2.5-
6 hours (depending on the type of stimulus used) and a second at 9-20 hours.
A recent report (Fenton et al, 1987) in which THP-1 cells, (a human
monocytic leukemia cell line) was used, shows a single peak of mRNA
accumulation which corresponds to the first peak that we observe. It is
possible that the second peak of induction in our experiments is the result
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of the use of a total mononuclear cell population, susceptible to
interactions between the cellular subsets and possibly new IL1 induction
through a cytokine network. However, a different study in which pure human
monocyte populations had been used, confirmed high levels of IL1 beta mRNA
still being produced at 16 hours (Matsushima et al. 1986B).
In the kinetics of TNF alpha mRNA accumulation, an early peak of mRNA
(1-3.5 hours) occurred upon stimulation by LPS or MSU and extracellular
protein could be detected in association with mRNA indicating efficient
protein synthesis, processing and translocation.
Unstimulated cells accumulated low levels of TNF alpha mRNA in the
second day of incubation which was not followed by translocation of
immunoreactive protein. In view of the previous work on the secretory
nature of TNF alpha, this could indicate the existence of an untranslated
mRNA pool accumulating in monocytes at late stages of incubation. Such a
phenomenon had been previously reported in elicited macrophages from mice
(Beutler et al. 1986B) but has never been tested before on human mononuclear
cells beyond the initial few hours of incubation.
Recent work has elucidated further the nature of TNF alpha and IL1
beta gene regulation. Nuclear transcription experiments have shown that
stimulation determines the appearance of mRNA by direct activation of TNF
alpha (Sariban et al. 1988) and IL1 beta (Fenton et al. 1987) transcription.
In the same experiments, no transcription was active in unstimulated cells,
demonstrating that TNF alpha and IL1 beta regulation differs from that of c-
myc in activated T cells (Thompson et al. 1986) and of interferon beta in
human fibroblast (Raj, Pitha, 1983). In these cases, the accumulation of
short-lived mRNA was not regulated at a transcriptional level but by
temporary inactivation of cytoplasmic nuclease, which was degrading a steady
state pool of nuclear RNA transcribed at constant rate.
Both IL1 beta and TNF alpha mRNA's appear to have relatively short
half lives, as in our experiment levels of accumulated mRNA decreased fairly
rapidly during kinetic studies. The half-life of TNF alpha mRNA has been
quantified as 20 mins (Sariban et al. 1988). Such mRNA instability has been
associated in most-cytokines with the presence in the 3' flanking region of
a repeating and overlapping octameric sequence, thought to confer message
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instability (Caput et al. 1986; Shaw, Kamen, 1986): presumably the sequence
facilitates nuclease degradation of mRNA. The observation that the protein
synthesis inhibitor cycloheximide (CHX), when appropriately administered,
paradoxically increases total cytokine accumulation (Billiau et al. 1973;
Mizel, Mizel 1981), provided further insight into cytokine gene regulation.
CHX augments IL1 beta (Collart et al. 1986; Fenton et al. 1987) and TNF
alpha (Sariban et al, 1988; Collart et al. 1986) transcription, and prolongs
the half-lives of their mRNA's. This latter could be related to inhibition
of specific RNAse synthesis or inhibition of cytokine synthesis below the
level where its intracellular concentration could provide a negative
feedback on its own synthesis.
The increase in transcription might be related to the existence of a
transcriptional repressor protein (Fenton et al, 1987) whose synthesis is
stimulated by high-dose LPS and inhibited by CHX. This work has been
followed, and regulatory sequences in the IL1 beta gene have been identified
(Clark et al, 1988), suggesting a specific site of action for a
transcriptional activator and a transcriptional repressor.
The work presented in this chapter analyzes quantitative changes in
cytokine-specific mRNA under different conditions of cellular stimulation.
These data, along with similar reports in this rapidly evolving field,




Human immunity is based on a system of transiently-expressed genes
encoding proteins ("cytokines") with powerful receptor-mediated effects on
the different cellular elements of the immune system. The "adaptive"
response is triggered by the binding of antigen to the lymphocyte antigen
receptor (on B or T cells) selecting cells for clonal expansion and making
them responsive to cytokine stimulation.
The work presented here stresses a different aspect of host defence,
based on the induction of cytokines by microbial agents via a non-antigenic
mechanism. In the case of IL1 and TNF, this response is likely to precede
and augment antigen-activation of lymphocytes, and represents transient gene
transcription with activation of protein synthesis, processing and release.
We report evidence that, in this process, IL1 beta and TNF alpha are mainly
released to the extracellular space (for autocrine, paracrine or endocrine
actions) and IL1 alpha mainly accumulates within the producing cells,
possibly for action during cell-cell interactions, as a membrane-associated
form.
To test a potential role for cytokines in the pathogenesis of human
arthritis, we studied the ability of sterile, LPS-free pro-inflammatory
crystals to induce synthesis and release of IL1 and TNF. MSU crystals,
whose deposition has been associated with gout (Seegmiller et al. 1962) were
a powerful, dose-dependent stimulus for the production of these cytokines in
normal human monocytes. In the same experiments, HA and CPPD, two other
crystal-types associated with human arthritis, failed to induce cytokine
production, suggesting that this is not a non-specific monocyte response to
perturbation by particulate agents.
These results, and the arthritogenic, pro-inflammatory and catabolic
properties of these cytokines in vivo (Pettipher et al, 1986) and in vitro
(Dayer et al, 1976, 1985; Saklatvala, 1986) and the observation of
immunoreactive IL1 and TNF in gouty synovial effusions (Wood et al. 1983;
data presented in Section II, p. 161), provide evidence for a role of IL1
and TNF in urate crystal arthropathy.
Gene expression of IL1 beta or TNF alpha in human monocytes appears
regulated at transcriptional level and the presence of specific mRNA is
related to cellular activation with subsequent production of biologically
159
active protein. Abnormally high levels of these cytokines could result by
dysregulation of gene expression, persisting stimulatory conditions, absence
of negative feedback mechanism or reduced elimination rates.
To propose a role for these cytokines in the pathogenesis of human
arthritis, evidence must be provided first for their presence in vivo at the
site of inflammation. This was the aim of the work reported in the next
section (Section II: "The presence of IL1 and TNF alpha in joint effusions
from patients with rheumatic diseases").
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SECTION II :




The concept of soluble leukocyte products as mediators of joint tissue
destruction in arthritis (Bodel, Hollingsworth, 1967; Dayer et al. 1977;
Dingle et al., 1979) is supported by the known pro-inflammatory,
immunopotentiating and catabolic activities of cytokines, such as IL1 and
TNF.
Further evidence might include:
1. Identification of such mediators at the site of inflammation.
2. Demonstration of a significant correlation between the presence of the
cytokines and disease activity.
3. Reproduction of disease by administered cytokines.
4. Interruption of the pathogenic process by antagonists of cytokine
production or effects.
An example where these criteria have been satisfied is the role of TNF
alpha in lethal endotoxic shock. Circulating TNF is present in patients
with endotoxic shock (Waage et al, 1986), lethal outcome in humans is
related to TNF levels (Waage et al, 1987; Girardin et al, 1988), injection
of TNF reproduces a toxic syndrome (Tracey et al. 1986B) and pretreatment of
primates with anti TNF mab protects them from the otherwise lethal effects
of LPS injection (Tracey et al, 1987). Some pathological conditions in
which the presence of IL1 or TNF has been documented are summarized in Table
3.1.
The presence of IL1 -like activity in joint fluids has been reported by
several authors. The pioneering studies of Bodel ad Hollingsworth (1967),
who detected EP activity in most synovial fluids tested were followed by the
detection of IL1 bioactivity in unfractionated (Fontana et ai, 1982B) or
affinity purified (Wood et al. 1983: Bendtzen et ai, 1985) synovial fluids.
Because of the presence of powerful biological inhibitors in these
effusions, purification was required, which made these studies non-
quantitative and resulting in only a small number of patients being
assessed.
As well as the many effects in vivo of IL1 and TNF on the immune
system, liver and bone marrow (previously indicated in Table 1.9, p. 19 and
Table 1.12, p. 28), IL1 also has potent arthritogenic properties in vivo. A
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significant inflammatory exudate was obtained by injection of LPS or EP in
rabbit joints (Hollingsworth, Atkins, 1965), and injection of recombinant
IL1 (Pettipher et al. 1986) induced polymorphonuclear cell accumulation in
the joint space and proteoglycan loss from the cartilage.
In the studies reported here the presence of IL1 or TNF was tested in
synovial effusions from a large population of patients with rheumatic
diseases. Biological assays and specific immunoassays were used and
cytokine levels were compared with a full range of laboratory and clinical
markers of disease activity within the population.
These experiments were performed for three reasons: Tumour necrosis
factor, despite its pro-inflammatory actions in vitro, had not been
previously studied at this site of inflammation; differential measurement of
IL1 beta and IL1 alpha had not been performed in synovial fluids; the use of
specific immunoassays for these cytokines allows quantitative comparison
with clinical data.
Biologically significant levels of IL1 alpha, IL1 beta and TNF alpha
were found in most synovial fluids from patients with different rheumatic
conditions and their relationship to markers of disease activity is
discussed.
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Table 3.1 Detection of IL1 or T\F proteins or biological activity EX VIVO*
Study
IL1
Circulating levels during human fever
LAF activity in normal urine
IL1 activity in fractionated human plasma
after exercise
IL1 activity in fractionated human plasma
after ovulation
IL1 alpha activity in human amniotic fluid
during normal pregnancies
LAF activity in cerebrospinal fluid in a
model of multiple sclerosis (CREAE, guinea
pigs) correlates with relapse
LAF activity in extracts of human psoriatic
skin lesions
Serum IL1 beta (RIA) correlates with
severity of meningococcaemia in children
Plasma IL1 beta (ELISA) correlates with disease
activity in rheumatoid arthritis
Authorfsl
(Bendtzen et al.. 1984)
(Kimball et al.. 1984)
(Cannon, Kluger, 1983)
(Cannon, Dinarello, 1985)
(Brody et al. 1987B)
(Symons et al. 1987)
(Camp et al. 1986)
(Girardin et al. 1988)
(Eastgate et al. 1988)
TNF
Lethal circulating levels in rabbits with
endotoxic shock
Raised serum TNF levels in human parasitic
infections
Association of TNF serum levels and fatal
outcome in meningococcal disease
Serum TNF levels in severly burned patients
are raised and correlate with complications
and death rate
Raised TNF levels in renal allograft rejection
Serum TNF levels correlate with severity of
purpura fulminans in children
(Abe et al. 1985)
(Scuderi et al. 1986)
(Waage et al, 1987)
(Reuter et al. 1988)
(Maury, Teppo, 1987)
(Girardin et al. 1988)
*N.B. Studies on synovial effusions are discussed in the text.
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3.b MATERIALS AND METHODS
3.b.l. Patients and clinical specimens
Synovial exudate fluids (SF) were obtained from patients undergoing
aspiration of symptomatic knee joints. Clinical diagnoses covered a wide
range of rheumatic diseases as indicated in the results section. All of the
patients were receiving non-steroidal anti-inflammatory drugs, some of them
were on second-line drugs (such as gold salts, chloroquine or penicillamine)
and a small number were receiving low dose oral corticosteroids. The SF
tested were mainly from patients with chronic rheumatic diseases but there
were a few cases of septic arthritis or acute gout. Cytokine levels in
synovial fluids were tested in different studies (over a period of 2 years)
and compared with diagnosis, presence of radiological bone erosions, sex,
age, duration of disease, and with drug therapy. Clinical laboratory tests
included: haemoglobin (Fib), white cell count (WCC), platelet count (Pit) and
erythrocyte sedimentation rate (ESR).
Synovial fluids were collected in EDTA (5mM) under sterile conditions.
After centrifugation at 1800G for 30mins at 4° C, supernatants were aliquoted
and stored at -7CP C until analysis. Some aliquots of SF underwent an
additional hyaluronidase digestion (37° C, 30 mins, 150U/ml bovine testicular
hyaluronidase, Sigma, UK) followed by a second centrifugation. These
supernatants were stored for subsequent parallel testing with the non-
treated samples. A total of 228 SF were collected and used in these
studies. Of these, 15 were tested for IL1 biological activity, 137 for TNF
biological activity, 32 for immunoreactive IFN gamma, 119 for IL1 beta by
RIA, 130 for IL1 alpha (IRMA) and 134 for TNF alpha (IRMA). Thirty two
patients also had blood taken at the same time as joint aspiration with
plasmas or sera being stored at -2(f C.
3.b.2. Reagents
Human recombinant (hr) IL1 alpha and IL1 beta were provided by Biogen
(Geneva, CH), Immunex (Seattle, USA) and Dainippon (Osaka, Japan). Human
recombinant TNF alpha, hr TNF beta, monoclonal antibody ("TNF-E") specific
for hr TNF alpha and rabbit antiserum to hr TNF beta were all kindly donated
by Dr G Adolf (Boehringer Inst, Wien, Austria). Mouse mab to human MHC
class II was kindly provided by Dr M Steele (MRC Cytogenetics Unit,
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Edinburgh). Human recombinant IFN gamma was kindly donated by Dr C A
Dinarello (Tufts Univ., Boston, USA).
3.b.3. Assays for biological activity
The D10.G4.1 T cell proliferation and L929 cytotoxicity assays
(described in 2.b.3.2, p. 45 and 2.b.6.1, p. 50) were used to test for IL1
and TNF biological activity in synovial fluids. Both of these biological
assays have been previously tested for specificity and synergistic
interactions against a panel of human and murine cytokines. In particular,
D10.G4.1 T cell proliferation was not influenced by the presence of hr TNF
alpha and L929 cytotoxicity could not be obtained by a wide range of IL1
alpha or hr IL1 beta concentrations (experiments shown in Fig. 5, p. 57 and
Fig. 12, p. 63).
To confirm that L929 cytotoxicity by SF was due to TNF, some positive
samples were assayed in the presence or absence of mab to hr TNF alpha or a
control mab. These quantitative experiments indicated that some cytotoxic
samples could not be neutralised by anti human TNF alpha mab. In order to
determine the proportion of fluids with TNF alpha biological activity, a
further 44 fluids were subsequently tested for L929 cytotoxicity in
triplicate at one dilution only (1:8), after 1 hour preincubation with
either culture medium, anti hr TNF alpha mab, anti-human DR (control ab) or
rabbit antiserum to hr TNF beta.
3.b.4. Assays for biological inhibition
Eight SF were tested for inhibitory activity of L929 cytotoxicity by
hr TNF alpha. Dilution of each synovial fluid were tested in the presence
or absence of hr TNF alpha (40pg/ml). Each plate included wells in which
only hr TNF alpha was added (40pg/ml, in one case lng/ml). Calculation of
the TNF alpha-inhibitory activity of each SF dilution was possible after 24
hours culture. This was quantified by plotting SF dilutions against
percentage of biological inhibition (Fig. 62). One inhibitory unit was
defined as the dilution of SF able to neutralize 75% of the cytotoxicity
induced by 40pg/ml hr TNF alpha. This concentration was chosen as it is
easily detectable in L929 cytotoxicity but it is still in the suboptimal
range of the assay. Details on biological inhibition assay and calculations
are in Appendix (p. 211). Inhibition of IL1 biological activity was tested
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in 4 synovial fluids using the D10.G4.1 assay, by comparing the
proliferative response (expressed in proliferation units) to a suboptimal




Immunoreactive human IL1 beta was assessed using a commercially
available radioimmunoassay (Cistron Biotech/Lab. Impex) according to a
published protocol (Lisi et al, 1987). This assay is based on the
• • • 125
competition for specific anti-human IL1 beta rabbit antiserum between I-
labelled IL1 beta and IL1 beta in the sample or standard tubes. The
detection limits of this assay are 0.25-5ng/ml hr IL1 beta. Determinations
were in duplicate tubes and experiments were performed to control for
specificity (Fig. 64), recovery of exogenously added hr IL1 beta (78±5%;
Table 3.2) linearity of dilutions (Fig. 65) and interassay variability (less
than 10% in 5 samples tested in different assays).
Interleukin 1 alpha
Levels of human IL1 alpha in aliquots of synovial fluids were assessed
by Dr S. Poole (N.I.B.S.C., Potters Bar, UK) using a sensitive two-site
immunoradiometric assay (Thorpe et al. 1988). Briefly, wells of a flexible
96 well microtitre plate were coated with monoclonal ab to IL1 alpha. After
washes and blocking of remaining protein binding sites, samples or standard
hr IL1 alpha were added followed by overnight incubation. After further
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washes, I-labelled "developing" antibody (sheep antiserum to hr IL1
alpha) was added and after final vigorous washes residual radioactivity was
estimated in a gamma counter. This assay was demonstrated to be suitable for
SF determinations by studying interassay variability, recovery of
exogenously added hr IL1 alpha and linearity of dilutions (Thorpe et al.
1988). Detection limits were 0.02-10ng/ml hr IL1 alpha.
Interferon gamma
A commercially available IRMA (Sucrosep-Gamma, Boots-Celltech, UK) was
used to test human IFN gamma levels in 32 synovial fluids. The test samples
125
were incubated with I-labelled monoclonal antibody to IFN gamma, followed
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by capture of the I-labelled complex with a sheep-antihuman IFN gamma
antibody coupled to a solid phase. Bound labelled mab was isolated by
sucrose layering separation, with radioactivity in the lower, denser phase
being proportional to the IFN gamma content in the sample or standards. To
detect the presence of interfering substances, different dilutions of IFN
gamma were tested in presence of two synovial fluids (Fig. 66). Detection
limits for this assay were l-1024U/ml.
Tumour necrosis factor alpha
The presence of immunoreactive human TNF alpha in SF samples was
determined by Dr A Meager (N.I.B.S.C., Potters Bar, UK) using a solid phase,
two-site "sandwich immunoassay" method, with less than 10% inter-assay or
intra-assay variation over the range 25pg to 25ug/ml hr TNF alpha (A.
Meager, Personal Communication). This IRMA is based on the capture of
ligand in the samples or standards on etched polystyrene beads which have
been coated with hr TNF alpha monoclonal antibody. After extensive
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washings, ""'I-labelled anti-human TNF alpha is used to assess the amount of
ligand trapped by the first antibody. Under these conditions, the IRMA has
a lower detection limit of 12.5pg/ml hr TNF alpha. Although hyaluronidase
treatment dramatically reduced SF viscosity, when paired samples (n=9) were
tested in blind experiments (Fig. 67) no significant difference was observed
(signed rank test, p=>0.5) in TNF immunoreactivity. Other blind controls
included testing the recovery of exogenously added hr TNF alpha
(104.32±8.35%; Table 3.3) and linearity of dilutions (Fig. 68).
3.b.6. Statistical analysis
This was performed with an "EPISTAT" statistical package for IBM PC.
Analysis included:
1. Assessment of correlation between different cytokines in SF samples.
Qualitative agreement was studied by Kappa statistic (Everitt, 1968),
quantitative correlation by Spearman's rank correlation, before and
after selection for samples which were "positive" for both cytokines.
2. Comparison between levels of one cytokine in SF samples, and clinical
data from patients:
a. continuous variables (Hb,ESR, Pit, WCC, age, duration of disease)
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were tested by Spearman's rank coefficient, and by one-way analysis
of variance (after division of patients in 3 groups, according to the
cytokine levels in their SF)
b. dichotomous variables (x-ray erosions, sex) were tested by unpaired
T-test, on two groups divided according to sex or the presence
of erosions
c. non-continuous variables (diagnosis, drug treatment) were analysed by
one-way analysis of variance, and by chi-square test (dividing the
patients in 3 groups, according to the cytokine levels in their SF).
3. Differences in cytokine levels between paired samples. Signed rank-test
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Fig. 62 Inhibition of TNF alpha biological activity by SF dilutions
Typical dilution curves of TNF alpha-inhibiting activities in some of
the SF tested; SF 10 was tested against hr TNF alpha at Ing/ml, while SF 73,
45 and 116 against 40pg/ml hr TNF alpha. The four fluids have respectively
no inhibition of lng/ml TNF alpha and about 8, 58 and >512 inhibition U/ml
on 40pg/ml hr TNF alpha.
SF rec. dll
Fig. 63 Inhibition of IL1 biological activity by SF dilutions
Dilutions of SF were tested for their ability to inhibit ILl-driven
D10.G4.1 proliferation. T-cell mitogenesis, expressed in proliferation
units (cpm sample + cells + Con A/cpm cells + Con A) were compared in
triplicate cultures incubated with hr IL1 beta (60pg/ml) and in the presence
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Fig. 64 Interleukin 1 beta specificity control
Different IL1 beta and IL1 alpha proteins were tested in the IL1 beta
radioimmunoassay. IL1 alpha was not detected in the assay, indicating no
antibody-crossreactivity. Other cytokine preparations tested and similarly
undetected by the RIA included hr IFN gamma (lOOOU/ml) and hr TNF alpha
(5ng/ml).
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< 0.125 0.304 0.731 1.632






0.821 0.972 1.582 2.687
73.6 % 84.1 % 95.25 %
Table 3.2 "Spiking" of fluids with hr IL1 beta
Human recombinant IL1 beta was tested in the presence or absence of
SF. hr IL1 beta solutions or BSA buffer were mixed with four volumes of SF









Fig. 65 Immunoreactive IL1 beta in SF dilutions
Two synovial fluids were tested in different dilutions to test for
linearity. The two fluids tested had 4.41ng/ml (closed circles) and
18.05ng/ml (open circles) IL1 beta.
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Fig. 66 "Spiking" of fluids with human IFN gamma
Different concentrations of human IFN gamma were tested in presence or
absence of two different synovial fluids. These did not influence IFN gamma









Fig. 67 Hyaluronidase treatment of synovial fluids
In each of nine SF, supernatants from one aliquot (A) were stored at.
-80° C after centrifugation (1800G, 30 mins); a second aliquot underwent
hyaluronidase treatment (150U/ml, 37° C, 30 mins) prior to a second
centrifugation. These aliquots (B) were stored until testing in parallel
with (A) in a TNF alpha IRMA. Signed-rank test confirmed that hyaluronidase
treatment does not influence yield of TNF alpha from synovial fluids.
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hr TNF alpha added ( pg/ml )
- 50 500 5000
expected 4250 4700 9700
SF 73 determined 4200 4500 5500 9000
% recovered 105.9 % 117 % 92.8 %
expected 50 500 5000
SF 159 determined < 12.5 70 340 4500
% recovered 140 % 68% 90 %
expected 73 523 5023
SF 133 determined 23.0 105 48.0 4500
% recovered 143.8% 91.8 % 89.6 %
Table 3.3 "Spiking" of synovial fluids with TNF alpha
Recovery of hr TNF alpha added to different SF was studied in these
experiments. Overall recovery was 104.3±8.35%. Dilutions performed as in
Table 3.2 legend.
rec. dilution
Fig. 68 Dilutions of immunoreactive TNF alpha in synovial fluids
Three different synovial fluids were tested for immunoreactive TNF
alpha in a blind experiment, in different dilutions. The three SF had been




3.C.I. Interleukin 1 biological activity in synovial fluids
Our preliminary attempts to demonstrate IL1 bioactivity in
unfractionated joint effusions revealed strong inhibitory activity of the
fluids (at 1:100 or higher concentrations) on D10.G4.1 T-cell proliferation
in tissue culture (Fig. 63). When tested in the presence of a suboptimal
concentration of hr IL1 beta (60pg/ml) which gave 67.4±2.7 p.u., synovial
fluids were powerful inhibitors of T-cell mitogenesis. However, at higher
dilutions of SF an increased response of 86.9±5.05 p.u. (3 SF in triplicate)
was observed, suggesting the unmasking of IL1 biological activity by
dilution of the inhibitory action of synovial fluids.
3.C.2. Interleukin 1 beta RIA
A total of 119 joint fluids were tested for the presence of
immunoreactive IL1 beta (Table 3.4). High levels of IL1 beta (up to
18ng/ml) were present in most of the fluids tested (76.5%) without
association with any particular rheumatic condition. The "miscellaneous"
group included two samples from a patient with septic arthritis (before and
after two weeks antibiotic therapy), one palindromic rheumatism, one gout
(three days after the acute attack: 2.44ng/ml IL1 beta) one ankylosing
spondylitis, one recurrent monoarthritis and one psoriatic arthritis.
Interleukin 1 beta was not related to TNF alpha (n=55), IL1 alpha
(n=54) or IFN gamma (n=7) levels in fluids which had been tested for these
cytokines. No correlation with clinical and laboratory parameters could be
demonstrated.
Circulating levels of IL1 beta (in 23 sera and 9 plasmas) were below
the assay detection limit (250pg/ml), while parallel synovial fluids had
high levels of immunoreactive cytokine (up to 4.85ng/ml IL1 beta in 31 out
of 32 samples).
3.C.3 Interleukin 1 alpha IRMA
Levels of immunoreactive IL1 alpha were determined in 130 synovial
fluids (Table 3.5). Of these, fifty (38.5%) had detectable levels of IL1
alpha (up to 3.5ng/ml). The "miscellaneous" group included one patient with
Behcet's syndrome and four with ankylosing spondylitis (all negative), five
psoriatic arthritis (2 being positive), three seronegative monoarthritis
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(one was positive), one gout (62pg/ml IL1 alpha), three septic arthritis
fluids (all positive, two from the same patient after two weeks therapy),
one hairy-cell leukemia synovitis (82pg/ml), two palindromic rheumatisms
(both positive). No correlation was demonstrated with other cytokines in
fluids which had been tested for several proteins (TNF alpha : n=130; IL1
beta; n=54; IFN gamma; n=25). Clinical and laboratory tests of disease
activity did not correlate with IL1 alpha levels in this cross-sectional
study.
3.C.4. Interferon gamma IRMA
Interferon gamma levels were studied in 32 synovial fluids (27
rheumatoid arthritis, 5 osteoarthritis). All fluids read below the
detection limit of the IRMA used (lU/ml). This could not be attributed to
the presence of interfering substances in the fluids as demonstrated by
"spiking" experiments.
3.C.5. Tumour Necrosis Factor biological activity in joint fiuids
Of the initial 93 SF tested, 35 had TNF-like activity of 4U/ml or
greater. Table 3.6 summarizes the clinical diagnoses and levels of TNF-like
activity. The two positive fluids in the miscellaneous group were from
patients with recurrent monoarthritis. Several SF with the highest levels
had been assayed fresh, suggesting that activity may be lost after freeze-
thawing or storage at -7CP C.
To test for specificity of these readings, eight of the 35 fluids with
TNF-like activity were tested in full titrations alone or with anti-TNF
alpha or control mab (Table 3.7). Six were completely neutralized by anti-
TNF alpha but two were not, suggesting that other cytotoxic factors were
present in these samples.
To determine the proportion of SF that contained cytotoxic activity
attributable to TNF alpha, we tested a second group of 44 SF in triplicate
at one dilution only (1:8) following pre-incubation with medium control or
antibodies (1:1600, 30 mins, room temp.). Of these 44 fluids 13 (30%)
contained TNF activity that was unaffected by control antibody but
completely neutralized with anti TNF ab. These included SF from patients
with rheumatoid arthritis, septic arthritis, ankylosing spondylitis,
osteoarthritis, psoriatic arthritis, reactive arthritis and gout. Twenty
three samples (52%) had no TNF cytotoxicity, and eight (18%) were cytotoxic
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for L929 cells but were either not neutralized with anti-TNF ab or were
affected by the irrelevant mab. Interestingly, of the 21 SF cytotoxic for
L929 cells, none was neutralized by antiserum to lymphotoxin.
No association was found between levels of TNF activity in SF and
clinical or laboratory parameters. No correlation was demonstrated between
levels of IL1 beta (n=53) or IL1 alpha (n=127) and TNF biological activity.
3.C.6. Inhibitors of TNF biological activity in SF
Of the nine fluids tested, one fluid did not inhibit lng/ml hr TNF
alpha cytotoxicity at any of the concentrations tested (1:4 to 1:512). Five
SF contained TNF inhibitory activity quantifiable at between 8 to 54U/ml
(respectively 8,12,12,48,54 U/ml, representing inhibitory activity of 0.24
to 1.62ng/ml TNF alpha. Three other SF showed very high inhibitory activity
against 40pg/ml hr TNF alpha that did not dilute even at 1:512 dilution.
3.C.7. Tumour Necrosis Factor alpha IRMA
Because of the presence of such powerful biological inhibitory
activity in SF, TNF alpha was tested by TNF IRMA on a total of 134 fluids.
Of these, 64 (47.8%) had levels of TNF exceeding 12.5pg/ml (range: 12.5pg/ml
to 4.9ng/ml) (Table 3.8). The miscellaneous group included patients with a
variety of rheumatic diseases. The eleven positive SF in this group were
from one juvenile chronic arthritis, one palindromic rheumatism, one gout,
two ankylosing spondylitis, one psoriatic arthritis, one polymyalgia
rheumatica and three septic arthritis (two from the same patient at
different times).
No significant correlation was noted with clinical parameters in the
whole population, nor within each disease group. There was no significant
difference in TNF titres between disease groups and no relation to drug
therapy. No quantitative correlation existed with IL1 beta (n=55), IL1
alpha (n=130) and IFN gamma (n=26) levels, nor with TNF biological activity
in the forty samples which were positive in both assays. This last
observation was not surprising in view of the presence of powerful
inhibitors of biological activity differentially distributed in SF.
When qualitative comparison was performed on 130 SF tested for TNF
alpha IRMA and L929 cytotoxicity (Table 3.9) however, 61 fluids were
negative in both assays and 40 positive in the two different tests (77%
agreement). Seven fluids out of 130 (5.4%) were negative in the IRMA and
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positive in the L929 assay, possibly indicating degradation of TNF alpha in
the fluids between the experiments (12 to 6 months) or cytotoxic activity
not mediated by TNF alpha. Of the 22 fluids positive in the IRMA and
negative in the L929 assay, 20 had a level of TNF alpha that was below the
sensitivity of the L929 assay. When these 20 fluids are excluded on the
basis of different assay sensitivities, agreement increases to 91.8%
(101/110). K value for these comparisons were 0.506 (n=130) and 0.830 after




RA+ RA- OA RT MISC TOTAL
< 0.25 9 * 8 4 7 28
0.25-1.0 11 9 1 2 23
1.0-2.5 21 7 1 3 2 34
2.5-4.0 11 2 1 3 17
4.0-5.5 4 1 1 2 8
5.5-10.0 2 2 1 3 9
> 10.0 1 1
TOTAL 58 30 8 16 7 119
% "positive"
★★
84.5 73 50 56.2 100 76.5
Table 3.4. Immunoreactive IL1 beta in joint exudate fluids
RA+ = seropositive rheumatoid arthritis; RA- = seronegative rheumatoid
arthritis; OA = osteoarthritis: RT = reactive arthritis; Misc =
miscellaneous group. Each fluid was tested in duplicate tubes.
* Number of patients in this category.




RA+ RA- OA RT MISC TOTAL
< 0.025 32 * 21 10 6 11 80
0.025-0.1 7 6 3 2 5 23
0.1-0.5 11 4 2 3 2 22
0.5-1.0 1 1
» 1.0 1 1 2 4
TOTAL .52 31 16 11 20 130
1 "positive"** 38.5 32.2 37.5 45.5 45.0 38.5
Table 3.5 Immunoreactive IL1 alpha in synovial fluids
Abbreviations used are as in Table 3.4 legend. Each sample tested in
triplicate.
* Number of patients in this category.





RA+ RA- OA RT PA AS Misc Total
<4 29 * 11 6 2 3 1 6 58
4-16 9 7 3 4 2 1 1 27






















Table 3.6 TNF biological activity in SF from patients with different
rheumatic diseases
RA+ = seropositive rheumatoid arthritis; RA- = seronegative rheumatoid
arthritis; OA = osteoarthritis; RT = reactive arthritis; PA = psoriatic
arthritis; AS = ankylosing spondylitis; Misc = miscellaneous group. Each
fluid was measured at least three times in 11 dilutions in different assays.
* Number of patients in this category.
** Percentage of patients with TNF levels >4U/ml (detection limit)
Sample Sample with Sample with
only anti-TNF * anti-DR **
SF 73 (OA) 39 < 4 34
SF 69 (AS) 42 < 4 41
SF 78 (OA) 14 < 4 ND
SF 158 (OA) 11 < 4 11
SF 161 (RA+) 50 < 4 49
SF 91 (RA+) 5 - 4 ND
SF 116 (RA+) 19 5 10
SF 112 (RT) 7 9 ND
hr LT ( lng/ml) *** 24 22 30
hr TNF ( 1 ng/ml) 22 < 4 21
Table 3.7 Antibody neutralization of synovial fluid TNF-like activity
All values are expressed in L929 cytotoxicity units/ml.
* mab to human recombinant TNF alpha (1:1600)
** mab to human MHC class II product as control antibody (1:800)
*** hr LT = human recombinant lymphotoxin (TNF beta); ND = not done; other




RA+ RA- OA RT Misc Total
< 0.0125 29 18 11 3 9 70
0.0125-0.025 6 2 1 5 14
0.025-0.25 16 9 1 4 3 33
0.25-2.5 3 1 5 3 3 15
> 2.5 1 1 2
Total 55 30 18 11 20 134
% "positive" 47.3 40.0 38.9 72.7 55.0 47.8
Table 3.8 Immunoreactive TNF alpha in SF
Fluids were tested in triplicate tubes. "Positive" samples are those
with >12.5pg/ml TNF alpha (detection limit). Other abbreviations as in
legend for Table 3.4.
TNF alpha IRMA
























Table 3.9 Qualitative comparison between bioactive and immunoreactive TNF
in SF
Of the 22 fluids labelled with [*], 20 had TNF alpha IRMA levels
between 12.5 to 160pg/ml, below the detection limit of the L929 bioassay
("negatives" for L929 cytotoxicity) but detectable in the immunoassay
("positives" in the TNF alpha IRMA).
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3.d. DISCUSSION
The aim of this study was to test whether unfractionated synovial
fluids from arthritic patients contained biologically active or
immunodetectable levels of IL1 alpha, IL1 beta, IFN gamma or TNF alpha.
Different proportions of the fluids tested contained immunoreactive
IL1 alpha (38.5%), IL1 beta (76.5%), TNF alpha (47.8%) in biologically
significant levels. These cytokines, but not IFN gamma, were present in
synovial effusions from different rheumatic diseases, arguing against any of
these cytokines being a specific factor in the pathogenesis of any
particular disease. There have been previous reports (Fontana etal. 1982B)
of detected bioactive IL1 in unfractionated fluids from patients with
rheumatoid arthritis but not with osteoarthritis. In our studies,
osteoarthritis patients had comparable levels of IL1 alpha and IL1 beta to
the rheumatoid patients and we failed to detect any IL1 biological activity
in unfractionated fluids. This is in contrast with the high levels of
immunoreactive IL1 beta protein that we detected in most of the samples. It
is possible that IL1 beta is present in the fluids only in its inactive
precursor form. This seems unlikely given the presence in SF of proteolytic
enzymes and particularly of elastase (Pryce-Jones, Wood, 1975), which
cleaves the IL1 beta propeptide to its mature form (Webb et al, 1987).
Furthermore, we have previously shown that RA synovial cells release
bioactive IL1 (chapter 3), and in other studies this has been reported to be
mainly of the pI7 form (Wood et al. 1985).
An explanation for this lack of IL1 biological activity is provided by
the observations that SF from RA and osteoarthritis contain powerful
biological inhibitor(s) of murine T cell co-mitogenesis. Their presence has
been documented previously (Wood et al, 1983; Bendtzen et al, 1985) and
could be of potential importance, but specific inhibitors have not been
characterized and their actions in a human system are only hypothetical.
Tumour necrosis factor biological activity could be measured in 35
(38%) of 93 unfractionated synovial fluids. In six of eight positive SF
tested, this activity was neutralized by monoclonal anti-TNF alpha. Of a
further 44 fluids which were tested in a single dilution assay, 13 (30%)
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contained TNF activity which was neutralized only by mab for TNF alpha.
None of the 21 cytotoxic samples in this series was neutralized by antiserum
to LT. When compared with TNF measurements by immunoassay, they showed
excellent qualitative agreement (92%) when the difference in assay
sensitivity was taken into account. Among the samples in which TNF alpha
was tested by a specific IRMA, a large proportion (47.8%) were "positive",
the difference being related to the higher sensitivity of the assay
(12.5pg/ml was detectable against 160pg/ml TNF alpha in the bioassay). On a
quantitative basis, however, no correlation could be demonstrated between
TNF alpha bioactivity and immunoreactive protein in SF. In analogous
experiments to those previously discussed for IL1, we could demonstrate the
presence in SF of inhibitor(s) of TNF biological activity, whose pattern of
distribution may account for this lack of correlation.
Aside from the issue of biological inhibition, immunoreactivity and
bioactivity of a peptide ligand measured ex vivo, will be different at any
time, immune recognition not being restricted to receptor binding regions.
Inert molecules, both larger and smaller than the mature peptide could react
with antibody raised to the mature form. However, immunoreactive levels
reflect cytokine production over time (rather than what happens to be
biologically active at any one moment) and may well be a better indicator of
chronic disease activity.
Nonetheless, when in our study synovial fluid levels of immunoreactive
TNF alpha, IL1 beta or IL1 alpha were compared with a variety of clinical or
laboratory parameters of disease activity, no significant association could
be demonstrated. The conclusions are that systemic markers of inflammation
are more likely to be related to levels of cytokines in the circulation
rather than in the synovial space. In addition, the well known inter-
individual variability in cytokine production (Endres et al, 1987) suggests
that it may be more appropriate to correlate disease activity with cytokine
levels in a longitudinal study, which would require the study of blood
levels.
In preliminary experiments we could not detect immunoreactive IL1 beta
in sera and plasma from 32 patients, probably related to the low sensitivity
of the RIA used (0.25ng/ml IL1 beta lower detection limit) or the presence
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of carrier protein(s) for IL1, masking binding sites.
As a development of these studies, and using a sensitive IL1 beta
ELISA (detection limit : 20pg/ml) in combination with a recently developed
extraction method (Cannon et al. 1988), a study from our group (Eastgate et
a!, 1988) has, for the first time, correlated IL1 beta levels in plasma with
several laboratory and clinical parameters of disease activity in patients
with rheumatoid arthritis. This longitudinal study also demonstrates that
IL1 levels correlate with patient clinical score both during clinical
improvement and exacerbation.
The only "longitudinal" data in the present study are from a patient
with septic arthritis, where diagnostic joint aspirations could be performed
at the clinical onset, and repeated after two weeks of antibiotic therapy.
Clinical improvement was accompanied by a dramatic fall of the cytokine
levels in SF (TNF alpha: from 1.22 to 0.43ng/ml; IL1 alpha: from 0.110 to
undetectable levels; IL1 beta: from 8.09 to 4.02ng/ml).
Since cytokine genes are not constitutively expressed, the findings of
IL1 beta, IL1 alpha and TNF alpha in rheumatic patients ex vivo strongly
suggests that these genes are activated in vivo in the course of the
disease. We have previously shown that synovial cells of rheumatoid
patients released IL1 and TNF without deliberate induction. This has been
more appropriately confirmed by demonstrating cytokine-specific mRNA in snap
frozen surgical specimens, by using in situ hybridization in this laboratory
(Duff et al. 1988).
A more complete understanding of the interactions between these
cytokines in the immunoregulatory network and their roles in the
pathogenesis of arthritic diseases is now accessible with the reagents
available and should allow for the development of novel treatments.
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CONCLUDING DISCUSSION
The data presented in the first section of this work support the idea
that IL1 and TNF protein are produced in human cells only following specific
stimulation and that their synthesis is mainly regulated at the level of
transcription. Further studies, in which we reported the presence of these
cytokines at the site of inflammation in patients with rheumatic diseases,
indicate that IL1 and TNF genes are activated in these patients during the
course of disease.
Interleukin 1 has been shown to be arthritogenic in vivo (Pettipher et
al, 1986) and plasma IL1 beta levels correlate with disease activity in
patients with rheumatoid arthritis (Eastgate et al. 1988). IL1 and TNF mRNA
have been detected in synovium from RA patients (Buchan et al. 1988; Duff et
al, 1988) and both cytokines are capable of bone and cartilage resorption in
organ culture.
Several unanswered questions remain and will provide scope for further
investigations in this area:
1. Can we identify a common pro-inflammatory event in the cytokine
network? Several cytokines other than IL1 and TNF have been identified at
the site of inflammation in rheumatic diseases. These include IL2, IL6
(Houssiau et al. 1988) and TGF beta (M. Sporn, unpublished), each of which
is able to play a role both as effector molecule or in feed-back networks.
The regulation of cellular receptors certainly plays a role in determining
the final biological function of the system, and soluble receptors that
retain their binding capacities, must also be regarded as immunoregulatory
entities. Among the latter, soluble CD8 and soluble IL2R have been recently
demonstrated to correlate with clinical status in rheumatic patients (Symons
et al. 1988A; Wood et al. 1988A).
A more complete understanding of the physiology of immunoregulation
might facilitate the identification of the "lesion" in chronic inflammatory
diseases such as RA. More direct approaches, i.e. testing a monoclonal
antibody to an effector or regulatory molecule, have been frustrated partly
by the lack of adequate reagents, and mainly by the absence of a suitable
animal model of rheumatoid arthritis.
2. Which cell populations produce these pro-inflammatory cytokines in the
course of disease? Methods involving cell separation procedures are
probably not suitable for such studies, because of the high risk of
186
inadvertent cell activation. Furthermore, the availability of human synovium
is mostly from patients undergoing joint replacement surgery, and therefore
at a late stage of disease. The study of cytokine gene expression in
earlier disease will require the use of needle - biopsy specimens, with
obvious problems related to the quantity of tissues available. Combined in
situ-hybridization-immunophenotyping has, so far, demonstrated IL1 beta to
be predominantly produced in the stromal areas of the synovium, while the
IL6 gene is expressed mainly in perivascular cells and lymphoid follicles.
In contrast to IL1, the predominant cell-type expressing IL6 appears not to
be the macrophage (Wood et al. 1988B). To study cytokine gene abnormalities
in such small numbers of cells will probably require amplification of DNA
sequences using polymerase chain reaction (PCR) to overcome the extremely
low yield of cells; combination with in vitro transcription could provide
material for qualitative mRNA studies. Quantitative mRNA analysis could be
achieved by reverse transcription followed by automated PCR.
Assessment of immune functions in synovium at different stages of
disease and identification of cell-types and their activities, is clearly
still a basic goal in the understanding of rheumatic inflammation.
3. Why and how does a pro-inflammatory cytokine become pathogenic?
Sustained cytokine production could be related to abnormal
transcriptional activation (due to persistence of the stimulus - i.e.
chronic infection - or dysregulation of transcriptionally-active
regulatory elements) or to lack of active repressor mechanisms. Our
data, showing induction of IL1 and TNF by MSU crystals and the
detection of these cytokines in gouty patients, suggest that gout
could be a model of arthritis in which IL1/TNF over-production is the
key mechanism of the acute attack with fever, swelling and all the typical
inflammatory signs.
For the establishment of chronic inflammation, self-sustaining
mechanisms are needed. The reduction of T cell sensitivity to potentiating
factors such as IL2 is an early observation in several chronic inflammatory
diseases. Such reduced susceptibility could lead to failure of appropriate
immune responses (such as eradication of foreign antigen). In autoimmune
diseases, failure to respond to IL2 stimulation has been correlated with
increased levels of sIL2R (Symons et al, 1988B). As soluble IL2R could
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mediate deficient T cell activation in RA, it could also determine the lack
of T-cell derived inhibition of IL1 synthesis, which is thought to be
mediated by IFN gamma (Ghezzi et al. 1988). This view of the pathogenic
cycle is supported by the absence of IFN gamma in SF, which we have
reported, by the correlation between sIL2R and IL1 beta levels in synovial
fluids and the correlation of both indexes in plasma with clinical signs of
disease activity (Wood et al. 1988A; Eastgate et al. 1988).
A possible positive contribution to the net action of these pro¬
inflammatory cytokines could be decreased production of agents that inhibit
their biological actions. We have demonstrated the presence of inhibitory
activities for IL1 and TNF in SF, and several inhibitory moieties have been
described (Lotz et al. 1986; Seckinger et al. 1987; di Giovine et al. 1987;
Seckinger et al. 1988). Dysregulation of such inhibition might underline an
imbalance of the normal cytokine-homeostatic mechanisms.
Current biotechnology and the huge recent interest in this area of
research make these objectives within reach in the years to come. It
should be possible soon, with the development of therapeutic agents able to
block specific pathogenic mechanisms, to take a new approach to the
treatment of chronic rheumatic conditions and, at least, bring them into the
same clinical category as hypertension or diabetes in which therapeutic
intervention can effectively control the development of tissue damage and
disease progression. With the recognition and characterization of the
different cytokine systems we can now give a molecular substrate to the
associations between fever, inflammation and host defence that were familiar
to ancient peoples some 6000 years ago.
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Preparation of crude TCGF
1. Remove spleen from Wistar rats under aseptic conditions.
2. Dissociate into a single cell suspension in PBS, between two sterile
ground glass slides.
3. Wash the cells by spinning at lOOg (10 mins) and resuspend at
1x10^cells/ml in serum-free RPMI 1640.
4. Add Concanavalin A (5ug/ml) and incubate 20-24 hours (37° C, 5% CO2).
5. Collect supernatants, spinning first at 300G, then at 1800G (10 mins
each).
6. Cell-free supernatants (crude rat TCGF) are stored in aliquots at -3(P C
and sterile-filtered before use.
Inactivated feeder/antigen presenting cells
1. Dissociate H-2K spleen (i.e. from C3H mice) as in 6.1.
2. Lyse the red blood cells by hypotonic shock.
3. Wash the cells by centrifugation at 100G (10 mins) and resuspend at
2x10 cells/ml in PBS containing mytomycin C (50ug/ml; Sigma) and
incubate at 37° C for 60 mins.
4. Wash the cells by centrifugation 4 times in PBS to remove the
mitomycin C and add to D10.G4.1 cultures at a final concentration of
5-10x10^ cells/ml.
Limulus gelation test (LAL assay)
1. Ensure all materials and reagents at LPS-free.
2. Reconstitute lyophylized LAL (limulus amebocyte lysate) on ice,
according to manufacturer's instructions.
3. Add lOOuls of LAL solution and lOOuls of standard LPS or test
solution to the bottom of LPS-free tubes (Falcon, 10x75mm stoppered
plastic tubes) and mix gently. Include as negative control pyrogen-
free PBS.
4. Transfer the tubes to a motionless water bath at 37° C. Leave
undisturbed for 1 hour.
5. The presence of an adherent gel (which remains adherent on gentle
inversion of the tube) indicates a positive tube.
Several dilutions of standard LPS solution should be assayed to check
the sensitivity of the lysate. If the sample is tested at different
dilutions, quantitative data can be produced. It is also necessary to check
that negative samples do not contain inhibitors of LAL gelation (by addition
of a known amount of LPS to the sample).
False negatives have been reported such as when testing trypsin
inhibitors or calcium chelants like EDTA (Levin and Bang, 1968), high
molarity salt concentrations (>2M; Nandan and Brown, 1977), semisynthetic
penicillins (Rhodes et al. 1974), tetracyclines and dexamethazone (van
Noordwijk and de Jong, 1977). False positives can take place with trypsin-
like enzymes (Sullivan and Watson, 1975), thromboplastin, poly I:C (Elin and
Wolff, 1973), ribonuclease (Jorgensen and Smith, 1973), high concentration
of calcium (Sullivan and Watson, 1974), muramyl dipeptide (Dinarello et al,
1978), peptidoglycan (Kotani et al, 1977) and exotoxins A, B and C from
streptococci (Bruson and Watson, 1976).
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Polymyxin B co- incubation
In this experiment, LPS (lOOng/ml) and MSU (0.5mg/ml) were tested for
their ability to induce IL1 activity from blood monocytes (1x10 /ml) in


















The IL1 biological activity in supernatants is expressed as mean (±SEM)
of proliferation units of triplicate measurements of supernatants (1:25
dilution indicated) assayed in a C3H/HeJ proliferation assay (cell + Con A =
10164 ± 906.4 cpm).
The presence of PMB did not modify the ability of MSU crystal to induce
IL1 release, while completely neutralized the IL1-inducing property of LPS.
MSU-crystals do not release soluble activators of IL1 production
To test the presence of soluble activators of IL1 production in
association with the crystal preparation, aliquots of crystals (lOmg/ml)
were resuspended in PBS. After incubation (30 mins) and centrifugation,
supernatants (crystal "wash") were added to human monocyte cultures (10%
vol/vol). Monocyte supernatants (20 hrs) were then assayed in D10.G4.1



















Shown are results from the 0.1% dilution of supernatant. These
indicate that no soluble activator of IL1 production was released by the
crystals (cells + Con A = 311.6 ± 39cpm).
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Effects of hrlLl on L929 cytotoxicity
In this experiment, different amounts of hrlLl alpha and hrlLl beta,
previously demonstrated to be active on T cells, were tested for L929
cytotoxicity in presence or absence of different concentrations of hr TNF
alpha.
hrlLl beta hrlLl alpha
(ng/ml) (ng/ml)
0 0.1 1 10 0 0.1 1 10
0 A 4^. • <4 <4 <4 <4 <4 <4 <4
hr TNF 0.1 <4 <4 <4 <4 <4 <4 <4 <4
alpha 1 11.32 11.73 9.94 10.33 11.32 10.57 10.38 10.34
(ng/ml) 10 121.96 105.17 132.80 103.40 121.96 128.37 118.24 116.48
IL1 preparations failed to induce L929 cytotoxicity or to synergize
with hrTNF alpha in its activity.
* L929 cytotoxicity expressed in half-maximal U/ml.
TNF alpha inhibition studies
1. Seed L929 cells in the inner 60 wells of a microtiter plate (3x10^
cells/lOOul EMEM - 10% FCS/well).
2. After 20hrs incubation (5% CO2, 36.5° C), remove spent medium and
replace with 50ul Actinomycin D in EMEM (final conc. = lug/ml).
3. Dispense double dilutions of the sample to be tested for inhibition
(synovial fluids 1:4 to 1:512) in each row, in absence or presence of
hrTNF alpha (final conc : 40pg/ml). Five wells receive only hrTNF
alpha (40pg/ml) and five EMEM 10% FCS ("total cells" control).
Incubate the plate for 18-20hrs at 38.5° C.
4. Remove the medium, add 0.5% crystal violet in 20% methanol in all
wells. After vigorous washing, O.D. is assessed by microELISA
spectophotometry at 470mm.
5. For each single well, percentage cytotoxicity (%CTX) is calculated
with the formula
% CTX = O P- total cells" - O.D. sample x ^qq
O.D. "total cells"
6. The ability to inhibit the cytotoxic action of 40pg/ml hrTNF alpha is
calculated for each SF dilution with the formula
% inhibition - <%CTX bv SF)+(%CTX bv TNF)-(%CTX bv TNF with SF! 1QQ
(%CTX by SF)+(%CTX by TNF)
7. Dilutions of SF are plotted against % inhibition. One inhibitory
unit is defined as the dilution of SF able to neutralise 75% of the
cytotoxicity induced by 40pg/ml hrTNF alpha.
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INTERLEUKIN 1 (IL 1) AS A MEDIATOR OF CRYSTAL ARTHRITIS
Stimulation of T Cell and Synovial Fibroblast Mitogenesis by Urate
Crystal-Induced IL l1,2
FRANCESCO S. DI GIOVINE,* STEPHEN E. MALAWISTA,' GEORGE NUKI,* and
GORDON W. DUFF3*
From the *University ofEdinburgh Rheumatic Diseases Unit, Northern General Hospital, Edinburgh (UK) and the
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We reported before that monosodium urate (MSU)
crystals were potent stimulators of endogenous py¬
rogen (EP) production from human and rabbitmono¬
nuclear phagocytes, and proposed that this prop¬
erty of MSU crystals may be important in the path¬
ogenesis of gout. EP activity is now attributed to
interleukin 1 (IL 1) peptides but IL 1 is not the only
pyrogenic monocyte-derived cytokine, since both
interferon-a (a-IFN) and tumor necrosis factor (TNF)
are also pyrogenic in rabbits. Using a T cell comi-
togenic assay based on a murine helper T cell clone
that does not respond to IFN or TNF, we now report
the release of IL 1 activity from human blood mon¬
ocytes and synovial fluid mononuclear cells (MNC),
following stimulation with MSU crystals. MSU-in-
duced supernatants with IL 1 activity were neutral¬
ized with rabbit antiserum to human IL 1 and also
stimulated the growth ([3H]thymidine incorporation)
of long-term fibroblast-like cell lines derived from
human synovial rheumatoid exudate. Two other
crystals associated with articular inflammation
were tested: hydroxyapatite was a much less potent
stimulus compared with MSU c. stals, and calcium
pyrophosphate dihydrate did l. t stimulate IL 1
release from human monocytes or synovial fluid
MNC. As a model for the inflammatory conse¬
quences of acute and chronic overproduction of IL
1, gout is the only sterile inflammatory disease
where the local and systemic pathology is compati¬
blewith such overproduction; raised IL 1 levels have
been found at the site of inflammation, and a nec¬
essary etiologic agent, crystalline urate, has been
shown unequivocally to be a direct activator of
mononuclear IL 1 release.
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We have previously found that crystals of monosodium
urate (MSU) were potent stimulators of monocyte IL l4
release measured in vivo as endogenous pyrogen (EP)
activity. This property of MSU crystals was dose-depend¬
ent, did not require phagocytosis of the crystals, was
independent of serum factors and mediation by other
blood leukocytes, and could not be attributed to contam¬
ination of the crystals with Gram-negative bacterial
endotoxin (lipopolysaccharide: LPS) (1).
In further studies we reported that EP/IL 1 induction
was not a universal property of arthritis-associated crys¬
tals and specifically that crystalline hydroxyapatite (HA)
and calcium pyrophosphate dihydrate (CPPD), when
tested over a range of concentrations and particle sizes,
failed to stimulate significant EP/IL 1 release from mon¬
ocytes (2).
Pyrogenicity is only one of a wide range of biological
activities of recombinant IL 1 peptides (3) and is not
unique to IL 1 since both recombinant tumor necrosis
factor (TNF) (4), and a-interferon (a-IFN) (5) are also py¬
rogenic. We have, therefore, in the present study reex¬
amined IL 1 stimulation by inflammatory crystals mea¬
suring IL 1 activity in a T cell comitogenic assay in which
neither TNF nor a-IFN is stimulatory (6).
We found that MSU crystals stimulated both blood
monocytes and adherent synovial exudate mononuclear
cells (MNC) to release IL 1 activity but CPPD crystals had
no activity and HA crystals were only minimally stimu¬
latory at the highest concentration of crystals tested.
Urate crystal-induced monocyte supernatants that con¬
tained IL 1 activity in the T cell assay also stimulated the
growth of human synovial long-term fibroblast lines.
Since we have now shown that urate crystals stimulate
the release of IL 1 activity from synovial exudate cells
and that urate-induced, IL 1-containing cellular super¬
natants are active on target cells derived from human
synovium, we believe these present findings support our
earlier hypothesis that IL 1 may be an importantmediator
of the inflammatory reactions that occur in gouty arthri¬
tis.
4 Abbreviations used in this paper: IL 1, interleukin 1: MSU, monoso¬
dium urate; HA, hydroxyapatite; CPPD, calcium pyrophosphate dihydrate;
EP, endogenous pyrogen; LAF, lymphocyte activating factor: IFN, inter¬
feron; TNF, tumor necrosis factor; RA, rheumatoid arthritis; D10,
D10.G4.1 murine T helper cell clone; IL 2, interleukin 2; P.U., prolifera¬
tion units; BRMP, biological response modifier program; AVU, anti-viral
units.
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MATERIALS AND METHODS
Media and reagents. All media and reagents used were demon¬
strably free from significant endotoxin contamination as assessed
by the high sensitivity limulus lysate gelation assay (Sigma Chemical
Co., St. Louis, MO) (7). In all experiments we used RPMI 1640 medium
(GIBCO Ltd, Paisley, Scotland) supplemented with penicillin 100 U/
ml, streptomycin 100 /jg/ml, glutamine 2 x 10"3 M, 2-mercaptoeth-
anol (6 x 10"5 M) (Sigma), and MOPS buffer (1.25 x 10~2 M) (Sigma).
In some experiments culture medium contained 10% fetal calf serum
(GIBCO) ("complete medium"). For positive controls in IL 1 production
experiments, LPS was used (Escherichia coli 0127:B8,TCA ex¬
tracted, Sigma). Polymyxin B (Aerosporin-Wellcome Foundation Ltd.,
London) was used to check for LPS activity in stimulatory crystals
(8). A rabbit antiserum to highly purified human IL 1 (kindly donated
by Dr. C. A. Dinarello, Tufts University, Boston) was used to check
the specificity of responses in lymphocyte activating assays for IL 1.
Crystals. The three crystal types studied here, MSU, HA, and
CPPD, were chosen for their associations with arthritic diseases.
Details of crystal manufacture and sizing have been previously
published (2). Additional crystals of MSU, HA, and triclinic CPPD
were prepared and generously donated by Dr. Paul Dieppe (Bristol
University, UK). All crystal types were sterile and supernatant fluid
from crystal suspensions did not stimulate monocytes to release IL
1 activity in 20-hr cultures indicating that no soluble activators of
IL 1 production were associated with the crystal preparations. The
crystals were also LPS-free since all three types at 1 mg/ml scored
negative in the Limulus assay but did not inhibit Limulus lysate
gelation in response to 500 pg/ml E. coll LPS. Further evidence
against significant LPS contamination of crystals was obtained by
using polymyxin B (200 U/ml) which completely prevented the in¬
duction of monocyte IL 1 activity in response to 100 ng/ml LPS (3.59
to 0.66 thymocyte P.U.) but had no effect on MSU-induced IL 1
activity (3.05 to 3.18 thymocyte P.U.). In most experiments, crystals
were used in concentrations of between 0.1 and 1.6 mg/ml. MSU
crystals were between 8 and 40 /im in length, HA 3 to 15 nm, and
CPPD 15 to 50 (im. Crystals were suspended at 10 mg/ml in pyrogen-
free phosphate-buffered saline (PBS) and stored at -30°C in 500 /d
aliquots until used. Before use, some crystal aliquots (see figure
legends) were pretreated with fresh normal human serum (10 mg
crystal/ml serum) at 37°C for 1 hr followed by two washes in PBS.
Cells. In most experiments human blood from normal volunteers
was taken into preservative-free heparin (10 U/ml) (Unihep—Leo
Labs Ltd, Aylesbury, Bucks, UK) and mononuclear cells were ob¬
tained by density centrifugation (Lymphoprep, density 1.077, Nye-
gaard, Oslo) in pyrogen-free conditions. MNCs were allowed to adhere
to multiwell plates (24 flat-bottomed well plates, Linbro, Flow Labs,
Herts, UK) at 37°C for 2 hr and after removal of the nonadherent
population, culture medium was added to achieve a final concentra¬
tion of 1 x 106 adherent MNCs/ml. In some experiments adherent,
synovial exudate mononuclear cells were used. These were obtained
from fresh synovial fluid aspirated from acutely inflamed knee joints
of patients with rheumatoid arthritis (RA). The fluids were taken
into EDTA (5 x 10"3 M) and treated with bovine testicular hyaluron-
idase type VIII (Sigma, 100 U/ml synovial fluid) for 45 min at 37°C.
Cells were removed by centrifugation at 400 x G for 20 min and
washed in serum-free medium before density centrifugation and
culture in tissue culture flasks (25 cm2. Corning, Corning, NY) at 1
x 106 adherent MNCs/ml in complete medium. In IL 1 production
cultures these cells were used immediately but similar cells were
kept in long-term culture in the presence of 0.1% highly purified
human monocyte 22,000-dalton peptide with potent IL 1 activity
(from Dr. J. van Damme, Leuven, Belgium) (9). After 2 wk in culture
the remaining viable cells were entirely of fibroblast morphology
and these cells continued in culture for up to 18 wk with cultures
divided at approximately three weekly intervals following treatment
with trypsin-EDTA solution (lx) (GIBCO) to loosen the cells. These
cells were used in assays for growth factor activity in later experi¬
ments.
Exposure of cells to crystals. Adherent blood or synovial exudate
MNCs at 1 x 106/ml in complete medium were incubated for 20 hr
either alone or with different concentrations of crystals as indicated
in the figure legends. Crystals were either untreated or pretreated
with fresh human serum for one hour at 37°C. In early experiments
culture medium was serum-free but 10% fetal calf serum was added
in later experiments since the presence of serum did not significantly
influence supernatant IL 1 content induced by any of the three
crystal types except at the highest concentrations tested. After 20
hr of incubation, supernatants were aspirated and centrifuged at
1800 x G, 4°C for 30 min. Supernatants were either stored at —80°C
or tested immediately for IL 1 content.
Assay of IL 1 activity. 1. T cell assay. IL 1 activity in most
experiments was tested in a co-mitogenic assay using the murine.
antigen-specific (conalbumin) helper T cell clone D10.G4.1 (D10)
from Drs. Charles Janeway and Jonathan Kaye of Yale University
(10). Briefly, 2 X 10" D10 cells per well were added to microtiter
plates (96-well, flat bottom—Titertek, Flow Labs) with concanavalin
A (Con A) (Sigma) 2.5 Mg/ml, and different dilutions of supernatants
to be tested for IL 1 content as indicated in the results section. Total
volume per well was 200 #il. After 70 hr (37°C, 5% C02) 1 #iCi of [3H]
thymidine (5 mCi/ml, TRK296, Amersham, Little Chalfont, Bucks,
UK) was added to each well. After 5 hr, cells were lysed on glass
fiber filters (PHD cell harvester—Cambridge Technology Inc.) and
incorporated [3H]thymidine was measured by beta scintillation
counting. The assay was calibrated using human recombinant IL 1)3
(pI7) (11) and IL la (pI5) (12) (gifts from Dr. C. A. Dinarello, Tufts
University, Boston, and Dr. S. Gillis, Immunex Corporation, Seattle,
WA) and highly purified pig IL 1 (from Dr. J. Saklatvala, Cambridge,
UK). All of these IL 1 peptides gave optimal responses at 70 to 100
pg/ml. We also tested recombinant human tumor necrosis factor
(13) (Genetech Inc., San Francisco, CA) which, in the range 0.1 pg/
ml to 1 Mg/ml. had no activity alone in the D10 assay and did not
modify the response to purified or recombinant IL la and IL 1/3 (e.g.,
64 ± 2.8 D10 P.U. with purified pI5 IL 1 vs 65.4 ± 1.9 P.U. with pI5
plus 10 ng/ml TNF). This TNF-a preparation was active in the L929
cytotoxicity assay at 256 half-maximal bioassay units for 10 ng/ml
recombinant peptide.5 Highly purified human leukocyte IFN-a
(Boots-Celltech, Slough, UK) tested over the range 20 to 2000 U/ml.
suppressed the D10 background (293 ± 19 cpm to 182 ± 28 cpm
with 200 U/ml) and reduced the D10 responses to recombinant IL
1/3 by 50% at 200 U/ml.
2. Thymocyte assay. As indicated in Results, in some experiments
the T cell co-mitogenic assay was performed using fresh thymocytes
from 6- to 8 wk-old CBA/Ca mice. Details of the murine thymocyte
assay for lymphocyte activating properties of IL 1 have been previ¬
ously published (14). Both of these assays (D10 clone and thymo¬
cytes) are based on the induction of T cell growth factors such as
interleukin 2 (IL 2) by II 1. Both assays are sensitive to exogenous IL
2. Our supernatants were also tested for IL 2 content using IL 2-
dependent cells (3-day-old Con A-induced lymphoblasts (15) or the
cytotoxic T cell line CTLL-2 (16). Urate crystal-induced supernatants
that stimulated D10 or murine thymocytes had no detectable IL 2
content in these assays (<2BRMP U/ml). The concentrations of
recombinant human IL 1 that gave optimal responses (70 to 100 pg/
ml) were similar in both the thymocyte and D10 assays. A rabbit
antiserum raised against purified human monocyte IL 1 completely
inhibited the response to optimal concentrations of recombinant
human IL 1 pI7 (100 pg/ml) at a dilution of 1:1600 in both thymocyte
and D10 assays (Table I). At 1:400 this antiserum did not affect the
CTLL-2 response to IL 2 (1 to 125 BRMP U/ml) and did not inhibit
the response of D10 cells to IL 2: 125 BRMP U/ml gave 15 ± 4.5 D10
P.U. alone and 45 ± 6.4 P.U. in the presence of anti-IL 1 antiserum.
This augmentation by IL 1 antiserum of the D10 response to IL 2
also occurred with IL 1 a-stimulated D10 cells and is being investi¬
gated. We have never observed nonspecific suppressive effects of
this antiserum on D10, thymocyte, or CTLL cells.
3. Fibroblast assay. Urate crystal-induced supernatants were also
tested for stimulation of fibroblast growth (17). These experiments
employed 8- to 14-wk-old fibroblast-like cell lines obtained by out¬
growth from human RA adherent synovial exudate cells in the
presence of highly purified IL 1 (as described above). These fibro¬
blasts were allowed to readhere for 24 hr to the bottoms of flat
microtiter wells (Titertek, Flow Labs) at 1 x 104 cells/well (noncon¬
fluent). Urate crystal-induced monocyte supernatants or 22,000-
dalton factor (highly purified monocyte-derived peptide with IL 1
activity) (9) were then added to the wells. After 70 hr, [3H]thymidine
(0.5 MCi/well) was added. After 6 hr the medium was replaced with
100 m1 trypsin-EDTA solution (lx) (GIBCO) (37°C, 30 min) to loosen
the cells before harvesting. Incorporated [3H]thymidine was mea¬
sured by scintillation counting.
RESULTS
Crystal-induced IL 1 activityfrom blood monocytes.
Crystals of MSU at 0.1 to 1.6 mg/ml were potent inducers
of monocyte supernatant IL 1 activity (Fig. 1). MSU crys¬
tal-induced IL 1 activity was completely neutralized by
rabbit antiserum to highly purified human IL 1 (Table I).
In the same experiments, CPPD and HA crystals did not
stimulate any significant extracellular IL 1 activity from
human blood monocytes. At higher concentration (2.0
5di Giovine, F. S., G. Nuki, and G. W. Duff 1987. Tumor necrosis
factor in rheumatic diseases. Submittedfor publication.
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TABLE I
Effect of IL 1 antiserum on D10 mitogenlc responses"
Anti-IL 1 Antiserum



















"Mitogenic responses of D10 cells (in proliferation units = cpm Con A + sample divided by cpm with Con A alone).
Mean ± SEM of triplicate responses to IL 1 and mononuclear cell supernatants are shown. Abbreviations: IL 1, human
recombinant IL 1/3 (100 pg/ml); MSU-PBMC, 1% supernatant of 1 x 10" adherent blood mononuclear cells cultured with
0.4 mg/ml MSU crystals; MSU-SC, 1% supernatant of 1 X 106 adherent mononuclear synovial cells cultured for 20 hr with
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Figure 1. Pyrogen-free crystals of MSU (size 8 to 40 fim), HA (3 to 15
^m), and CPPD (15 to 50 /tm) were added at different concentrations to
human monocytes (1 x 106/ml) and incubated for 20 hr (37°C, 5% C02)
in complete medium. Supernatants were than assayed in triplicate, in
three dilutions (1:1000, 1:100, 1:10) in theD10.G4.1 assay for LAF/IL 1
activity. The figure shows the results (in proliferation units = cpm with
sample plus Con A divided by cpm with Con A alone) for 1:100 dilution
(in complete medium) of supernatants. Data are expressed as mean
(+SEM) for the number of experiments shown. The same supernatants
were tested for IL 2 content and all contained less than 2BRMP n/rnl
compared with NCI standard IL 2.
mg/ml) CPPD crystals also consistently failed to stimulate
but HA crystals occasionally stimulated a very small
release of IL 1 calculated to be at least 100- to 200-fold
less potent than urate crystals. When cell lysates ob¬
tained by rapid freeze-thawing were assayed CPPD-stim-
ulated cells contained no co-mitogenic activity. Both MSU
and to a lesser extent HA-stimulated cells contained in¬
tracellular co-mitogenic activity but only the intracellular
co-mitogenic activity induced by MSU crystals could be
neutralized by the IL 1 antiserum (data not shown). The
behavior of MSU, CPPD, and HA crystals in IL 1 induction
experiments was not consistently influenced by serum
pretreatment of the crystals (Fig. 2).
IL 1 adsorption by crystals. Inflammatory crystals are
known to adsorb proteins to their surfaces (18, 19) and
it was possible that HA and CPPD might be stimulating
extracellular IL 1 release and adsorbing the IL 1 which
would not then be detectable in a centrifuged superna¬
tant. To test this we added each of the three crystals
(made and stored in protein-free conditions) to monocyte
supernatants with known IL 1 content. Following 20 hr
of incubation at 37°C the crystals were precipitated by
centrifugation (1800 x G, 4°C, 30 min) and the superna-
Flgure2. Untreated crystals and serum pretreated crystals were
tested for their ability to induce IL 1 activity from human peripheral blood
monocytes. Serum treatment of aliquots of crystals was performed by
incubation with fresh human serum (10 mg crystals/ml of serum) at 37°C
for 1 hr on a rotating agitator. At the end of the incubation the crystals
were washed twice in pyrogen-free PBS. The "untreated" crystals received
the same treatment in PBS instead of serum. Crystals were then Incubated
at the concentrations shown with human monocytes (lxl 06/ml) and the
20-hr supernatants were tested at different dilutions for IL 1 content in
the D10 assay. Results are expressed as (+SEM) of proliferation units (see
Fig. 1 legend) in triplicate measurement of supernatants diluted 1:100 in
complete medium.
tant IL 1 content tested on D10 cells and compared with
the same IL 1-containing supernatant that had been
incubated in parallel in the absence of crystals. Neither
HA, CPPD, nor urate (Fig. 3) reduced the amount of
biodetectable soluble IL 1 in serum-free culture medium
after 20 hr co-incubation. We take this as an indication
that the failure of HA and CPPD to stimulate detectable
IL 1 in our earlier experiments cannot be attributable to
significant IL 1 adsorption to the surface of the crystals
in the culture conditions that we employed. The same
results were obtained when crystals were exposed to IL 1
in an agitated incubation (data not shown).
Co-culture ofHA and CPPD crystals with LPS. It was
also possible that HA and CPPD crystals stimulated in¬
tracellular IL 1 production but had nonspecific inhibitory
effects on IL 1 processing, release or detection. We tested
this directly by co-culturing HA or CPPD crystals with
bacterial LPS, an independent stimulus of IL 1 synthesis
and release. The LPS concentration used (1 ng/ml) was
found in preliminary experiments to be in the suboptimal
range for IL 1 induction from human monocytes. Figure
4 shows that alone, HA and CPPD did not stimulate
significant IL 1 release, and the presence of HA or CPPD
in co-culture with LPS did not alter the amount of bio-
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Figure 3. To test whether surface adsorption of IL 1 peptides by any
of the three crystal types might remove significant quantities of IL 1 from
solution, we added human monocyte supernatants with known IL 1
content to each of the crystal types at 37°C for 20 hr. The centrifuged
supernatants were then tested for IL 1 content in the D10 assay and
compared with the same IL 1 containing supernatants that had been
incubated for 20 hr in the absence of crystals. Supernatants were tested
in triplicate at dilutions of 1:10, 1:100, 1:1000. Means (+SEM) of prolif¬














Figure 4. To test whether HA and CPPD crystals might be inducing IL
1 synthesis but interfering with release or biodetection in an unknown
way, we co-incubated both crystals and bacterial LPS, an independent
stimulus for both IL 1 synthesis and release. The LPS was used at a
suboptimal concentration (1 ng/ml) so subsequent augmentation or de¬
pression of IL 1 release in the presence of crystals would have been
detectable. Data are expressed in mean (+SEM) of proliferation units (see
legend in Fig. 1) in triplicate. Results shown were obtained with super¬
natants diluted 1:100 in complete medium.
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Figure 5. MSU-induced monocyte supernatants with IL 1 content by
D10 assay were tested for their ability to stimulate human articular
fibroblast proliferation. The fibroblast-like cells were obtained by out¬
growth from RA synovial effusion MNC in 8 to 14 wk cultures in the
presence of 22,000 dalton factor (a highly pure human IL 1-like peptide).
Cells were loosened with trypsin-EDTA and allowed to re-adhere in non¬
confluent conditions at 1 x 104/well for 24 hr before addition of 22,000-
dalton factor or dilutions of urate-induced monocyte supernatants. After
70 hr in culture [3H]thymidine incorporation was measured following a
6-hr pulse. The results are expressed as means (-TSEM) (cpm) of triplicate
wells.
detectable IL 1 activity stimulated by LPS alone.
Fibroblast proliferation. MSU crystal-induced mono¬
cyte supernatants with IL 1 activity in the D10 assay
were also tested for their growth-stimulation of human
synovial fibroblasts. Figure 5 shows dose-dependent fi¬
broblast growth stimulation by MSU crystal-induced su¬
pernatants. For comparison the response of the same
synovial fibroblast cells to a highly purified monocyte IL
1-like peptide (9) is also shown. Human recombinant IL
1/3 (pi 7) also stimulated [3H]thymidine incorporation to a
comparable extent in these synovial fibroblasts (data not
shown).
Crystal-induced IL 1 activity from synovial fluid
cells. In these experiments freshly obtained human RA
synovial exudate mononuclear cells were found to release
significant amounts of IL-1 activity measured in the mu¬
rine thymocyte assay without the need for extrinsic stim¬
ulation. This might indicate that the cells were activated
for IL 1 release in vivo or that they were inadvertently
activated during our separation procedures. Although
these cells were already releasing IL 1 activity, they could
be further stimulated by MSU crystals but again, as with
normal peripheral blood monocytes, HA crystals failed to
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Figure 6. A. Synovial fluid MNC were tested for IL 1 release in re¬
sponse to MSU crystals. The cells were separated by density centrifuga-
tion from freshly-aspirated RA synovial exudate fluids and adhered to
plastic for 1 hr. Final cell concentration was 1 X 106 adherent MNC/ml
of complete medium. Crystals of MSU or HA at the concentrations shown
were added, and after 20 hr of incubation supernatants were tested at
different dilutions for IL 1 content in a murine thymocyte assay (CBA).
The IL 1 activity in the supernatants was completely neutralized by IL 1
antiserum at a dilution of 1:800. Results are from supernatants diluted
1:100 with complete medium and are means (+SEM) of triplicate cultures
(proliferation units). B. Activity of human recombinant IL 1/3 is seen in
the same murine thymocyte assay as shown in A. Optimal responses
were obtained with IL 1 concentrations of 70 pg/ml. Thymidine incorpo¬
ration by thymocytes stimulated with Con A alone (without added IL 1)
was 2493 ± 68 cpm.
Cells alone 0 1 033 1% 01 0 33 1%
MSU induced IL-1 V.D. 22k factor
(1000-10000 AVU/ml)
RASF 12 cell line
2U hrs adherence
72 hrs growth
URATE CRYSTAL INTERLEUKIN 1 INDUCTION 3217
response of the same murine thymocytes to human re¬
combinant IL 1/3 is shown (Fig. 6B). MSU-induced syn¬
ovial cell IL 1-like activity was also neutralized by anti¬
serum to purified human monocyte IL 1 (Table I).
DISCUSSION
The wide-ranging biological activities of IL 1 that have
been reported from studies with highly purified natural
IL 1 (20) and recombinant human and mouse IL 1 (21)
suggest that IL 1 may play an important role as a mediator
of the acute phase response, as a regulator of cellular
andmatrix components in skeletal and connective tissue,
and as a powerful immunopotentiator with activities on
both T and B cells (22). Inappropriately high or sustained
release of IL 1 has been suggested as a possible mecha¬
nism contributing to the pathogenesis of inflammatory
joint diseases. In support of this idea, raised IL 1 levels
have been detected in joint effusion fluids in several
arthritic conditions including RA (23, 24) and gout (25)
and synovial cells have been found to release IL 1 in vitro
(26-28).
We have previously reported that crystals of MSU but
not HA or CPPD were potent stimulators of endogenous
pyrogen (EP) activity from human monocytes and rabbit
peritoneal macrophages (2). EP activity has been associ¬
ated with IL 1 (29, 30) but IL 1 peptides are not the only
"endogenous pyrogens" since both recombinant human
IFN-a (5) and TNF (4) are pyrogenic when injected into
animals. Indeed TNF and IL 1 seem to share a large
number of biological effects which can cause confusion
in several bioassay systems (31). We have, therefore, in
the present study used the in vitro lymphocyte activating
factor assay for IL 1 activity (32) with both an antigen-
specific murine helper T cell clone (10) and murine thy¬
mocytes. First we established that the proliferation of
these cells was not stimulated by recombinant TNF (or
IFN-a) which makes the LAF assay an important differ¬
entiator of IL 1 and TNF bioactivities. It is, of course,
possible that urate crystals stimulate the production of
TNF in addition to IL 1 from mononuclear phagocytes
and that the multiple catabolic effects of TNF may con¬
tribute independently or synergystically with IL 1 to the
pathogenesis of gout and other inflammatory rheumatic
diseases. As in our earlier studies, we found that MSU
crystals but not HA or CPPD were potent stimulators of
IL 1 activity from human blood monocytes. This property
of MSU crystals was independent of serum factors and
the failure of HA and CPPD crystals to stimulate biode-
tectable IL 1 release is unlikely to be due to IL 1 adsorption
by these crystals since a direct test of crystal-adsorption
of IL 1 from monocyte supernatants failed to demonstrate
any loss of IL 1 activity from the supernatants.
It is also unlikely that HA or CPPD crystals could have
induced IL 1 synthesis but then failed to stimulate or
subsequently inhibited intracellular IL 1 processing and
release since the presence of neither crystal altered the
amount of extracellular IL 1 produced by monocytes in
response to a suboptimal concentration of an indepen¬
dent stimulus—bacterial LPS. This conclusion is also
supported by the absence of significant levels of IL 1 in
lysates of monocytes following exposure to CPPD crystals
for 18 hr.
These results indicate that IL 1 release is not a nonspe¬
cific monocyte response to perturbation by particulate
agents. The same HA and CPPD crystals that failed to
stimulate monocyte IL 1 in these experiments were, like
MSU crystals, potent stimulators of human polymorpho¬
nuclear cell superoxide anion production demonstrating
that they were capable of proinflammatory leukocyte
activation (33). Stimulation of IL 1 by MSU crystals ap¬
parently does not require serum factors and the precise
nature of the MSU stimulus for IL 1 production is unclear.
Our previous work showed that internalization of crys¬
tals was not necessary (1) and the different properties of
MSU, CPPD, and HA crystals were unlikely to be related
to different crystal sizes (2).
The potential relevance of MSU crystal-induced IL 1 to
the pathogenesis of gouty arthritis is increased by the
present findings that human synovial adherent mono¬
nuclear cells, like blood monocytes, released IL 1 activity
following exposure to MSU crystals. Further, the prolif¬
eration of synovial fluid fibroblast-like cells was stimu¬
lated by urate crystal-induced monocyte supernatants
with known IL 1 content. Thus, cells derived from human
synovial fluid both released IL 1 and responded to IL 1
containing supernatants induced by MSU crystals.
Although HA and CPPD, the other crystal types tested
here, are also associated with inflammatory arthritic syn¬
dromes (34-37) neither appeared to provide a direct stim¬
ulus for IL 1 production in our experiments. This does
not, however, exclude a role for IL 1 in the pathogenesis
of inflammation induced by these crystals since IL 1
release may be activated by mechanisms other than di¬
rect crystal stimulation of IL 1 producing cells (2).
Gout is probably the only sterile inflammatory disease
where: the local and systemic pathology is entirely com¬
patible with overproduction of IL 1 (2); raised IL 1 levels
have been found at the site of inflammation (25); and a
necessary etiological agent, crystalline urate (38-40), has
been shown to be a direct activator of mononuclear cell
IL 1 release.
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The powerful proinflammatory and catabolic activities of tumour necrosis fac¬
tor (TNF), the presence of its mRNA and biologically active TNF in inflamed
joints, suggest a role for TNF in the pathogenesis of inflammation and joint de¬
struction in rheumatic diseases. We have tested unfractionated joint exudate
fluids for the presence of biologically active TNF alpha, and inhibitors of TNF ac¬
tivity. Different degrees of inhibition were observed in most samples. To avoid
biological interference, 134 synovial fluids were tested by a specific and highly
sensitive TNF alpha IRMA which detected significant TNF alpha levels in about
48% of the samples. Immunoreactive TNF alpha titres in synovial fluids were not
clearly related to clinical parameters or type of disease.
Keywords: Arthritis; Synovial fluids; TNF; inhibitors.
Tumour necrosis factors (TNF) are inducible cytokines with multiple biological
activities of which the first described was the necrosis of inducible tumours in animal
models. Two members of this family have been biochemically characterized (1,2) and
their cDNAs cloned and expressed (3,4).
TNF alpha (also known as cachectin) is a 17Kd protein resulting from cleavage of a
larger precursor (5). It is mainly produced by activated macrophages and forms biolo¬
gically active oligomers. TNF beta (or lymphotoxin) is predominantly a T cell product
with similar biological actions but different structure, and its production is regulated
independently of TNF alpha (6). TNF alpha and TNF beta compete with equal affini¬
ty for the same receptor on a variety of target cells (7).
Freshly isolated human mononuclear cells do not express TNF protein or mRNA
(8), but soon after activation TNF alpha production and extracellular translocation
occurs (9,8), often representing up to 1-5% of total protein synthesis in an activated
macrophage (9).
The biological activities of TNF include a wide range of actions including fever
(10), induction of acute phase proteins (11), actions on lipid and carbohydrate meta-
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bolism (12) and membrane potential (13). Its different antimicrobial actions (14,15)
and direct cytotoxicity for some tumour cells (16) point to a role in host defence
against pathogens and transformed cells. Raised TNF alpha levels have been found in
cancer (17), parasitic (18) and bacterial (19) infections.
Other activities of TNF are relevant to the pathogenesis of chronic inflammation
and arthritis. These include induction of fibroblast proliferation (20), bone (21) and
cartilage (22) resorption, polymorphonuclear cell activation (23) and adherence to ac¬
tivated endothelial cells (24), induction of GM-CSF (25), class I and II MHC genes
(26,27), and induction of PGE2 and collagenase from synoviocytes (28). These ac¬
tions are very similar to those of IL-1 alpha and IL-1 beta which have been strongly
implicated in the pathogenesis of several rheumatic diseases (29). TNF acts in synergy
with IL-1 in a number of systems (30) and directly activates macrophages to produce
IL-1 (10). IL-1 itself is also able to induce TNF alpha activity directly (31) or via IL-2
(32).
We previously demonstrated the presence of bioactive TNF alpha in synovial exu¬
date fluids from patients with rheumatic diseases (33,34). When synovial fluids (SF)
from a variety of rheumatic conditions were tested, about one third contained TNF-
like bioactivity on L929 cells that was specifically neutralized by monoclonal antibo¬
dy (mab) to hr TNF alpha.
In this study we present data describing the presence of inhibitor(s) of TNF alpha
activity in synovial fluids. To bypass the interference of such inhibitors, a specific
and highly sensitive TNF alpha IRMA was used to test immunoreactive TNF alpha
levels in 134 joint exudate fluids and the results compared to the clinical parameters
in the population tested.
MATERIALS AND METHODS
Synovial Fluids
Synovial fluids were aspirated from 134 consecutive patients attending a Rheumatology
Out-Patient Clinic for therapeutic joint aspiration and/or injection. Fluids were collected in
EDTA (5 x 10-3M) in sterile conditions. After centrifugation at 1800G for 30 mins 4°C, su-
pernatants were aliquoted and stored at -70°C. Several aliquots of SF underwent an additio¬
nal hyaluronidase digestion (37°C, 30min, 150U/ml bovine testicular hyaluronidase (Sigma))
followed by a second centrifugation. These supernatants were stored for subsequent parallel
testing with the non-treated samples. No evidence of significant cellular carry over and release
of TNF was obtained (double centrifugation ± hyaluronidase treatment did not influence SF
TNF content).
Patients
The SF assayed were mainly from patients with chronic rheumatic diseases and a few
with acute syndromes such as gout or septic arthritis. Patients (female 57%) with a mean age
of 56.4 ± 16.4 years (mean±SD), were studied.
TNF alpha levels in synovial fluids were compared with diagnosis, presence of radiological
bone erosions, sex, age, duration of disease, and drug therapy. Clinical laboratory tests inclu¬
ded: haemoglobin (Hb), white cell count (WCC), platelets (Ptl), erythrocyte sedimentation ra¬
te (ESR).
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Cell Cytotoxicity Assay and Inhibition Studies
L929 cells were used as targets for TNF cytotoxicity in vitro (35). Cells were grown in
EMEM (Sigma) with Penicillin (lOOU/ml), Streptomycin (100/rg/ml, Sigma), and 5% fetal
calf serum (FCS) (heat inactived 56°C, 30mins (Gibco)). For maximum sensitivity to TNF ac¬
tivity, cells were grown for at least two weeks in non-confluent status. To assay TNF, cells we¬
re seeded at 3 x lCU/well in the inner 60 wells of 96 well microtiter plates (Costar). After
20hrs incubation in a 5% CO2, 36.5°C, 95% humidity atmosphere in antibiotic-free
EMEM-10% FCS, the spent medium was removed and replaced with 50/d actinomycin D in
EMEM (final conc. = 1/rg/ml).
Double dilutions of synovial fluids (1:4 to 1:512) in the absence or presence of hr TNF al¬
pha (final concentration: 40pg/ml) were dispensed in each row (final volume: 200/d/well).
Each plate included wells in which only hr TNF alpha was added (40pg/ml, in one case
lng/ml), or EMEM 10% FCS ("total cells" control). Plates were incubated for 18-20hrs at a
higher temperature (38.5°C) to achieve increased cytotoxicity (36). Under these conditions
half maximal killing was obtained with 40-50pg/ml hr TNF alpha. After removal of medium,
the adherent, living cells were fixed and stained with 0.5% (v/v) crystal violet in 20% metha¬
nol). After vigorous washing, optical density (O.D.), which is proportional to cell survival,
was assessed by microELISA spectrophotometry at 470nm. For each single well, percentage
cytotoxicity (% CTX) was calculated with the formula
% CTX- O.D. "total cells"-O.D. sample v ^qq
O.D. "total cells"
The ability to inhibit the cytotoxic action of 40pg/ml hr TNF alpha was calculated, for each
SF dilution, with thj formula
% inhibition = (% CTX by SF) + (% CTX by TNF)-(% CTX by TNF with SF) x 100
(% CTX by SF) + (% CTX by TNF)
To measure inhibition by synovial fluids, dilutions were plotted against % inhibition (Fig
1). One inhibitory unit was defined as the dilution of SF able to neutralize 75% of the cytoto¬
xicity induced by 40pg/ml hr TNF alpha.
Using this assay, 8 samples were tested for inhibition of hr TNF alpha activity (40pg/ml),
and one sample was tested against lng/ml hr TNF alpha.
Immunoradiometric Assay for TNF alpha (TNF alpha IRMA)
This immunoassay was based on a solid phase two-site "sandwich immunoassay" method
(37). Etched polystyrene beads (Northumbria Biologicals, UK; 6mm diam.) were immersed in
a solution of 3.101.23 anti hr TNF alpha monoclonal antibody (200/rg Ig protein/ml PBS) (38)
and stored overnight at 4°C. Before use, antibody-coated beads were washed four to five ti¬
mes with washing buffer, 0.5% BSA-PBS and then stored in this buffer at 4°C before use.
LP4 tubes (Luckham, UK) were blocked with 5% BSA-PBS for at least one hour before use.
For the assay, LP4 tubes were emptied and synovial fluid samples and serial dilutions of hr
TNF alpha interim standard (86/659) transferred to the tubes (0.225ml/tube). To lower the
viscosity of synovial fluids, they were either pretreated with hyaluronidase (40 u/ml, 30 mins)
or diluted 1:5 in PBS. Human recombinant TNF alpha standard was serially diluted in a syno¬
vial fluid known to be negative for TNF alpha. Monoclonal antibody-coated beads were dried
by blotting on paper towels and then one bead was transferred to each tube. Incubation was
for 18 hours at 4°C, following which samples were removed by aspiration and the beads wa¬
shed three times with 3ml washing buffer.
Radio-iodinated anti-human TNF alpha Ig (2-33-G2) (38) was appropriately diluted in wa¬
shing buffer and approximately 2 x 105 cpm in 0.225 ml added to each tube.
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SF rec.dilution
Fig. 1. Typical dilution curves of TNF alpha-inhibiting activities in some of the synovial fluids (SF) te¬
sted; SF 10 was tested against hr TNF alpha lng/ml, while SF 73, 45 and 116 against 40pg/ml hr TNF al¬
pha. The four fluids have respectively no inhibition of lng/ml TNF alpha and about 8 and 58 inhibition
U/ml, and >512 inhibition U/ml of 40pg/ml TNF alpha.
Following further incubation at 4°C for 4-5hr, excess 125 I-2-33-G2 was removed and the
beads washed three times with washing buffer before counting in an LKB gamma counter.
The IRMA had in these counditions/ a detection limit of 0.5U(12.5pg/ml) when calibrated
with the hr TNF alpha interim standard (86/659).
In several fluids, exogenous hr TNF alpha was added in concentrations ranging from
50pg/ml to 5ng/ml: percent recovery was 115.16± 14.86 (n = 9); dilutions of synovial fluids
were also tested (1/2, 1/4, 1/8), with a recovery from expected values of 112.02 ± 10.96%
(n = 9). In both cases, differences between TNF alpha titres obtained and TNF alpha values
expected was not significant by signed rank test (p >0.5) Interassay variability was less than
10% and intra-assay variation less than 10% over the range 25pg-25/tg/ml TNF alpha.
Statistical Analysis
Qualitative agreement was assessed by Kappa statistic (39), quantitative differences bet¬
ween groups by one-way analysis of variance, quantitative correlation by Spearman's rank
coefficient, analysis of dichotomous variables in different groups were tested by chi-square
test. For estimations on paired samples, differences were tested by signed rank test.
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RESULTS
The presence of inhibitors of TNF bioactivity in SF.
Of the nine fluids tested, one fluid did not inhibit lng/ml hr TNF alpha cytotoxici¬
ty at any of the concentrations tested. Five synovial exudates contained TNF inhibi¬
tory activity quantifiable at between 8 to 54 u/ml, representing potential inhibitory
bioactivity of 0.24 to 1.62ng/ml TNF alpha. Three other synovial fluids showed very
high inhibitory activity against 40pg/ml TNF alfa that did not dilute out even at the
1:512 dilution.
TNF alpha IRMA
Tumour necrosis factor alpha was tested by IRMA on a total of 134 fluids. Of the¬
se, 64 (47.8%) had levels of TNF alpha exceeding 12.5pg/ml (range = 12.5pg/ml to
4.9ng/ml) (Table I). The miscellaneous group included patients with a variety of rheu¬
matic diseases. The eleven positive exudates in this group were from two juvenile
chronic arthritis, two ankylosing spondylitis, one psoriatic arthritis, one palindromic
rheumatism, one gout, one polymyalgia rheumatica and three septic arthritis. Signifi¬
cant levels were well distributed in each disease category.
The possibility of mononuclear cell carryover and production of TNF within the
assay was not an issue as the assay was carried out in the presence of lug/ml Actino-
mycin D (L929 assay) or 50ug/ml Azide (TNF IRMA). To determine the effect of
hyaluronidase treatment, paired samples were assayed by IRMA. The treatment dra¬
matically reduced SF viscosity. However, in paired samples (n = 9) no significant dif¬
ference was observed (signed rank test, p = >0.5) in TNF immunoreactivity.
Qualitative comparison between bioactive and immunoreactive TNF alpha in synovial
fluids
Of the fluids tested in the TNF alpha IRMA 130 had previously been tested for
L929 cytotoxicity (34). Table II shows the qualitative comparision between these da¬
ta. Sixty one fluids were negative in both assays and 40 positive in the two different
assays (total = 77.7% agreement). Seven fluids out of 130 (5.4%) scored negative in
the IRMA and positive in the previous L929 assay. Of the 22 fluids positive in the
IRMA and negative in the L929 assay, 20 had a level of TNF alpha that was below
the sensitivity of the L929 assay (between 12.5 and 160pg/ml). When these 20 fluids
are excluded on the basis of different assay sensitivities, agreement increases to
91.8% (101/110). K value for these comparisions was 0.506 in the first case (n = 130)
and 0.830 after eclusion (n = 110) (ideal agreement: K = +1; complete disagree¬
ment: K = -1).
Quantitative correlation between bioactivity and immunoactivity
The forty samples that were positive for L929 cytotoxicity and for TNF alpha
immunoreactivity were analyzed for quantitative correlation. These values did not si¬
gnificantly correlate, as might be expected due to the presence of inhibitors of the
bioassay.
22 F. S.di GIOVINE ET AL.
Correlation with Clinical Parameters
No significant correlation was noted with clinical parameters in the whole popu¬
lation, nor within each disease group (synovial fluid TNF vs Hb, WCC, Ptl, ESR, di¬
sease duration, bone erosions). There was no significant difference in TNF titres bet¬
ween disease groups, and no relation to drug therapy.
DISCUSSION
In a previous study (34), we demonstrated the presence of TNF-like activity that
was neutralizable by a specific anti-hr TNF mab in approximately 30% of synovial
fluids from patients with rheumatic diseases.
The levels of bioactive SF TNF alpha did not correlate with routine laboratory
markers of inflammation in patients or disease group. This could be due to several
factors, the most likely of which seemed to be the presence of biological inhibitor(s)
in the fluids tested. In this study we demonstrated the presence of such inhibitory ac¬
tivity in most of the exudates fluids tested. To measure reliably TNF alpha levels, a
TNF alpha IRMA was used on 134 fluids, 130 of which had been previously tested
for TNF bioactivity. Significant TNF alpha levels (range: 12.5pg/ml to 4.9ng/ml) we¬
re detected in 48% of the SF tested.
Qualitative agreement between bioactivity and TNF alpha immunoreactivity was
excellent (about 92% for the fluids (n = 110) with titres exceeding 160pg/ml or below
12.5pg/ml) but, as expected, no quantitative relationship was evident when positive
fluids were compared. Seven fluids out of 130 (5.4%) scored negative in the IRMA
and positive in the L929, possibly indicating degradation of TNF in the fluids bet¬
ween the experiments (12 to 6 months) or cytotoxic activity not mediated by TNF al¬
pha. Non-specific killing in a small proportion of samples was in fact previously recor¬
ded (34).
However, clinical laboratory measurements (ESR, platelets, Hb, WCC) related to
systemic inflammation, radiological joint erosions, and disease category did not corre¬
late with TNF alpha levels in synovial fluids.
The lack of correlation with markers of disease activity is unlikely to be explained
by dissociation between immunoreactivity and bioactivity of TNF alpha as TNF pro¬
peptide is apparently fully processed before extracellular translocation (5). In human
monocyte supernatants, L929 bioactivity significantly correlates with TNF alpha im¬
munoreactivity as determined by RIA (8). It is possible however that different aggre¬
gation states of TNF in synovial fluid might give unequal exposure of receptor bin¬
ding sites and immunoreactive epitopes.
It is also possible that TNF production varies between individuals similarly to IL-1
beta (40). This might suggest that comparision of TNF alpha levels between patients
is inappropriate and that longitudinal studies in individuals could be more useful.
This, of course, is not feasible for synovial fluids, but is possible with blood samples.
Interestingly, of two patients with septic arthritis in which repeated aspiration was
performed, TNF alpha levels were initially raised and fell with treatment as joint in¬
flammation resolved (e.g. 1.22 to 0.43ng/ml after 2 weeks'antibiotic therapy).
The estimation of TNF in plasma would probably be more helpful in studies on the
role of TNF in the pathogenesis of rheumatic diseases bec-ause it would allow compa¬
rision with a normal population, who have low but detectable levels of plasma TNF
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Table I. Immunoreactive TNF alpha in Synovial Fluids
Diagnoses RA + RA- OA RT Misc Total
No. of cases 55 30 18 11 20 134
<12.5 pg/ml 29 18 11 3 9 70
12.5-25 pg/ml 6 2 — 1 5 14
25-250 pg/ml 16 9 1 4 3 33
0.25-2.5 pg/ml 3 1 5 3 3 15
>2.5 pg/ml 1 — 1 — — 2
Total "positives" 26 12 7 8 11 64
% "positives" 47.3% 40% 38.9% 72.7% 55% 47.8%
Table I. A total of 134 synovial fluids were assayed for TNF alpha with a specific and sensitive TNF al¬
pha IRMA. Of these, 47.8% had a level of TNF alpha over the detection limit ("positive" =
> 12.5pg/ml). RA + = rheumatoid arthritis seropositive; RA- = rheumatoid arthritis seronegative; OA
= osteoarthritis; RT = reactive arthritis; Misc = miscellaneous group of arthritis, including ankylosing
spondylitis, psoriatic arthritis, septic arthritis, juvenile chronic arthritis, palindromic rheumatism and
gout.
Table II. Qualitative Comparison Between Bioactive and Immunoreactive TNF in
Synovial Fluids
TNF alpha IRMA





















Table II. Qualitative comparision between L929 cytotoxicity assay and TNF alpha IRMA on 130 joint
exudate fluids tested by both methods. Of the 22 fluids labelled with (*), 20 had TNF alpha IRMA levels
between 12.5 to 160pg/ml, below the detection limit of the L929 bioassay ("negative" for L929 cytoto¬
xicity) but detectable in the immunoassay ("positive" in TNF alpha IRMA).
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alpha (J. Eastgate, personal communication). It would also allow serial measurements
on the same patient and testing of correlation with clinical disease activity in indivi¬
duals.
It would be predicted that markers of systemic disease activity such as those mea¬
sured in this study would be more likely to correlate with TNF levels in blood rather
than levels in individual inflammed joints.
Synovial fluid TNF concentration though, is higher than autologous blood levels.
TNF is produced in the synovium of rheumatoid patients (41) and synovial cells
"spontaneously" release immunoreactive TNF alpha (42), indicating TNF is produ¬
ced within the synovium during inflammation.
Clearly, the local and systemic biological effects of this TNF production will de¬
pend upon a complex balance between TNF and synergystic cytokines on one hand
and inhibitory factors on the other.
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Tumour necrosis factor in synovial exudates
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Hospital, Edinburgh, UK
summary The actions of tumour necrosis factor (TNF) include resorption of bone and cartilage,
suggesting a potential role in the pathogenesis of arthritis. TNF activity was looked for in synovial
fluids from 137 patients with different rheumatic diseases. Unfractionated samples were tested in
the L929 bioassay. Significant TNF activity that was neutralised by monoclonal antibody to TNF
alpha occurred in 13 (30%) of 44 samples. Raised TNF levels were not associated with any
particular disease type or routine laboratory markers of inflammation but were related to disease
duration in osteoarthritis. The finding of biologically active TNF in symptomatic joints of arthritic
patients supports the idea that it may contribute to the pathogenesis of joint damage in chronic
rheumatic diseases.
Key word: arthritis.
Cytokines are inducible peptides with receptor
mediated biological actions on many different cellu¬
lar targets. Cytokine production has mainly been
associated with leucocyte or fibroblastoid cells
during responses to injury or infection.1 2 Tumour
necrosis factors (TNFs) are cytokines that have
recently been characterised at molecular level.3 4
TNF alpha (also called cachectin) is a 17 000 Mr
peptide that forms biologically active oligomers.5
Mononuclear phagocytes are potent sources of TNF
alpha,6 but T cells also produce a similar molecule7
as well as the related product, lymphotoxin (also
called TNF beta).* Resting cells release little or no
TNF alpha, but after activation rnRNA accumulates
and TNF peptide appears soon after.9 The biological
activities of human TNF alpha are similar to those of
interleukin 1 (IL1) alpha and beta except that
human TNF does not activate murine T cells.10
The biological role of TNF has not yet been
completely defined, but its properties in vitro and in
vivo suggest it could be an important mediator of
host defence against tumours and pathogens." It is
also likely that TNF may contribute to autoimmune
and inflammatory pathology such as occurs in
rheumatic diseases. The defined activities of TNF
relevant to arthritis include resorption of cartilage
and bone12 13; endothelial adherence and activation
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of granulocytes14 15; stimulation of fibroblast
growth16; stimulation of synovial cell prostaglandin
and collagenase release17; and the systemic reactions
of fever, liver acute phase protein synthesis,19 and
catabolism of protein and fat leading to muscle loss
and cachexia. Whether resident cells in healthy
skeletal tissues include populations that produce
TNF is not known, but the mononuclear infiltrating
cells that characterise synovial pathology in many
arthritic diseases are likely sources of TNF. Cyto¬
kine studies in arthritis have previously concen¬
trated on interleukins 1 and 2 and interferons,21 but
the connective tissue effects of TNF raise the
possibility that it may mediate bone and cartilage
injury in chronic joint disease.20
As there was no previous information on the
occurrence of TNF in human arthritic diseases we
tested unfractionated synovial exudate fluids from
137 patients with different rheumatic diseases and
report here that biologically significant levels of




Synovial effusion fluids (SF) were obtained from
patients referred for aspiration of symptomatic knee
joints. Clinical diagnoses covered a wide range of
rheumatic diseases as indicated in the results sec¬
tion. All of the patients were being treated with non¬
steroidal anti-inflammatory drugs and some
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received slow acting anti-inflammatory drugs or low
dose oral corticosteroids. Fluids were collected in
sterile containers in the presence of 5xl()~3 M
edetic acid, centrifuged at 1800g for 30 minutes, and
sample aliquots stored at —70°C or tested im¬
mediately for TNF content. The fluids were col¬
lected over 16 months.
REAGENTS
Human recombinant (HR) TNF alpha, human
recombinant lymphotoxin (TNF beta), mouse
monoclonal antibody specific for human TNF alpha
and rabbit antiserum against HR lymphotoxin were
all kindly donated by Dr Gunther Adolf (Ernst-
Boehringer-lnstitut fur Arzneimittel-Forschung, A-
1121 Wien, Austria). HR IL1 alpha and IL1 beta
were obtained from Biogen (Geneva). Reagents for
immunoradiometric assay for human interferon
gamma were from Boots-Celltech (Slough, Berk¬
shire).
TNF ASSAY
The conventional bioassay for TNF activity based on
cytotoxicity for the mouse connective tissue cell line
L929 was used.22 Briefly, L929 cells were cultured in
Eagle's minimum essential medium (Sigma, St
Louis, MO) with 5% fetal calf serum (Gibco,
Paisley, UK) at 4xl04 cells/well for 20 hours in flat
bottomed, 96 well, microtitre plates. The medium
above the non-confluent cell layer was replaced with
fresh medium containing actinomycin D (1 pg/ml)
and serial dilutions of standard HR TNF alpha or
samples to be tested for TNF content. After a
further 20 hour incubation the medium was removed
and a 0-5% in 20% methanol solution of crystal
violet was added to the wells. The number of viable
(adherent) cells remaining in each well was assessed
by scanning spectrophotometry (Dynatech MR 700)
at 540 nm. The concentration of TNF giving 50%
maximal cell killing (one bioassay unit) was equiva¬
lent approximately to 50 pg/ml of recombinant
human TNF alpha. A range of cytokines, including
recombinant and purified natural IL1 alpha and
beta, purified interferon alpha and recombinant
interferon gamma, and crude interleukins 2 and 3,
gave no appreciable activity (less than 4 units/ml) in
this assay but HR lymphotoxin was equipotent
with TNF alpha.
Synergy between interferon gamma and TNF has
been reported for human cell cytotoxicity2 and in
other human systems.24 Therefore we measured
interferon gamma levels in these synovial exudates.
Of 27 SF tested for IFN gamma in a specific
radioimmunometric assay, none reached the detec¬
tion limit (1 U/ml). With this assay there was no loss
of detection of HR interferon gamma added to
osteoarthritis or rheumatoid arthritis synovial fluids
compared with culture medium.
Ninety three SF were tested at 11 serial dilutions
in at least three separate assays, from which
quantitative data (units of TNF activity) could be
derived.
SPECIFICITY TESTING
To test that the L929 cytotoxicity of the SF was
mediated by TNF alpha some positive samples were
reassayed in the presence of monoclonal antibody
(MAb) specific for HR TNF alpha or MAb specific
for human major histocompatibility complex
(MHC) class II product (control antibody). These
quantitative experiments indicated that some cyto¬
toxic samples were not neutralised by anti-TNF
alpha. To determine the proportion of fluids with
cytotoxic activity that were neutralised by anti-TNF
alpha we tested a further 44 fresh fluids at one
dilution only (1:8) after preincubation with culture
medium, anti-TNF alpha, irrelevant MAb, or a
rabbit antiserum against HR lymphotoxin.
It is known that both IL1 alpha (di Giovine,
Poole, and Duff, unpublished observation) and
beta23 are detectable by radioimmunoassay in hu¬
man synovial exudate fluids. IL1 is reported to act
synergistically with TNF in a number of biological
systems.2<>~2's To test whether our bioassay estimate
of TNF content might be influenced by synovial
fluid IL1 we performed L929 bioassays of HR TNF
in the presence of HR IL1 alpha and beta. Fig. 1
shows that IL1 did not affect the L929 response to
TNF alpha.
Results
TNF-LIKE ACTIVITY IN SYNOVIAL FLUIDS
Of the first 93 SF tested, 35 had TNF-like activity of
4 U/ml or greater. Table 1 summarises the clinical
diagnosis and level of TNF-like activity. The two
positive fluids in the miscellaneous group were from
patients with recurrent monarthritis. Several SF
with the highest levels had been assayed fresh,
suggesting that activity may be lost after freeze-
thawing or storage at -70°C.
ANTIBODY NEUTRALISATION OF TNF-LIKE
ACTIVITY
Eight of the 35 fluids with TNF-like activity were
retested in full titrations alone or with anti-TNF
alpha, or control MAb (Table 2). Six were com¬
pletely neutralised by anti-TNF alpha but two were
not, suggesting that other cytotoxins were present in
these samples. To determine the proportion of SF
that contained cytotoxic activity attributable to TNF
alpha we tested a new group of 44 SF in triplicate at
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one dilution only, either alone or with antibodies.
Of these 44 fluids, 13 (30%) contained TNF activity
that was unaffected by control antibody but com¬
pletely neutralised with anti-TNF. They included SF
from patients with rheumatoid arthritis, osteoarthri¬
tis, ankylosing spondylitis, psoriatic arthritis, reac¬
tive arthritis, septic arthritis, and gout. SF that did
not contain TNF activity were also found from
patients in most of these disease groups. Twenty
three samples (52%) contained no TNF-like activity
at all and eight (18%) were cytotoxic for L929 cells
but either were not neutralised with anti-TNF or
were affected by the irrelevant MAb. Notably, of
the 21 SF that were cytotoxic for L929, none was
neutralised by antiserum to lymphotoxin. This
antiserum at 1:800 dilution completely inhibited the
activity of 10 ng/ml human recombinant lympho¬




















HR TNF (1 ng/ml) mean (SEM) (n=4)
HR IL 1(3 (n=5)
HR IL 1/3+ HR TNF (1ng/ml)
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Fig. 1 Human recombinant tumour necrosis factor (HR TNF) alpha and HR interleukin 1 beta (IL If) were
tested for synergy in the L929 cytotoxicity assay, (a) Different concentrations ofHR TNFalpha were tested in
the presence or absence of HR ILI beta (I ng/ml). (b) HR TNFalpha (1 ng/ml) was tested in the presence or absence
ofdifferent concentrations ofHR ILI beta. No synergy in L929 cytotoxicity was observed and HR ILI beta alone in a
wide concentration range was inactive in this assay. Identical results (data not shown) were obtained in separate experiments
in which TNF was tested at higher concentrations (10 ng/ml) or HR ILI alpha was used. Biological activity of both ILI
preparations was confirmed by EL4.NOB. IICTLL conversion assay.
Table 1 TNFactivity in SFfrom patients with different rheumatic diseases
TNF activity*
(Ulml)
RA + RA- OA ReA PsA AS Misc Total
<4 29t 11 6 2 3 1 6 58
4-16 9 7 3 4 2 1 1 27




Total 41 18 11 7 5 3 8 93
% Positive/ 29 39 46 71 40 67 25 38
RA+=seropositive rheumatoid arthritis; RA—=seronegative rheumatoid arthritis; OA=osteoarthritis; ReA=reactive arthritis;
PsA=psoriatic arthritis; AS=ankylosing spondylitis; Misc=miscellaneous group.
'Each synovial fluid was measured at least three times at 11 dilutions in different assays.
tNumbcr of patient SF in this category.
/Percentage of patients in each category with TNF levels> 4 U/ml (detection limit).
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Table 2 Antibody neutralisation ofsynovial fluid
TNF-like activity
Sample Sample with Sample with
alone anti-TNFf anti-DRt
SF 73 (OA) 39* <4 34
SF 69 (AS) 42 <4 41
SF 78 (OA) 14 <4 NDS
SF 158 (OA) 11 <4 11
SF 161 (RA+ ) 50 <4 49
SF 91 (RA+ ) 5 <4 ND
SF 116 (RA + ) 19 5 10
SF 112 (RcA) 7 9 ND
HR LT (1 ng/ml)§ 24 22 30
HR TNF (1 ng/ml) 22 <4 21
'Values are TNF bioassay units/ml.
tMonoclonal antibody against human recombinant TNF alpha
(1:1600).
^Monoclonal antibody against human MHC class II product as
control antibody (1:800).
§HR LT=human recombinant lymphotoxin; ND= not done; other
abbreviations as in Table 1.
Discussion
The purpose of this study was to test whether
unfractionated synovial exudate fluids from arthritic
patients contained biologically active TNF. Using a
bioassay for TNF based on cytotoxicity for the
murine L929 connective tissue cell line we tested a
total of 137 synovial exudate fluids. In quantitative
assays for TNF activity 35 (38%) of 93 samples were
positive at a concentration of at least 4 U/ml (the
limit of detection). In six of eight positive SF tested,
TNF-like activity was neutralised by monoclonal
anti-TNF alpha. Of a further 44 fluids that were
tested in a single dilution assay, 13 (30%) contained
TNF activity neutralised only by MAb for TNF
alpha. None of the 21 cytotoxic samples in this series
was neutralised by antiserum to lymphotoxin.
TNF alpha was found in SF from patients with a
variety of rheumatic diseases, but in this preliminary
study we noted no association between synovial
fluid TNF level and disease category, drug treat¬
ment, or laboratory data (haemoglobin, white cells,
platelets, erythrocyte sedimentation rate). The only
significant difference in clinical terms was in disease
duration in osteoarthritis and reactive arthritis,
where those with detectable TNF levels had a mean
duration of disease of 9-3 years (n=10), while
similar patients with no detectable TNF had mean
disease duration of 3-3 years (n=14, p=0-0067).
Presumably, systemic markers of inflammation are
more likely to be related to levels of TNF in the
circulation rather than in the synovial space.
There have been recent reports of TNF in samples
from patients with meningococcal29 or protozoal30
infections and in cancer,31 but no previous reports of
TNF in sterile inflammatory diseases seem to be
available. Our results indicate that about 30% of
synovial exudates from different rheumatic diseases
contain biologically detectable levels of TNF alpha
(equivalent to nanomolar concentrations of FIR
TNF). The presence of TNF in synovial exudate
from several rheumatic diseases argues against TNF
production as a specific factor in the pathogenesis of
any particular disease. It seems that TNF may be
associated with the process of joint effusion that is
common to a number of articular disorders with
apparently different aetiologies. This is in keeping
with the known variety of stimuli able to induce
TNF production in mononuclear cell populations.
For example, monosodium urate crystals stimulate
monocyte TNF release in vitro,3- which could
account for TNF in gouty effusions. Presumably, in
septic arthritis macrophage TNF production is
directly stimulated by microbial products, and TNF
release could be a direct or indirect result of
lymphocyte activation in both acute and chronic
rheumatic diseases. It is likely that these biodetec-
tion results underestimate the amount of TNF
present as in some fluids we could detect only
50-60% of known quantities of added HR TNF
alpha. It is also possible that TNF activity was lost
on prolonged storage or during freeze-thawing as
the highest levels we found were in fresh or recently
collected samples. Finally, the assay itself is rela¬
tively insensitive and preliminary findings with more
sensitive immunoassays indicate that TNF is detect¬
able in a much larger proportion of samples.
As TNF is known to activate polymorphonuclear
cells,14 15 stimulate synovial prostaglandin produc¬
tion,17 and increase bone13 3 and cartilage12 de¬
struction in vitro, its presence in synovial effusion
fluids may well be significant. Recently, TNF has
also been shown to induce other cytokines, includ¬
ing IL1 and granulocyte-monocyte colony stimulat¬
ing factor.13 ~4 IL1 is, like TNF, proinflammatory
and catabolic21 and is found in human synovial
exudates.25 35 36 It is made by synovial cells37 38 and
was reported to be arthritogenic when injected into
rabbit joints.39 In addition to IL1 induction by TNF,
IL1 itself has been shown to increase TNF activity,40
suggesting a mechanism for the maintenance of
inflammation.
This report now provides evidence that TNF
alpha in a biologically active form occurs at the site
of inflammation in several types of arthritis and
supports the idea that mononuclear cytokines
mediate joint tissue destruction.41 An understand¬
ing of the cellular origins and activators of these
cytokines should help elucidate the pathogenesis of
several types of rheumatic disease.
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